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Abstract 
Paediatric human immunodeficiency virus (HIV) infection has become a 
major socio-economic health problem in recent years as the number of HIV-I 
infected children steadily increases. The majority of these infants are 
infected through mother-to-child transmission, with the frequency of vertical 
transmission varying between 12,9% and 65%. In order to implement 
appropriate management and possible treatment of these infected 
neonates, it is essential to have reliable laboratory tests for the early 
diagnosis of an HIV infection. At the time that this study was initiated, the 
diagnosis of HIV-I infection in the Groote Schuur Hospital Virology 
Laboratory depended almost exclusively on serological assays. Such 
assays are of limited value for infants under 18 months of age, as maternal 
lgG antibody to HIV-I is transferred via the placenta and may persist in the 
baby for up to 18 months. Available lgG antibody tests do not distinguish 
reliably between passively acquired maternal antibody and that produced by 
the infant itself. A valuable method of establishing the presence of true 
infection is provided by the polymerase chain reaction (PCR) technique 
which allows the identification, and subsequent exponential amplification of 
low levels of specific viral nucleic acid using specific oligonucleotide 
primers. 
A major aim of this study was to develop and instigate a (PCR) assay for the 
early diagnosis of HIV infection in infected infants. This was successfully 
achieved by the adaptation and optimization of an existing standard PCR 
protocol to suit the specific needs of a routine diagnostic service. 
Preliminary requirements involved the selection of primers and probes and 
establishing optimal parameters for: ionic strength, Taq DNA polymerase 
concentration, primer concentration, deoxynucleotide triphosphate 
concentration, and hybridization conditions for most efficient functioning of 
1 
the test. The devised method entailed the extraction of proviral DNA from 
peripheral blood mononuclear cells, amplification of HIV-I specific 
sequences by PCR, and identification by Southern blot hybridization with 
digoxigenin (DIG)-labelled probes. 
Thereafter the efficacy of the assay was tested on 45 infants (under 15 
months of age) all born to seropositive mothers and therefore at risk for HIV 
infection. Forty-two of these infants had antibodies to HIV-I and the 
remaining 3 were seronegative. The latter 3 also tested negative for HIV 
proviral DNA when PCR was performed, using at least 2 different HIV-I 
primer pairs and their respective DIG-labelled probes. However, 27 . (64%) 
of the 42 seropositive infants were also HIV-PCR positive and the remaining 
15 (36%) seropositive infants were negative for HIV proviral DNA. Positive 
PCR tests correlated well with clinical data indicative of active HIV-I 
infection for the majority of infants in the neonatal period, although it could 
not provide proof of infection in newborn babies (less than 1 week of age). 
The development of an in-house PCR protocol specific for HIV-I has not 
only provided a valuable diagnostic assay for neonatal infection, but has 
also given insight into the parameters required for high sensitivity and the 
stringent precautionary measures that need to be applied to avoid 
contamination problems. 
The second part of this study was devoted to DNA sequence analysis of 
cloned HIV isolates from an infected mother and her 3 month old infant. 
Nucleotide sequence variation between isolates of HIV-I has been well 
documented. Examination of the third variable region (particularly the V3-
loop) in the env gene of HIV-I of our mother-infant pair confirmed this 
variation and provided the first genetic epidemiological data of this nature in 
the local community. 
Proviral DNA from both mother and baby was amplified using V3-specific 
degenerate primers and cloned. Clones containing the insert DNA were 
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identified by colony-blot hybridization. Their nucleotide and amino acid 
sequences were analyzed by using various computer programs. The 
degree of similarity between variants from the mother and infant in this study 
differed to a large extent from previous studies. The virus population 
harboured by the mother displayed highly homogeneous V3 sequences 
(1,04% variation) compared to the isolates from her 3 month old infant, 
which showed a higher degree (1,8%) of heterogeneity. Phylogenetic 
analysis of the different isolates from mother and infant demonstrated that 
an HIV-I subtype C virus was the infectious agent. This classification was 
confirmed by the characteristic amino-acid sequence of the tetrapeptide 
motif of the V3 loop present in the isolates from both mother and infant as 
well as the absence of a potential N-linked glycosylation site proximal to the 
first cysteine of the V3 loop, which is characteristic of subtype C viruses. 
Based on the amino acids present at positions 306 and 320 of the V3 loop, 
it could also be concluded that isolates from both the mother and her baby 
were consistent with the non-syncytium inducing (NSI) phenotype of HIV-I, 
thus indicating that, contrary to popular belief, NSI variants can be 
responsible for initiating infection. 
Data obtained from these genetic investigations of variants involved in 
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Chapter 1 
Overview of HIV-I 
1.1 Historical Aspects 
A s the human immunodeficiency virus (HIV-I) continues to infect millions of people throughout the world, understanding the role of 
this retrovirus as the etiological agent of acquired immunodeficiency 
syndrome (AIDS) requires an historical detour through the puzzling 
connection between retroviruses and animal cancers. The first oncovirus 
was isolated in 1911 when Peyton Rous reported that tumours in chickens 
could be caused by a virus readily transmissable by filtered extracts (Rous 
1911 ). This virus was later known as the Rous sarcoma virus (RSV). 
Since then, innumerable retroviruses have been isolated from many 
groups of vertebrates. 
In the early 1960's, a feline cancer-inducing virus was discovered, now 
called the feline leukaemia virus (Jarret et al., 1964). This virus proved to 
be important in understanding the biology of retroviruses for two reasons; 
firstly, it induces an immunodeficiency in cats similar to that later observed 
in AIDS patients, and secondly, because feline leukaemia virus is 
transmitted among cats in a household setting, it provided a valuable 
model for epidemiological analysis of retrovirus infection. Until the late 
1960's, there was still considerable scepticism that a virus could mediate 
the transmission of cancer. Because cancer appeared to be_ caused by a 
genetic alteration, it was difficult to conceive how ribonucleic acid (RNA) 
contained in retroviruses could interact with the deoxyribonucleic acid 
(DNA) of the host cell to produce oncogenic changes. The discovery of 
reverse transcriptase suggested a mechanism for the induction of 
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permanent genetic change (Abrell and Gallo, 1973). This enzyme uses 
RNA as a template and reverses the conventional flow of genetic 
information by synthesizing a copy of complementary DNA (cDNA) that 
ultimately integrates into the genome of the host cells. This DNA, called 
provirus, serves as an intermediate stage in the replicative cycle of the 
virus. 
The first indication that AIDS could be caused by a retrovirus came in 
1983, when Barre-Sinoussi at the Pasteur Institute recovered a reverse 
transcriptase-containing virus from the lymph node of a man with 
persistent lymphadenopathy syndrome (LAS) (Barre-Sinoussi et al. , 1983). 
The characteristics described for the retroviruses recovered by the 
Pasteur Institute group included some that were also reported for the 
human T-cell leukaemia virus (HTLV) (Blattner et al. , 1983). Thus, many 
investigators decided initially that the lymph node isolate was a member of 
this already recognized human retrovirus group. The concurrent 
publication of a paper by Gallo (Gallo et al. , 1983) in the same issue of 
Science, reporting the isolation of HTLV from individuals with AIDS, 
supported this conclusion. However, HL TV as the etiological agent of 
AIDS seemed unlikely since it was known to be strongly cell-associated 
and to display poor replication in culture, yet AIDS had reportedly been 
transmitted to haemophiliacs (Meissner et al., 1992) by cell-free plasma 
products such as factor VII I. The characteristic loss of CD4+ lymphocytes 
in AIDS patients (Gottlieb et al., 1981) could also not be explained by an 
HTL V infection, since HTL V does not lyse lymphocytes, in fact, it often 
immortalizes them into continuous growth (Miyoshi et al., 1981 ). 
Further studies in 1983 by Montagnier and co-workers clarified these 
questions in relation to the LAS agent (Montagnier et al. , 1984 ). Their 
results indicated that this human retrovirus, later called lymphadenopathy-
associated virus (LAV), although similar to HTLV in its ability to infect 
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CD4+ lymphocytes, had quite a distinct property in that it grew to 
substantial titre in CD4+ cells and killed these targets instead of 
maintaining them in culture as does HTLV (Montagnier et al. , 1984 ). 
These observations on LAV provided important evidence to support the 
potential etiological role of a retrovirus in AIDS. Thus, 3 years after the 
first description of the disease in 1981, it was shown that AIDS was 
caused by a retrovirus. 
Several · other laboratories were also searching for the agent responsible 
for the immune deficiency syndrome, and in early 1984 Gallo and 
associates reported the characterization of another human retrovirus, 
distinct from HTLV, which they called HTLV-111 (Gallo et al. , 1984). It was 
isolated from the peripheral blood mononuclear cells (PBMC) of adult and 
paediatric AIDS patients. At the same time Levy and his co-workers 
reported the identification of retroviruses which they named the AIDS-
associated retroviruses (ARV) (Levy et al., 1984 ). These viruses were 
recovered from AIDS patients from different known risk groups, as well as 
from other symptomatic and healthy people. Finding ARV in 
asymptomatic individuals was the first indication of a carrier state for the 
AIDS virus. This retrovirus grew substantially in PBMC, killed CD4+ 
lymphocytes and did not immortalize them. Thus, the three newly 
identified retroviruses had similar characteristics. Most importantly, 
infection by these viruses was not limited to AIDS patients. They were 
also recovered from individuals with other clinical conditions, including 
lymphadenopathy. 
Within a short period, the three prototype viruses were recognized as 
members of the same group of retroviruses. Their proteins were all 
distinct -from those of HTLV and their genomes showed only remote 
similarities to the genome of that agent. Thus, the suspected cross-
reactivity of HTLV-111 with HTLV was proved to be incorrect. For all these 
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reasons, in 1986, the International Committee on Taxonomy of Viruses 
recommended that the AIDS virus be given a separate name, the human 
immunodeficiency virus (HIV) (Coffin et al. , 1986). Soon after the 
discovery of HIV type one (HIV-I), a separate subtype, HIV type two (HIV-
11) was identified in western Africa (Clavel et al., 1986). Both HIV subtypes 
can lead to AIDS, although the pathogenic course with HIV-II might be 
longer. 
1.2 Classification 
T he retroviruses belong to the family Retroviridae, which is taxonomically divided into three subfamilies, based primarily on 
pathogenicity rather than on genome relationships. The 3 subfamilies 
comprise the Oncovirinae, which includes those retroviruses that cause 
tumours in the host, or transformation in tissue culture (HTLV-1 and -II 
belong to this subfamily); the Lentivirinae, which includes a number of 
viruses that cause slow virus diseases with progressive degeneration of 
the central nervous system (HIV-I and HIV-II are included in this 
subfamily) and the Spumavirinae including the foamy viruses which may 
result in persistent infections and vacuolar pathological findings in tissue 
culture, accounting for their name (Coffin , 1990; Dodd, 1994; Dalgleish 
and Weiss, 1990). 
The subfamily Lentivirinae, to which both HIV-I and HIV-II belong, includes 
a large number of different viruses that infect a diverse group of animal 
species (Table 1 ). The genomes of these viruses are characterized by a 
complex combination of genes encoding multiple structural proteins and 
non-structural regulatory gene products. 
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Table 1 Lentivirinae 
Group Virus Host Disease 
Lentiviruses Human immunodeficiency virus Human Cause of AIDS 
(HIV type I and II) 
Simian immunodeficiency virus Primate AIDS-like disease in 
(SIV) certain monkeys 
Feline immunodeficiency virus Cat Immunodeficiency 
(FIV) 
Bovine immunodeficiency virus Cattle Lymphadenopathy 
(BIV) L vmphocytosis 
Visna virus Sheep Neurological and 
lunq disease 
Equine infectious anemia virus Horse Hemolytic anaemia 
(EIAV) 
Caprine arthritis-encephalitis virus Goat Hemolytic anaemia 
(CAEV) Encephalopathy 
A method of classification has been proposed whereby the retroviruses 
are classified according to their genomic organization and gene 
regulation . This new system divides the retroviruses into 2 main groups, 
the Classic retroviruses, which will include the family Oncovirinae, and the 
Complex retroviruses, which will include all retroviruses without 
oncogenes but with extra regulatory genes (Cullen, 1991 ). 
1.3 Virion Structure 
I n common with the other retroviruses, HIV-I is a single positive-stranded RNA virus consisting of spherical particles slightly more than 
100 nanometers (nm) in diameter. By electronmicroscopy, the virions 
have the characteristics of a lentivirus, with a dense, cone-shaped protein 
core. This encases two identical genomic RNA molecules and viral 
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enzymes required for early steps of replication. The RNA molecules 
resemble eukaryotic messenger RNA (mRNA) because they contain a cap 
structure at the 5' end and a poly-adenylated sequence at the 3' end 
(Meissner and Coffin, 1992; Wong-Staal, 1990). The major structural 
proteins encasing the RNA are the p24 capsid protein and p17 matrix 
protein. 
The outermost layer of the virion (Fig. 1) consists of a lipid bilayer derived 
from the outer membrane of the host cell. This viral envelope contains 
numerous proteins of both viral and host-cell origin. Studding the outer 
membrane of the virus are morphological projections composed of the 
envelope glycoproteins, gp120 and gp41. Each stud comprises four 
molecules of gp120 non-covalently attached to four molecules of gp41 
which are embedded within the membrane (Pinter et al., 1989). These 
envelope proteins play a crucial role when HIV binds to and enters target 
cells (see chapter 1.4). 






Fig. 1 A schematic drawing of the structure of the HIV-I virion. 
12 
1.4 Genomic Organization 
I n general, the genomic size of HIV is about 9,8 kilobases (kb) with overlapping open reading frames (ORF) coding for several viral 
proteins. The HIV genome is a full-length viral mRNA which contains two 
long terminal repeat (L TR) elements, one at each end, along with three 
structural genes that are essential for virus replication, namely the gag, 
pol and env genes (Fig. 2) that code for the core, polymerase and 
envelope proteins respectively. 
HIV genome 
KbO 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 
Fig. 2 Genomic structure of HIV-I provirus (Adapted from Greene, 1993). 
The gag proteins are made as a single polypeptide chain, p55 which is 
cleaved late in virus maturation by a viral protease, giving rise to smaller 
proteins:- p24 and p17 which form the virion core; p15 which is RNA 
associated, and p6 and p2 which are found inside the core (Greene, 
1993). 
The pol precursor protein is post-translationally cleaved into products 
consisting of the reverse transcriptase, the protease and the integrase 
proteins. These enzymes occur in the precursor protein in the following 
order (amino-terminus to carboxy-terminus):- NH2, protease, reverse 
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transcriptase, integrase, COOH (Wong-Staal , 1990; Meissner and Coffin, 
1992). 
The envelope proteins, gp120 and gp41 are made as a single large 
polypeptide, gp160. This envelope protein is transported to the cell 
surface where it is cleaved by cellular proteases. The amino-terminal 
portion .of the protein is located entirely exterior to the cell membrane 
(gp120) and is non-covalently associated with the carboxy-terminus 
(gp41) that is anchored to the viral membrane. The association of the 
envelope proteins with the core occurs as the virus buds from the cell 
surface (Haseltine, 1990; Wong-Staal , 1990; Gallaher et al. , 1995). 
In addition to these structural genetic elements, HIV-I contains at least six 
accessory genes: tat, rev, nef, vif, vpr and vpu. Three of these are viral 
regulatory proteins: tat, rev and nef, with tat being a transactivating 
protein that, along with certain cellular proteins, interacts with an RNA 
loop structure formed in the 3' portion of the viral L TR called TAR (tat 
responsive region), and upregulates HIV replication . The viral regulatory 
protein, rev (regulator of viral protein expression), interacts with a cis-
acting RNA loop structure called the rev responsive element, located in 
the viral envelope mRNA. This interaction involves cellular proteins and 
multimers of the rev protein and permits unspliced mRNA to enter the 
cytoplasm from the nucleus and give rise to full-length viral proteins 
needed for progeny production. Thus, tat and rev are RNA-binding 
proteins that interact with cellular factors for optimal activity. The third 
protein, nef (negative factor) appears to have a variety of potential 
function_s initially thought to include down-regulations of viral expression 
(Greene, 1991 ; Wong-Staal , 1990), although more recent experiments 
have cast doubt on this. It appears that the nef protein may somehow 
modify the cell to provide a more appropriate environment for viral 
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maturation, and that production of net protein is required for the 
development of AIDS (Greene, 1993). 
The other three genetic elements vif, vpr and vpu are accessory proteins 
of which vif is presumably involved in the infectivity of free virus; vpr 
protein is found in the virion but the function is unknown and vpu protein is 
found in the cell membrane and may be required for optimal 
assembly/packaging of virions and the promotion of extracellular release 
of viral particles. Thus, all three seem to be significant in HIV 
pathogenesis (Myers et al., 1992; Wong-Staal , 1990; Greene, 1993). 
1.5 · Life Cycle of the Virus 
0 nee an HIV virion has entered a cell , a complex sequence of events follows which, if completed, leads to the budding of new 
virus particles from the infected cells. The replication cycle of HIV (Fig. 
3) includes the following steps: (1) Attachment and penetration, (2) 
Reverse transcription and integration, (3) Transcription and translation 
and ( 4) Assembly and release of progeny virions. 
1.5.1 Attachment and penetration 
Virus infection requires interaction of the viral envelope glycoprotein 
complex with the CD4 molecule, which serves as a high-affinity receptor. 
The CD4 molecule is a surface glycoprotein whose physiological function 
is to bind class II major histocompatibility (MHC) molecules on the surface 
of antigen-presenting cells. It is present on a variety of hematopoietic 
cells, including T lymphocytes, macrophages, and dendritic cells. Entry 
occurs via fusion of the viral and cellular membranes. This is triggered by 
a conformational change within the envelope glycoprotein complex that 
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occurs as a result of CD4 binding (Putney, 1992). A highly hydrophobic 
region located at the N-terminus of the membrane-bound gp41 molecule, 
called the fusion peptide, is believed to be "activated" and to mediate 
fusion of viral and cellular membranes. The subsequent internalization 
and uncoating processes are still poorly understood (Dalgleish et al., 
1984; Klatzmann et al., 1984). 
Fig. 3 Diagrammatic representation of the life cycle of HIV-I. 
Recently the possibility that infection with HIV might also start with 
invasion of intact epithelia has been considered. This possibility was 
ignored in the past, because epithelial cells do not express CD4, the 
principal cell surface receptor for HIV. Several reports have, however, 
concluded that HIV can infect co· cells, including epithelia (Adachi et al., 
1987; Zachar et al. , 1991 ). Evidence has also been presented that in 
situ hybridization can be used to detect HIV-infected epithelial cells in the 
gut of an AIDS patient (Nelson et al., 1988). Several theories have been 
put forward to explain how HIV particles could infect intact epithelia and 
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these include: 1) infection mediated by receptors other than CD4; 2) 
uptake by non-specific phagocytosis, followed by escape from the 
phagocytic pathway; and 3) uptake by specialized cells of the immune 
system that are scattered among epithelial cells (Phillips et al. , 1994 ). 
Recent reports have also suggested that gp120 can bind to 
galactocerebroside (galactosyl-1-ceramide: GalC) and its derivatives. 
This suggests that GalC is a receptor for HIV infection in neural cells. 
GalC and its derivatives are important components of myelin and are 
expressed on the surface of ol igodendrocytes in humans and rats. The 
binding of gp120 to GalC could therefore disrupt myelin formation 
(Kimura-Kuroda et al. , 1994). 
After the virion has attached to the cell-surface receptor (a process 
sometimes called "docking") the cell membrane and the virus envelope 
fuse. As a result, the viral genomic RNA and accompanying proteins are 
released into the cel l's cytoplasm (Fox, 1991 ). 
1.5.2 Reverse transcription and 
integration 
Once the viral genome has entered the cell as a ribonucleocapsid, the 
viral RNA, still associated with core proteins, it undergoes reverse 
transcription (Bukrinsky et al. , 1992) using its own RNA-dependent DNA 
polymerase and RNase H enzymes. The reverse transcriptase enzyme 
traverses the chain of viral RNA and synthesizes a complementary DNA 
molecule (cDNA) corresponding to the viral RNA genome. A second DNA 
strand is synthesized, resulting in a double-stranded (ds) DNA molecule 
(Lori et al., 1992). During this process, portions of ends of the genomic 
RNA are copied twice, leading to a structure at each end of the DNA 
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called the L TR (the L TRs serve as initiation sites for the translation of 
enzymes used later in the life cycle). The reverse transcription process is 
not particularly efficient and can result in a mutation approximately every 
two-thousand bases. The newly synthesized dsDNA is in circular form 
(Fox, 1991 ; Greene, 1991 ). 
These ds DNA copies of the viral RNA then migrate to the nucleus, where, 
as circular but non-covalently bound molecules, they are able to integrate 
into the cell chromosome. In the integrated state, viral genetic material is 
called the provirus. Integration appears to occur at random sites, but is 
thought ·to be an essential process for the production of progeny virions. 
There is speculation that HIV-I can be produced without integration 
(Greene, 1991 ; Fox, 1991) since this phenomenon has been described 
for the visna lentivirus, although it has not been confirmed (Harris, 1984). 
Integration is catalysed by integrase, a virus-coded enzyme, and involves 
joining the ends of each L TR to cut ends of cellular DNA When 
unintegrated, the viral DNA is unstable in the cells and decays after a few 
days. Recent observations on the early events in viral infection have 
revealed that HIV undergoes integration and replication in permissive 
activated T cells, within 24 hours (Kim et al. , 1990). In macrophages, the 
process is similar but progeny production appears to occur after 48 hours 
(Munis et al., 1992). 
1.5.3 Transcription and translation 
After the provirus has become established in the host cell's chromosome 
as a new set of genes, two phases of infection take place. The first 
represents the latent phase of the infection in that the new genes for HIV 
are inactive, with no viral RNA or proteins being expressed. A reservoir of 
latently infected cells in the host can be a common phenomenon in HIV 
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infection (Schnittman et al., 1989). Several hypotheses have been 
presented to explain the mechanism of cellular latency with HIV. This 
latency could be caused by methylation of certain portions of the 
integrated viral L TR needed for the induction of the replicative process, or 
by methylation of extrachromasomal viral DNA sequences (Bednarik et al., 
1987). It could also result from an inactivation of the tat or rev gene 
(Drysdale and Pavlakis, 1991 ). The integrated virus can be activated by a 
variety of stimuli such as antigenic/cytokine stimulation or co-infection with 
other viruses. The outcome is a high level of transactivation, resulting in a 
burst of virus production and rapid death of the cell. As previously 
mentioned, there are at least two HIV genes (tat and rev) that function as 
transactivating factors, which causes an increase in the expression of viral 
RNA and proteins. During this second productive phase, viral DNA is 
transcribed into messenger RNA by host cell RNA polymerase II. This 
process cannot start until the polymerase is activated by various 
molecular switches located in the L TRs. 
Two distinct phases of transcription follow. In the early phase, which lasts 
roughly 24 hours, RNA transcripts produced in the cell's nucleus are 
snipped into multiple copies of shorter sequences by cellular splicing 
enzymes. These early-phase short transcripts encode only the viral 
regulatory proteins, the structural genes are not transcribed. In the late 
phase, two new size classes of RNA - long (unspliced) transcripts and 
medium-length (singly spliced) transcripts - move out of the nucleus and 
into the cytoplasm. These longer transcripts encode HIV structural and 
enzymatic proteins. 
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1.5.4 Assembly and release of 
• • progeny v1r1ons 
Once the long and medium-length transcripts reach the cytoplasm, the 
components for new virions are synthesized and transported to the site of 
assembly at the cell membrane. Assembly of progeny virions occurs at 
the cell surface. Gag and gag/pol precursor molecules are transported to 
the cell membrane via a cytoplasmic pathway, whereas envelope 
glycopr6teins use the secretory pathway (Bclcgnesi et al., 1978). Virus 
assembly is orchestrated by the gag polyprotein, which interacts with the 
gag/pol precursor, the accessory proteins vpx and vpr, and the genomic 
RNA, thereby facilitating their incorporation into virions. Selective 
incorporation of viral envelope glycoproteins is also bel ieved to involve 
gag elements although these mechanisms are less well understood (Yu et 
a/. , 1992). After release from the cell surface, gag and gag/pol 
polyproteins are cleaved within the virus particle by viral protease. This 
step, which has a morphological correlate in the condensation of the 
particle core, is absolutely required for viral infectivity (Kohl et al., 1988). 
1.6 Genome Variability 
A characteristic of HIV is the very high degree of variability exhibited by some portions of the genome, particularly in selected segments 
of the env gene. This results in considerable antigenic heterogeneity 
between different isolates of the virus. Much has been learned about the 
molecular characteristics, mechanisms of gene expression and genomic 
complexity since the discovery of HIV-I and HIV-II. Isolates of both virus 
types have been characterized, their genomes cloned and their nucleotide 
sequences determined (Myers, 1992) and it has been shown that genetic 
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variation is a hallmark of these viruses. This variation could have an 
impact on many aspects of the biology of HIV, including (a) tissue and 
target cell specificity, (b) clinical spectrum of pathogenesis and (c) 
geographic and temporal distribution of the virus, and it also has bearing 
on the prospects of developing a broadly cross-reactive vaccine. This 
genotype diversity accumulates at a rate of approximately one nucleotide 
substitution per genome per replication cycle and is responsible for the 
rapid generation of drug-resistant and immunological escape mutants in 
infected individuals (Larder et al., 1989; Phillips et al., 1991 ). No two HIV 
strains are alike, and even within a single individual, HIV is present as 
quasi-species (a swarm of microvariants that are highly related, yet 
genetically distinct from each other) (Martins et al. , 1992; Milich, 1993; 
Howell et al., 1991 ). 
The first molecular description of HIV heterogeneity was based on 
Southern blot hybridization analyses of independent virus isolates that 
showed distinguishable restriction enzyme patterns (Shaw et al. , 1984). 
Heteroduplex analysis of two divergent HIV-I viruses, annealing under 
conditions of increasing stringency, revealed substitution loops that first 
appeared in the envelope region of the heteroduplexed molecules (Hahn 
et al., 1985). 
Subsequent nucleotide sequence comparisons confirmed that sequence 
differences among different viral genomes were not evenly distributed 
throughout. HIV genes that code for internal viral proteins (gag & pan 
showed relative stability from one isolate to the next, but the env gene 
displayed frequent mutations that lead to variation of its glycoprotein 
products. Not only is the degree of divergence different among these env 
genes, but the type of nucleotide and amino acid changes are very 
different. Nucleotide sequence changes in the gag and pol gene are due 
to point mutations, whereas changes in the env gene are due to deletions, 
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insertions and duplications. Furthermore, the majority of changes in gag 
and pol. are in the third base position of the codon, resulting in silent 
mutations. In contrast, more than half of the single nucleotide changes in 
env occur in the first or second base positions, resulting in amino acid 
changes. 
Despite the considerable variability of the HIV-I envelope proteins they do 
contain regions or structural features that are highly conserved. Within 
gp120 there are several highly conserved regions (C1-C4) that are 
interspersed with regions of high variability (V1-V5) (Fig. 4) . These 
hypervariable regions permit the virus to present new antigenic 
configurations to the host. The V3 loop is the third variable region of the 
env polyprotein. It comprises a 35 amino acid stretch of conserved length, 
linked to two cysteine residues by a disulphide bond, and plays a role in 
the cell-virion fusion process following receptor-binding. Type-specific 
antibodies to the V3 loop have been shown to neutralize this process 
(Putney and McKeating, 1990). Thus, the V3 loop has been a natural 
target of interest in vaccines and passive immunotherapy and V3 
sequences are the most numerous of the HIV gene sequences in the 
database. To date, HIV-I isolates can be divergent in as much as 13% of 
their genomes and in 30% of their extracellular envelope proteins (Murphy 
et al., 1993; Ait-Khaled and Emery, 1993; Gretz et al., 1994; Van den 
Haesevelde et al., 1994). 
Assuming a constant rate of evolution of HIV-I which is comparable to that 
of other retroviruses, it has been estimated that HIV-I entered the human 










Fig. 4 A computer derived model of the surface glycoprotein, gp120, of HIV-1 with 
double lines showing the proposed disulfide bonds (Gallaher et al., 1995). The V3 loop is 
depicted in the upper-left corner. 
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1.6.1 Subtypes of HIV-I · 
Myers and his co-workers first attempted to describe HIV subtypes using 
the env ·sequences. As mentioned before, env is the most variable of the 
larger genes, and it is thus expected that env sequences give the most 
phylogenetic information for closely related viruses (Myers, 1992). When 
the first isolates from Europe and North America (Ratner et al., 1985; 
Wain-Hobson et al. , 1985) were compared to the first isolates from central 
Africa, it became apparent that the African isolates were far more diverse 
at sequence level. At phylogenetic level , all European and North 
American isolates formed a discrete cluster within the radius of the African 
viruses. This, along with other epidemiological data, strongly indicated 
that the common ancestor of HIV-I originated in central Africa, and that 
one of several lineages later spread to North America (Myers et al. , 
1988). 
Through the impact of viral sequencing of many different isolates from 
different parts of the world , at least five genetic clusters of HIV-I could be 
identified by 1992. The North American cluster had been named subtype 
B. This group now contains isolates from most continents, which probably 
reflects the radiation of HIV-I to those locations from North America. The 
African isolates are clustered in a group, termed subtype D. All the 
viruses so far known to fall within this group came from Central Africa. 
Viruses · now placed in subtype A are from Western and Central Africa. 
Subtype C includes isolates from South Africa, India and Zambia, while 
members of subtype E are prevalent in Thailand. The more recently 
described cluster, termed subtype F, included viruses from Brazil , 
Romania and Zaire. Subtypes B and D appear to be somewhat more 
closely related to each other than to the other lineages. This may indicate 
that subtype B viruses, which initially brought AIDS to prominence in North 
America were, derived from a virus in Central Africa where the D subtype 
24 
is now found (Sharp et al., 1994). HIV-I is currently divided into two major 
groups, group Mand group 0 . 
While Myers continued his study, Louwagie and co-workers (1993) 
independently examined the diversity among HIV-I isolates from 15 
different countries on four continents by using a different genomic region, 
the gag gene. The phylogenetic trees based on the gag and env 
sequences were very similar for the majority of isolates but there were 
some interesting differences e.g. one of the earliest characterized African 
isolates has an env sequence similar to subtype D viruses, but in the gag 
tree it falls within subtype A Another example concerns more recently 
characterized viruses from Thailand that fall within subtype E on the basis 
of their env sequences, but cluster with subtype A on the basis of gag 
sequences. It is speculated that this probably reflects recombinations 
(Sharp et al., 1994). Meanwhile, two additional subtypes have been 
assigned on the basis of gag sequences, namely subtypes G and H, which 
each include viruses from Zaire and Gabon. This clearly indicates the 
need for co-ordinates of subtype assignments as well as generally 
accepted classification criteria. 
Recently two HIV-I isolates from Cameroon were sequenced and 
compared to the different subtypes. Both isolates showed an 
extraordinarily high level of diversity when compared to the subtypes A - H 
of group M, and have been termed subtype O (group 0) to indicate their 
outgroup position (Gurtler et al., 1994). It was suggested, based on these 
findings, that subtype O may represent a second major HIV-I cluster which 
differs from the first in it's evolutionary history, but probably also consists 
of num~rous distinct sequence subtypes. Compared to reference HIV-I 
strains, the percentage homology of the gag, pol, and env gene products 
of HIV-I subtype O isolates is in the region of 68%, 74%, and 50% 
respectively, while >90% homology has been found between O isolates. 
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Commercial manufacturers have also been advised to modify their HIV 
test kits to improve HIV-I subtype O sensitivity. 
1.6.2 Genomic HIV-I variation in 
mother and child after transmission 
A high degree of genetic variability (see section 1.5) in HIV-I can be found 
within infected individuals. Variations arise during retroviral replication by 
error-prone reverse transcription. The complex mixture of variants (quasi-
. species) in an infected individual may be · the result of immunologic 
pressure for change, alterations in cell tropism or replication efficiency 
among the variants. Studies of the relationship between virus populations 
in HIV-I .infected mothers and their infants indicate the role of selection in 
perinatal HIV-I transmission (Wolinski et al., 1992; Mulder-Kampinga et 
al. , 1993; Scarlatti et al. , 1993). The virus population observed in the 
child at birth represents a variant in the mother at the actual time of 
transmission earlier in pregnancy. 
Wolinski and his colleagues (1992) looked at viruses obtained from three 
mothers and their infants, who ranged in age from two to four months. 
They sequenced the V3 region containing the immune-dominant loop and 
the V4 - V5 regions that encompass a portion of the CD4-binding domain 
of the viral envelope gene. As expected, the virus transmitted from a 
mother to her infant was clearly more related to her own virus than to the 
virus in either of the unrelated infants. The V3 region nucleotide 
sequences varied between 0,59% and 6, 1 % for related pairs and 10% -
17,3% for unrelated pairs. An important observation was that although 
each mother clearly had numerous viral variants in her body, only a 
subset of these variants were detected in her infant. In all three cases, 
the virus found in the infants was lacking a site found in most (but not all) 
26 
of the mother's viruses where a sugar molecule attaches to a portion of 
the V3 region. The significance of the missing sugar is still unclear, but 
the occurrence is so rare that it suggests that some selection is occurring. 
In addition, although there was clear evidence of viral variants in the 
infants, the degree of variability in the infant V3 and V4 - VS was far less 
than in the mother. It was concluded from this study that only a few of the 
possible variants were passed on from mother to child. 
Mulder-Kampinga and co-workers (1993) examined the genetic 
relationship between the virus population in an HIV-I infected mother and 
her infant, and observed a continuous change in sequence populations in 
the mother. During pregnancy, a nearly complete replacement was 
detected at position 308 of the V3 loop, from a praline to a histidine amino 
acid. Replacements of amino acids at position 308 have been shown to 
influence the antigenic properties of peptides mimicking the central region 
of the V3 loop (Wolfe et al. , 1991 ). In the child, only a praline was 
observed in that position during the first weeks of life and remained 
unchanged until the age of 9 months. This may result in an antigenic 
distinction between the virus population in the mother and child at time of 
delivery . . The sequence population in the child was highly homogenous 
(up until the age of 6 weeks) . It was characterized by one particular 
sequence which appeared to represent the variant that had initiated the 
infection in the child as it was the major variant in the cord blood, although 
only a minor variant in the maternal sample collected during delivery. This 
excluded the possibility that viral RNA in the cord blood was due to 
contamination with maternal blood during delivery and suggests intra-
uterine acquired infection. The observed limited variation within the first 6 
weeks could mean that the infant had become infected shortly before 
birth. However, limited variation could also be due to a lower level of 
replication of HIV-I in utero compared to the period after birth, or to a 
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lower immune pressure in the unborn child and neonate (Borkowsky et al. , 
1992). 
The implication is that some HIV strains are more infectious than others in 
mother to child transmission. If this proves to be true, then future efforts to 
prevent ·perinatal infection can be targetted more accurately. 
1. 7 Transmission 
E pidemiological studies conducted during 1981 and 1982 first indicated that the major routes of transmission of HIV-I were 
intimate sexual contact and contaminated blood (Jaffe et al. , 1983). The 
syndrome (AIDS) was initially described in homosexual or bisexual men 
(Gottlieb et al. , 1981 and Siegel et al. , 1981) and intravenous drug users, 
but it's occurrence as a result of heterosexual activity was soon 
recognized as well (Harris et al. , 1983). Moreover, it became evident that 
transfusion recipients and haemophiliacs could contract the illness from 
blood or blood products, and that mothers could transfer the causative 
agent to newborn infants (Ammann et al. , 1983). These three principal 
means of transmission - blood, sexual contact and mother-to-child - have 
not changed. The different groups that are at risk for HIV transmission will 
be discussed. 
1. 7.1 Risk Groups 
1. 7 .1.1 Homosexual men 
The concept initiated by western observers that AIDS is primarily a 
disease of homosexual men, is rapidly becoming obsolete. The most 
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prominent risk factors for acquisition of infection in homosexual men are a 
high number of sexual partners and participation in sexual practices 
(mainly receptive anal intercourse) that increases the risk of transmission 
due to damage of the anorectal mucosa which allows the virus to enter the 
bloodstream. Direct infection of the epithelial cells of the rectum can also 
occur (Meissner and Coffin, 1992). In the United States of America (USA), 
the incidence of new AIDS cases since the early 1980's has reflected 
changes in the sexual behaviour of gay men, such as decreased numbers 
of sexual partners and protected anal intercourse. In San Francisco, the 
seroconversion rate in homosexual men has peaked at about 6000 new 
HIV infections per year in 1982 or about 10%-15% of the gay male 
population per year. The rate then declined sharply to 3%-5% by 1984. 
Since then it has continued to fall, but more slowly, to about 1 % per year 
in 1988 (Sachetti and Moss, 1989). The majority of HIV-infected gay men 
in San Francisco were infected in the 1979-1983 period. Using the full 
pattern of seroconversion and incidence data for San Francisco, the 
average incubation period for clinical AIDS can be estimated to be 9.8 
years from infection (Sachetti and Moss, 1989). The same flattening in 
the incidence of observed AIDS cases in gay men has been reported in 
New York, with reported AIDS cases peaking in 1987 and declining 
slightly since then. A similar trend has also occurred in Los Angeles. 
Thus, in the three major epidemic cities in America, AIDS cases in 
homosexual men seem to have peaked, and after a period of approximate 
stability, they can be expected to decline over the next few years. 
The decline in the gay male HIV epidemic can be seen as a triumph for 
health education. For homosexual men questions of prevention are now 
giving way to questions of early intervention and management of early HIV 
disease as the central issues in the medical politics of AIDS. 
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1. 7.1.2 Intravenous drug users 
As the AIDS epidemic has continued, new AIDS cases in the second major 
risk group, intravenous drug users (IVDU), has risen, both in the USA and 
in western Europe. In the USA, IVDU cases rose from 14% of new AIDS 
cases in 1987 to 20% in 1988 (AIDS update, 1989). AIDS is still believed 
to be under-reported in IVDUs as some clinical manifestations of HIV 
infection common in drug users are not regarded as reportable AIDS. It is 
estimated that AIDS in drug users is under-reported by as much as 50% 
(Stoneburner et al., 1988). The clinical pattern of AIDS in drug users is 
different from that in homosexual men, thus clinical experience based on 
homosexual men may be inappropriate in the case of IVDUs (Des Jarlis et 
al. , 1988). Drug users in the USA are largely impoverished blacks or 
hispanic, and in Europe they are predominantly unemployed youth. In 
both cases IVDUs are from social strata which are out of contact with the 
health care system and unresponsive to health education. Thus the 
prospects for long-term prevention in this group are less encouraging. 
Transmission among drug users occurs through sharing of contaminated 
needles and syringes that contain a residue of blood (including infected 
white blood cells). Sero-positivity among drug users correlates with 
frequency of injection, needle sharing and demographic factors (Meissner 
and Coffin, 1992). 
1. 7.1.3 Transmission by blood tranfusion 
In the years before screening of blood, transfusion recipients and 
haemophiliacs could be infected by HIV present in blood and blood 
products such as factors VI II and IX. The screening of blood for anti-HIV 
antibodies has now reduced the risk of infection by transfusion. Since 
1985, HIV transmission by blood transfusion has been exceedingly rare 
although more than 12 000 individuals may have been infected by this 
route before that time (Meissner and Coffin, 1992). 
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The potential risk of infection to transfusion recipients depends on the 
virus load, which appears to be greatest when an infected individual (as 
donor) advances to disease. In one study, the chance of infection was 
reported to be substantially increased if the donor developed AIDS within 
two to three years after donation. Other studies have also shown that 
individuals receiving blood from donors who subsequently developed 
AIDS within 29 months had a greater chance of progressing to disease 
than those recipients of infected blood from donors who became 
symptomatic after this period (Ward et al., 1989). In haemophiliacs, the 
transmission of HIV could be caused only by free virus and was 
associated with the receipt of many vials of unheated clotting factors 
thereby increasing the chance that an infectious HIV particle was present 
in the lyophilized product (Goedert et al., 1989). Nevertheless, evidence 
of viral nucleic acid in old clotting-factor preparations has been 
substantiated by subsequent analysis using the polymerase chain reaction 
(PCR) (Semple et al. , 1991 ). Attempts to isolate infectious HIV from these 
preparations have thus far been unsuccessful. 
At the present time, factor VIII concentrates are unlikely to contain HIV 
because plasma products are treated with heat or chemicals to inactivate 
contaminating viruses. Factors VIII and IX are heated to 60°C either 
before or after lyophilization (Levy et al., 1985). 
1. 7 .1.4 Heterosexual transmission 
Studies indicate that spread by heterosexual activity is now responsible 
for the large majority of infections worldwide (Stoneburner et al. , 1990). 
Seventeen percent (17%) of individuals who acquire HIV by heterosexual 
contacts are male and 83% are female (Meissner and Coffin, 1992). 
Transmission occurs more readily from infected males to female contacts 
than vice versa, but it does take place in both directions. However, this 
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apparent bias should be viewed with caution since very few female-ta-
male studies have been published mainly because most index cases in 
the Western epidemic are male. In a review of 16 cohort studies 
(Haverkos and Baltjes, 1992), male-to-female and female-to-male 
transmission rates were compared. Transmission rates varied widely 
among the studies, with higher rates generally observed in couples 
recruited in Africa or Haiti (female-to-male transmission 58%; male-to-
female transmission 53%) than couples recruited in Europe or the USA 
(female-to-male transmission 15%; male-to-female transmission 28%). 
Heterosexual transmission of HIV is more common in certain countries. In 
Western countries, as a whole, heterosexual transmission is relatively rare 
in the general population because transmission probabilities are low, 
ulcerative sexually transmitted diseases (STDs) are rare and the average 
number of sexual partners per year is close to one (Skegg, 1989). 
Regardless of differences in rates of transmission in the various groups, 
the prevention of major heterosexual epidemics must focus on all young 
sexually active individuals. 
The risk of !ransmission through oral sex during homosexual and 
heterosexual contacts is another controversial field. Several case reports 
suggest that transmission can occur via this route. During the follow-up 
(Detels et al., 1989) of initially seronegative homosexual men in a highly 
infected USA population, two seroconversions occurred among men 
practising fellatio but not anal sex, leading to a seroconversion rate of 0,6 
per 1000 persons followed for 1 year. 
Although sex with condoms should not be considered as "safe sex", it is 
definitely considered as "safer sex". During a prospective study of 
heterosexual couples in which one partner was HIV-negative, no 
seroconversion was found to occur among 100 partners who used 
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condoms during each episode of vaginal or anal intercourse, while 10 
seroconversions occurred among 104 partners who did not systematically 
use condoms (De Vincenzi and Ancelle-Park, 1991 ). 
1. 7.1.5 Vertical transmission 
Infection of children with HIV-I has been recognized since 1983. The 
number of HIV-I infected children has increased in recent years in parallel 
with the increase in HIV-I infected women of childbearing age (Soeiro et 
al., 1992). Although children have been infected by the inadvertent use of 
HIV-I contaminated blood or blood products, the overwhelming majority of 
childhood HIV-I infections, in the USA is believed to be the result of pre-
or perinatal transmission from infected women (Fallon et al. , 1989). 
Studies have shown that the frequency of materno-fetal transmission of 
HIV-I varies from 12,9% to 65% (Soeiro et al. , 1992). In general, a higher 
frequency of mother-to-child transmission was observed in Africa (Dunn et 
al., 1992; Lallemant et al., 1994 ). The reasons for this apparently higher 
transmission rate in Africa are not clear, but it appears that two factors 
may be implicated. The first is advanced immunodeficiency in the mother, 
which increases the risk for transmission. It is likely that the higher viral 
load associated with immune depletion and with early infection is a major 
determinant of the degree of infectiousness, whether transmission is 
sexual or vertical. A second factor contributing to materno-fetal 
transmission is breast feeding (see chapter 1. 7.1.5.3). Although mother-
to-child · transmission of HIV-II undoubtedly can occur, it seems less 
common and a much lower rate of transmission is observed than for HIV-I 
(Paulsen et al. , 1989). 
There are three basic routes by which HIV-I can pass from mother to child: 
(1) transplacental (2) during delivery, and (3) postpartum (mainly through 
breast milk) (Bardequez and Johnson, 1994; Borkowsky and Krasinski , 
1992; Dunn et al. , 1992; Sprecher et al., 1986; Maury et al. , 1989). 
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1. 7 .1.5.1 Transplacental route 
The role of the placenta in maternal-fetal transmission is poorly 
understood. The placental cells which are most likely to be susceptible to 
infection by the virus are the trophoblasts and the macrophages (Hofbauer 
cells) (Lewis et al., 1990). Potential routes whereby HIV gains access to 
the fetal circulation include direct infection of the syncytio-trophoblast 
layer, infection of the Hofbauer cells or invasion through the villous stroma 
into the fetal circulation. It is possible that free virus or HIV-laden 
maternal lymphocytes could be transferred to the fetus. In vitro studies 
suggest that the placenta could become infected with HIV by the 
interaction of virus-infected maternal lymphocytes with synctio-
trophoblasts in direct contact with maternal blood in the intervillous space, 
while trophoblast cells exposed to cell-free HIV for up to 24 hours showed 
no evidence of virus uptake or replication (Douglas et al., 1991 ). 
In an attempt to localize HIV-positive cells in the placenta, 
immunoperoxidase techniques were used (Martin et al. , 1991 ). HIV p24 
antigen was detected in villous Hofbauer cells, decidual macrophages, 
intermediate trophoblast and villous endothelium in four of nine placentas 
from HIV-infected women. Virological and histological evidence of HIV 
replication was found in about 25% of placentas obtained at term from 
HIV-infected women, but the presence of infection in the placentas did not 
correlate with infant infection status. Thus the role of placental 
macrophages in mother-to-child transmission of HIV remains unclear. 
Theoretically, the macrophages can either protect the fetus from HIV 
infection, or serve to breach the placental barrier, at times acting as an 
effective reservoir of HIV-infection. Isolated case reports of early HIV 
disease in neonates give supporting evidence for transplancental 
transmission. Beach and co-workers (1991) reported the diagnosis of 
Pneumocystis carinii pneumonia in a 19 day old infant, implicating 
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transplancental infection causing immune compromise in the newborn. 
Evidence also exists for the role of the placenta in preventing transmission 
of HIV. Borkowsky and co-worker (1992) found a significant increase in 
the maternal-fetal transmission rate (80% vs 20%) of HIV in women who 
have experienced untreated syphillis during their pregnancies. Since 
Treponema pallidum is known to cause a placentitis, it was suggested that 
the placenta is fairly effective in preventing HIV transmission in the 
absence of a secondary infection. Cytomegalovirus (CMV) infection was 
monitored as a control pathogen, and was not recovered more often from 
women who transmitted HIV to their offspring than from those who did not. 
This suggests that the placenta probably constitutes an effective barrier to 
viral transmission unless disrupted by processes such as syphillis. 
Prevention of such breaks in the trophoblast barrier and efforts to 
stimulate maternal and newborn HIV-specific immunity may further 
decrease the perinatal transmission rate. 
1. 7.1.5.2 lntrapartum (transmission during 
delivery) 
The large quantities of infectious blood and amniotic fluid present during 
delivery raises the possibility that, like hepatitis B, infection with HIV could 
occur around the time of delivery. HIV has been isolated from vaginal and 
cervical secretions from HIV-positive women (Vogt et al. , 1986; Henin et 
al. , 1993; Wofsy et al., 1986). 
In 1991, Goedert and co-workers investigated HIV infection rates in twins 
born to HIV-positive mothers. They showed a higher risk of HIV infection 
in first-born twins, with 25% of firstborns being infected compared to 8% of 
second-born twins. The data suggests that it is more likely for HIV 
infection to occur during the passage of the first twin through the birth 
canal. The European Collaborative Study Group ( 1994) assessed 1254 
HIV-infected mothers and their children and the effects of different modes 
of delivery on transmission risk. Caesarean section was estimated to 
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halve the rate of transmission since those women who had caesarean 
sections were more advanced in their disease progression, the protective 
effect of caesarean section may be underestimated. These findings are 
important as they provide insight into the timing of infection from mother-
to-child , as well as possible ways of preventing infection in the newborn. 
1. 7 .1.5.3 Postpartum (mainly breast feeding) 
The discovery of HIV-I in colostrum and breast milk (Thiry et al., 1985; 
Dunn et al., 1992; Hira et al., 1990) raised the concern that postnatal 
transmission could occur during breast feeding . However, it was not 
initially considered to be a significant route of transmission because of the 
inhospitable environment of the infant digestive tract and the presence of 
anti-HIV antibodies in breast milk. Nevertheless, transmission via breast 
milk was increasingly documented all over the world (Hira et al., 1990; 
Van de Perre, 1991; Ziegler et al., 1985). The European Collaborative 
Study Group (1992) analysed the rate of vertical transmission, based on 
721 children born to 701 mothers and found that the ratio of transmission 
was two-fold higher in breast-fed versus never-breast-fed children, despite 
the short (4 weeks) median duration of breast feeding. The balance of 
evidence was therefore in favour of HIV transmission through breast milk. 
If infection of newborn babies occurs through ingestion of HIV-I , then there 
is an urgency to learn more about mucosa! transmission. The question 
arises as to whether infection is initiated by cell-free virus or by HIV-1-
infected cells in breast milk? Cell-free virus could penetrate the mucosal 
lining of the gastrointestinal tract of infants, either by infecting CD4+ 
monocytes, lymphocytes or Langerhans cells in the gut or by direct entry 
into the bloodstream via mucosal breaches. If HIV-I infection occurs only 
through cell-associated virus, then colostral milk, which is richer in 
macrophages than later milk, would probably be more infectious. 
Transmission might be reduced by limiting breast feeding until after 
colostrum and early milk have been expressed and discarded (Van de 
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Perre et al. , 1993). The inhibitory qualities of human breast milk have 
recently gained considerable attention as a potential mechanism for the 
prevention of HIV infection. It was suggested that anti-HIV-I lgM in breast 
milk could be protective against postnatal transmission of the virus (Van 
de Perre et al. , 1993). In the developed world where resources are 
available, it might be possible to identify those HIV-I-infected women who 
are more likely to infect their infants through breast feeding, namely those 
with clinical AIDS, low CD4 counts at delivery or the presence of PCR-
positive cells in early milk, together with the absence of HIV-I-specific lgM. 
Individual advice regarding the advisability of breast feeding could then be 
offerred. 
Thus, factors such as the inhibitory properties of breast milk, the 
development of an effective local immune response, the stage of clinical 
disease of the index case and/or the virus load (either as cell-free or cell-
associated virus) appear to be important determinants of HIV 
transmission. 
1.8 Disease In Infants 
P aediatric AIDS is usually acquired perinatally from an HIV-infected mother. Most infected infants have no manifestations of the 
disease at birth, but 50% of HIV-infected children are symptomatic in the 
first 12 months of life and 78% have clinical disease by 2 years of age 
(Auger et al., 1988, Blanche et al. , 1994 ). Most children with symptomatic 
HIV infection have several of the following symptoms, which are presented 
in descending order of frequency: Lymphadenopathy, 
hepatosplenomegaly, splenomegaly, poor growth, recurrent diarrhoea, 
more than 10% weight loss and, more rarely, parotitis. The most 
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debilitating of these is significant weight loss, or the "wasting syndrome", 
which may be life-threatening. 
The majority of neurological manifestations of paediatric AIDS are 
believed to be the result of direct infection of the brain by HIV (Shaw et al., 
1985). A characteristic encephalopathy occurs that consists of 
developmental delay or deterioration of motor milestones, intellectual 
ability, or behaviour. The neurological disease may be static or slowly or 
rapidly progressive. The majority of symptomatic HIV-infected children 
have some degree of neurological involvement of which encephalopathy 
may be the dominant manifestation. 
Lymphocytic interstitial pneumonitts (LIP) is a chronic interstitial 
pneumo'nia that results from diffuse infiltration of the alveolar septa and 
peribronchiolar areas by lymphocytes and plasma cells. The exact role of 
Epstein-Barr virus (EBV) in LIP is not clear, but it is likely that an 
interaction between HIV and EBV-infected B cells in the lungs may 
account for the pathogenesis of this condition. LIP occurs in 
approximately 40% of children with AIDS, but is quite rare in adults. The 
mean survival time of children diagnosed with LIP is 91 months (Turner et 
al. , 1993). 
As in adults, Pneumocystis carinii pneumonia (PCP) is the most common 
opportunistic infection in children with AIDS, occuring most frequently in 
the first 6 months of life (Simmonds et al. , 1993). The high mortality 
associated with PCP is not diminished by intensive care or high-dose 
trimethoprim-sulphamethoxazole (TMP-SMX) and steroid therapy. Other 
important opportunistic infections include disseminated Mycobacterium 
avium complex infection, Candida esophagitis or pneumonia, 
disseminated cytomegalovirus or herpes simplex virus infections and 
intestinal cryptosporidiosis. 
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One of the more common problems associated with HIV infection in 
children is recurrent bacterial infections, such as sepsis, meningitis, 
pneumonia and soft tissue abscesses. Encapsulated organisms, such as 
Haemophilus influenzae and Streptococcus pneumoniae are most 
commonly observed. Recurrent bacterial infections occur in 
approximately 30% of children with AIDS, whereas similar repeated 
infections are considerably rarer in adults. Anti-bacterial immunizations 
are recommended for all HIV-infected children and should be given early 
in the course of the disease, since their efficacy is reduced in children with 
severe immune suppression (National Institute of Child Health and Human 
Development Intravenous lmmunoglobulin Study Group, 1991 ). 
The management of HIV-infected children will continue to evolve 
particularly with the increased use of PCP prophylaxis and the availability 
of anti-retroviral therapy. The challenge for the future is to prevent 
perinatal transmission, develop new and better therapies for opportunistic 
infections and HIV-associated complications and to improve outcome and 
prognosis. 
Recent ·studies (Boyer et al., 1994) have shown that zidovudine therapy 
can reduce HIV transmission from an HIV-infected pregnant woman to her 
baby by about two thirds. The analysis revealed a transmission rate of 
2,5% when both mothers and babies received zidovudine in comparison 
with a transmission rate of 8,3% among those receiving a placebo. 
Because the long-term consequences of zidovudine therapy are still 
unknown, the investigators plan to follow these infants for several years . 
They also plan to follow the women in the trial for 6 months after delivery. 
Even if these long-term studies indicate other mortality risks, the benefits 
of substantially reducing the risk of HIV transmission from infected women 
to their infants, will likely outweigh them. 
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1.9 Epidemiology 
1.9.1 Spread of HIV-I 
T he World Health Organization (WHO) has estimated that by mid-1993, over 13 million young people and adults would have become 
infected with HIV since the start of the pandemic, the majority through 
heterosexual intercourse, and that about 1 million children would have 
been infected perinatally. More than 8 million of the infections in adults 
have occurred in sub-Saharan Africa and over 1,5 million in North America 
and Western Europe, where the HIV pandemic is the oldest. Latin 
America and the Caribbean (1,5 million adult infections), North Africa and 
Middle East (75 000) and eastern Europe and central Asia (50 000) are 
showing a rise in HIV infections, with south and southeast Asia showing 
the steepest rises (over 1.5 million adult infections) (Merson, 1993). Up 
until the middle of 1993, over 2 million HIV infected adults have developed 
AIDS and most of them had died. 
Currently there are four patterns of epidemiology which have evolved and 
been described for HIV infection and AIDS. These patterns are based 
partly on time, risk factors and modes of transmission (Piot et al. , 1992). 
The four patterns are as follows: 
Pattern 1 - The extensive spread of HIV which began in the late 1970s or 
early 1980s. Most of these cases of AIDS occurred among homosexual 
and bisexual males and intravenous drug users. Heterosexual 
transmission is responsible for a small , but increasing, proportion of the 
total. This pattern is observed in the USA, most European countries and 
some Latin American countries. 
Pattern 2 - Occurs mainly among heterosexuals. The male to female ratio 
is approximately one, and perinatal transmission is common. Most sub-
Saharan and Latin American countries conform to this pattern. 
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Pattern 3 - Asian, north African and Oceanic countries fall into this 
category. Most of the cases have been introduced into the countries from 
elsewhere and there is no predominant mode of transmission. 
Pattern 4 - This pattern occurs in countries where there was first a 
predominantly homosexual transmission, later becoming heterosexual, 
with very few intravenous drug abusers. Some countries in the Caribbean 
basin fall into this group. 
A few countries in the developed world are showing trends that may 
change their pattern from 1 to 2 because of increased heterosexual 
transmission. In South Africa, patterns 1 and 2 are observed. 
1.9.2 AIDS in Africa 
1.9.2.1 Central African Region 
Cameroon, Congo, Central African Republic, Equatorial Guinea, Gabon, 
Zaire, Rwanda and Burundi comprise the Central African Region. These 
countries can be divided into 3 groups, A, B and C, based on HIV-I and 
HIV-II seroprevalence rates in each country. Group A countries (Zaire, 
Congo, Central African Republic, Rwanda and Burundi) are the most 
severely affected. The two countries (Group B) which appear to be 
moderately affected in the high risk urban populations are Gabon and 
some parts of the Republic of Cameroon. Equatorial Guinea (Group C), a 
country with very little data, appears to have minimal infection (Williams, 
1992). 
1.9.2.2 East African Region 
The nine countries which belong to the East Africa Reg ion are: Ethiopia, 
Djibouti , Somalia, Sudan, Kenya, Uganda, Tanzania, the Comores and the 
Seychelles. Here it is noteworthy that the seroprevalence rate is higher in 
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the southern portion of Sudan where there is ongoing civil strife. It is also 
in closer geographic proximity to Ethiopia, Uganda and Kenya, where up 
to 86% of urban prostitutes and barmaids have been shown to be HIV-I 
seropositive (Piot et al., 1987). 
1.9.2.3 Southern African Region 
Mozambique is the largest country in land mass in this region, but has one 
of the lowest published seroprevalence rates for HIV-I in southern Africa. 
This is in contrast to the relatively high prevalence rates for hepatitis B 
infection and liver cancer in that country. HIV-II, however, is not 
uncommon in Mozambique. Malawi, Zimbabwe and Angola appears to 
have moderate rates of infection while Zambia is the only severely 
affected country in southern Africa. In South Africa, the Department of 
Health reported more than 8500 confirmed AIDS cases by October 1995 
(Table 2). 
Table 2 Reported Al DS cases in South Africa as 
on 17 October 1995 (Department of Health, RSA, 
1995) 
AIDS in South Africa 
Reported AIDS cases as on 17 October 1995 
Number of AIDS cases reported by region 
Province 82 -86 87 88 89 90 91 92 93 94 95 Total 
Eastern Cape (EC) 4 10 32 69 146 255 19 536 
Western Cape (WC) 12 2 20 32 39 44 63 86 85 40 423 
Northern Cape (NC) 1 1 3 10 10 64 73 1 163 
KwaZulu-Natal (KN) 4 5 19 37 140 171 352 865 1912 625 4130 
Free State (FS) 1 2 4 9 8 38 45 60 421 322 910 
Gauteng (GT) 29 31 44 92 118 153 253 174 82 10 986 
Mpumalanga (MP) 1 2 9 64 40 120 188 53 477 
North West (NW) 3 5 16 78 255 113 471 
Northern Province (NP) 5 2 7 128 229 102 475 
Total SA 46 40 92 178 335 519 855 1721 3500 1285 8571 
Other countries 12 9 6 3 8 20 16 96 55 4 229 
Unknown 2 2 
Total 58 49 98 181 343 539 871 1819 3555 1289 8802 
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1.9.2.4 North African Region 
The seroprevalence rates for HIV-I in this region (Egypt, Libyan Arab 
Jamahiriya, Tunisia, Algeria, Morocco and Saharawi Arab Democratic 
Republic) are generally low (Giasudden et al., 1988), but relatively high 
among the high-risk groups of homosexuals, drug abusers and prostitutes 
who do not practice safe sex. All these countries belong to "Pattern 3" of 
the WHO epidemiological classification. 
1.9.2.5 West African Region 
Ivory Coast, which has its capital Abidjan, is the only West African country 
that has recently and suddenly become severely affected by both HIV-I 
and HIV-II infections (De Cock et al. , 1989). There is a predominance of 
infected males, over females, for both types of HIV. Cape Verde consists 
of a group of islands and belongs to the West African Region. HIV-II is 
relatively common in this area because of its proximity to Senegal and 
Guinea Bissau, where HIV-II was first identified and where its prevalence 
is relatively high (Clavel et al., 1986). Some of the islands, e.g. Sal Island, 
seem to have escaped the HIV epidemic because there have been no 
detectable or reported HIV-I or HIV-II infections so far. 
1.9.3 Worldwide epidemiology 
Sub-Saharan Africa is home to less than 10% of the world's population, 
yet it has almost 70% of the world's total of HIV infected people and over 
90% of the world's HIV infected women and children. HIV infection is now 
spreading rapidly in some countries in Asia, especially Thailand and India 
(De Cock, 1993). 
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The highest rates of HIV infection among asymptomatic persons in 
developing countries are found in female prostitutes, in whom rates in 
excess of 80% been described in some African cities. Blood donors and 
pregnant women, who have no special risk for HIV infection, have an HIV 
infection rate of about 10% in 1 O major cities of sub-Saharan Africa. 
Heterosexual transmission is rapidly becoming the dominant mode of 
spread and the driving force behind the epidemic in most countries. Since 
most HIV infections in children occur as a result of perinatal transmission, 
the childhood infection rate is directly related to that in adult women. 
1.10 Anti-viral drugs and 
vaccination 
1.10.1 Anti-viral drugs 
At p_resent, no cure exists for any retroviral infection, including HIV. However, in 1985 it was shown that 3' -azido-3' -deoxythymidine 
(AZT) inhibits the replication of HIV-I in vitro (Mitsuya, 1985). Zidovudine 
is a synthetic pyrimidine analog of AZT with its target being the reverse 
transcriptase enzyme which is essential for viral DNA replication and is 
unique to retroviruses (Furman et al., 1986). Phosphorylation of 
zidovudine to its active form, AZT-5'-triphosphate (AZT-TP) is 
accomplished by cellular enzymes. The AZT-TP form binds preferentially 
to HIV-1 reverse transcriptase, and the incorporation of azidothymidilate 
into the growing DNA strand leads to chain termination. Clinical trials that 
were undertaken in 12 different centers in the USA showed a decreased 
rate of mortality in AIDS patients who were treated with AZT. Individuals 
who received AZT generally showed an increase in peripheral blood CD4 
cells and also showed a general weight gain compared to placebo 
recipients who lost weight (Fischl et al., 1987). The treatment with AZT 
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did, however, produce some side effects. Macrocytic anaemia occurred 
frequently in the AZT group and made transfusions necessary. Another 
side effect was neutropenia, with headache, nausea, myalgia and 
insomnia also being reported more frequently in recipients of AZT. These 
side effects were reversible and generally tolerable for patients with AIDS 
or severe ARC. The currently recommended dosage of AZT for adults is 
200mg every 4hr (Hirsch and Curran, 1992). Other nucleic acid analogs 
that also target the enzyme, reverse transcriptase, include dideoxyinosine 
(ddl) and dideoxycytidine (ddC). These two drugs which have now been 
approved for therapy by the Food and Drug Administration (FDA) appear 
to be effective and less toxic to bone marrow than AZT (Butler et al., 1991 
and Yarchoan et al., 1988). Some studies have also suggested that it 
could be helpful to use ddl or ddC in combination with AZT. A recent 
report (Khan et al. , 1992) suggested that changing treatment from AZT to 
ddl in symptomatic individuals with low CD4+ cell counts could slow the 
progression of disease. 
There has, however, been one notable problem in AZT therapy, namely 
the emergence of resistant virus strains. Resistance to ddl and ddC has 
also been reported (St. Clair et al. , 1991 ; Gao et al. , 1992). Thus far, 
most data suggest that the use of anti-reverse transcriptase drugs alone 
will help to reduce and delay the symptoms of HIV infection. 
Nevertheless, because of the rapid development of drug resistance, other 
therapies must be found that can be used either alone or in combination. 
This latter approach offers the best chance of success for permanent 
control of HIV infection. 
Other approaches to antiviral therapy include blocking of the cellular virus 
receptor with recombinant CD4, or blocking virus attachment with sulfated 
polysaccharides, the use of interferons and strategies that destroy the 
virus-infected cells (Baba et al., 1988 and Poli et al., 1989). 
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Attempts at limiting virus replication have involved molecular procedures 
directed at inhibition of the viral protease or integrase. Protease-
inactivating analogs have been tried and certain selected compounds 
await clinical trials, but resistance to these drugs could also emerge 
(Dreyer et al. , 1989). 
1.10.2 Vaccines 
Several.features of HIV infection and transmission must be considered in 
vaccine work. They include the appreciation of viral heterogeneity, the 
potential for autoimmune responses, local mucosa! immunity and virus 
transmission by infected cells (Levy, 1988 and Forrest, 1991 ). The ideal 
properties of a vaccine are listed in table 3. 
Table 3 Desirable properties of a HIV 
vaccine 
Elicitation of neutralizing antibodies to all HIV strains and subtypes 
Induction of humeral and cellular immune responses against virus-
infected cells 
Induction of immune responses that recognize latently infected cells 
No induction of antibodies that enhance HIV infection 
No induction of autoimmune responses 
Induction of local immunity at all sites of HIV entry in the host 
Safe with no toxic effects 
Long-lasting effect 
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A number of different strategies are being persued for the development of 
efficacious AIDS vaccines. These different strategies include targeting of 
the immune response to specific HIV-I 8- and T-cell epitopes, and the 
development of candidate vaccines that mimic attenuated or inactivated 
HIV-I or are designed to induce an anti-HIV mucosa! immune response. 
Various obstacles have hampered the development of an effective 
vaccine against HIV-I. A major problem has been the lack of an 
appropriate animal model. Chimpanzees are expensive and do not 
replicate HIV to high titer or contract disease. Studies with simian 
immunodeficiency virus (SIV) have been helpful but may not always give 
results that are directly comparable with human lentiviruses. Recent 
reports showed that one macaque species, Macaca nemestrina, could 
also be infected with HIV-I, but this requires further confirmation (Agy et 
a/. , 1992). The high degree of genomic diversity and the rapid rate of 
viral mutation exhibited by HIV-I poses the second hurdle to vaccine 
development. A segment that codes for the third hypervariable region 
(V3) of the envelope glycoprotein gp120, that contains the principle 
neutralization domain (PND), exhibits the highest degree of heterogeneity 
(Putney et al., 1986; Javaherian et al., 1990 and Fisher et al. , 1988). 
Because of significant geographic diversity, vaccine candidates must be 
designed to incorporate immunogenic epitopes conforming most closely 
to HIV-I isolates prevalent in areas where the vaccine is to be used. 
Strains of HIV-I , as well as HIV-II and SIV, are under study by the 
Theoretical Biology and Biophysics Group of the Los Alamos National 
Laboratory (Myers et al. , 1992). Nucleotide and amino acid sequence 
databases of the env and the more conserved gag gene have been 
established. A third obstacle stems from the life cycle and mode of 
transmission of the virus. As previously mentioned, HIV-I can infect 
several cell types and may establish a state of latent infection during 
which the integrated proviral DNA does not express proteins that would 
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otherwise be recognized by the host immune system. Also, transmission 
of HIV-i infection can be initiated by either a cell-free virus or virus-
infected cells. Thus a vaccine capable of eliciting both neutralizing 
antibodies and cell-mediated immune response would likely be the best 
prototype vaccine (Mann et al., 1990). 
Finally, it has been impossible so far to establish a definitive biological 
correlate of immunity since the viral components/epitopes that induce 
protective immune responses have not yet been unambiguously 
delineated. The various approaches to HIV vaccines are listed in table 4. 
Table 4 Different approaches to potential 
HIV vaccines 
Whole inactivated virus 
Attenuated (nonpathogenic) variants 
Subunit vaccine using the envelope glycoprotein (gp120) 
Subunit vaccine using the transmembrane glycoprotein (gp41) 
Subunit vaccine using the gag protein 
Viral proteins in other vectors (eg vaccinia virus, poliovirus or baculovirus) 
Sequence-derived peptides of HIV 
The initial vaccine studies with Lentiviruses that showed some virus 
protection, involved the use of killed SIV in macaques (Desrosiers et al. , 
1989; Murphy et al., 1989). Protection against low-dose challenge with 
the homologous SIV strain were demonstrated by this approach. 
However, studies have also shown that killed-virus vaccines can protect 
against infection by intravenously delivered challenge dose but not 
against · virus inoculated onto the mucosa! lining of the genital tract 
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(Sutjipto et al., 1990). Immunization with a live attenuated S1Vmac strain 
have been explored and shown to prevent disease, but not to prevent 
infection, by a virulent challenge strain. As a model, the use of an 
attenuated agent comes closest to resembling natural infection and these 
studies should be continued to indicate whether conventional vaccine 
approaches with live attenuated virus would induce at least protective 
immunity against an agent such as HIV (Marthas et al. , 1990). 
Limited success has been achieved with a vaccine comprising purified 
envelope glycoproteins expressed in the baculovirus system or in 
mammalian cells. In a trial with chimpanzees, immunization with the 
purified HIV gp120 prevented infection after a low-dose HIV-challenge 
(Berman et al. , 1990). More recently, chimpanzees that were multiply 
immunized with HIV-I antigens showed resistance to intravenous 
challenge with infected PBMCs. This study provided the first evidence 
that immunization can induce host responses against HIV-infected cells 
(Fultz et al., 1992). 
The use of viral proteins and not whole virus as immunogens eliminates 
the possibility that viral nucleic acids will become transcribed or undergo 
cellular integration even though the virus has been killed. A killed-virus 
preparation cannot guarantee stability of expression (antigenicity) of all 
the viral proteins or exclude the possibility of residual infectivity. 
Potential AIDS vaccines are currently being evaluated in uninfected 
human volunteers for their safety and immunogenicity. A large number of 
these experimental vaccines are genetically engineered immunogens, 
mostly recombinant HIV-I envelope glycoproteins gp160 and gp120 
(Picard et al., 1990 ; Redfield et al., 1991 ). 
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Chapter 2 
Diagnostic assays for HIV-I 
2.1 Serological diagnosis 
2.1.1 Antibody assays 
T he diagnosis of HIV-I infection is generally based on the identification of specific anti-viral antibodies. These become 
detectable from as early as four to six weeks after exposure to the virus 




Fig. 5 Serological profile of HIV-1 infected patients (excluding perinatally infected 
infants). Viral antigen is elevated after initial infection, falls to low levels during the 
asymptomatic stages and becomes elevated again as symptoms develop and the 
disease progresses (Adapted from Rogers et al., 1991). 
Commercial assays were first licensed by the Food and Drug 
Administration (FDA) in 1985 (Hou et al., 1994). The enzyme linked 
immunosorbent assay (ELISA) is the most commonly used serological test 
(Weiss et al., 1985). In principle, HIV-1 antigens are bound to a solid 
50 
phase. Samples of patients' sera are incubated with the solid phase for 1-
2 hours and if antibodies to HIV-I are present they will bind to the 
antigens. After washing to remove any unbound material, enzyme-linked 
anti-human lgG antibody conjugate is added to the solid-phase antigen-
antibody complex and incubated for a period of time. After a second wash 
to remove excess unbound antibody, enzyme substrate is added, resulting 
in colour development. The intensity of the colour reaction correlates with 
the amount of anti-HIV-I antibody in the sample and can be quantitated by 
using a spectrophotometer. 
Early first generation ELISAs used a preparation of HIV-I antigens 
harvested from infected T4 lymphocytes. This partially purified HIV-I 
antigen standard reacted with antibodies to proteins of the viral envelope, 
core and polymerase, that may be present in test sera. These first 
generation antigen standards, however, were often contaminated with 
non-viral antigens, such as those of the major histocompatibility locus 
originating from the lymphocytes. The resulting cross-reactivity produced 
a relatively high rate of false-positive results. Soon thereafter, second 
generation (Fig. 6) tests were developed in which the viral antigens were 
either (i) recombinant, i.e. produced by the insertion of a portion of a viral 
genome into a vector (bacterial or yeast) that is easily cultured to generate 
large quantities of specific viral antigens, or (ii) synthetic, i.e. chemically 
synthesized peptide chains, 10 to 40 amino acids long, that are 
homologous in sequence to a portion of a viral antigen. 
Tests based on either recombinant or synthetic peptide antigens have 
sensitivities and specificities higher than first-generation tests. However, 
recombinant antigen tests may also yield some false-positive results due 
to contaminants from the vector, and the synthetic antigen tests may lack 
sensitivity. The generally excellent specificity and sensitivity of 
commercially available second generation test kits have been evaluated 
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and reviewed several times, sensitivity should approach 100% and 
specificity should be above 97%. 
In the third generation tests that are now available, enzyme-labelled 
recombinant or synthetic peptide antigens have been employed in the 
detection step, creating "sandwich" ELISAs, with further gains in 
sensitivity and specificity (Fig. 6). All classes of immunoglobulin 
antibodies are detected, thereby allowing earlier recognition of infections, 
and the window period between infection and seropositivity is shortened 
by an average of 5 days, the median length of the window having been 
estimated previously to be 6 weeks (Horsburgh et al. , 1989). 
2nd Generation 
.L 
:7\ HIV-specific £ antibody 
() ~~ Pl~ 
solid phase I~ 
HIV 1/2 rDNA proteins 
3rd Generation 
~----~~ 
HIV 1/2 rDNA proteins / peptides 
Also detects lgM 
Fig. 6 Second and third generation antigen-sandwich ELISAs for detection of 
immunoglobulin antibodies to HIV-I , -II. 
The conventional method of anti-HIV testing has been to apply a 
screening test in which all negative results are accepted as true, but 
repeatedly positive sera are subjected to an additional confirmatory assay, 
usually the western blot (WB) assay, or an equivalent test. The WB 
procedure enables the detection of antibodies to individual viral antigens, 
such as viral core proteins (p24, p55 and p17) and envelope glycoproteins 
(gp120, gp160, gp41 ). Viral proteins are first separated into well-defined 
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bands by electrophoresis through agarose gel. The separated bands are 
transferred or 'blotted' onto a nitrocellulose membrane that is cut into 
strips and sequentially exposed first to the patient's serum sample and 
then to an anti-human antibody conjugated to an enzyme. Serum 
antibodies to the antigen standards are detected as discrete coloured 
bands (Fig. 7). The diagnostic pattern of bands identified in the WB is 
more sp·ecific than the ELISA for viral antibodies. 









Fig. 7 Solid phase Western blot assay for the detection of anti-HIV-I antibodies. The 
negative test control is shown in lane 1, and the positive test control is shown in lane 2. 
Four patient sera were evaluated in lanes 3 to 6, with lane 3 showing a negative result; 
lane 4 an indeterminate result; lane 5 another negative result and lane 6 a positive result 
(Department of Virology, UCT, Medical School) . 
The WB assay has the disadvantage of being expensive, technically 
complicated and difficult to interpret. The Center for Disease Control 
(CDC) standard requires that at least two of the three main structural 
antigen bands (p24, gp41 and gp120/160) must be present before a 
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sample may be designated as positive for antibody to HIV-I. Blood 
specimens that do not meet the two-band requirement for WB but still 
exhibit some of the bands characteristic of HIV-I proteins are said to have 
an 'indeterminate' pattern (Jackson et al., 1990; Genesca et al., 1989). 
Such patterns are seen in three categories of patients: - those in the early 
stages of HIV-I infection, those infected with a closely related retrovirus 
(e.g. HIV-II) and truly false-positive results, i.e. healthy people who are not 
infected with HIV-I or HIV-II. For those in the early stages of HIV-I 
infection and also for those with HIV-II infection, one of the first HIV 
antibodies detectable by WB is the antibody to the viral core protein p24. 
Most people infected with HIV-I will eventually develop the other HIV-I 
antibodies within 6 weeks (Horsburgh et al., 1989). 
Testing for HIV could be simplified by the application of first one ELISA for 
screening, followed by a second different ELISA for confirmation (the latter 
replacing WB). The two tests should be based on different principles (e.g. 
indirect and competitive ELISAs) and have different sources of antigen 
(e.g. viral lysate and synthetic peptides). The first test should have high 
sensitivity, be technically simple and inexpensive, while the second test 
should have high specificity. Only the few sera giving discrepant or 
indeterminate results need to be referred for WB analysis, resulting in 
considerable savings in costs. 
2.1.1.1 Sensitivity and specificity of 
antibody tests 
A test with a high sensitivity will have few false-negative results. 
Therefore, only tests of the highest possible sensitivity should be used 
when there is a need to minimize the rate of false-negative results (e.g. in 
testing of blood/organ donations). A test of high specificity will have few 
false-positive results and should be used when there is a need to 
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minimize the rate of false-positive results (e.g. in diagnosis of HIV 
infection) (Meissner and Coffin, 1992). 
2.1.2 Elispot 
The technique of in vitro antibody production (IVAP) is based on the 
principle that 8-cells in HIV-I infected patients are usually activated in vivo 
and hence spontaneously secrete anti-HIV-I antibody (Pahwa et al., 
1989). Peripheral blood lymphocytes from infected individuals may be 
isolated and cultured in vitro and activated by mitogen such as pokeweed. 
th vitro antibody production involves coculture of mitogen-stimulated 
patient peripheral blood mononuclear cells (PBMCs) with normal healthy 
donor lymphocytes. The presence of HIV-I is confirmed by periodically 
testing the culture supernatant for the presence of anti- HIV-I antibody (De 
Rossi et al., 1988; Pahwa et al. , 1989). The ELIS POT test involves 
incubating antibody-producing patient PBMCs in polystyrene wells that 
have been coated with HIV-I antigen. In theory, exposure of the patient 
PBMCs ·to antigen results in production of detectable anti- HIV-I antibody. 
After the sample has been incubated and excess unbound antibody has 
been washed out, enzyme-linked anti-human lgG is added, and the 
presence of anti- HIV-I antibody is confirmed by detection of 'spots' at the 
bottom of the well , where the enzyme substrate had reacted. 
2.1.3 Serological assays for the 
early diagnosis of HIV infection in 
infants <18 months of age 
Serodiagnosis of HIV infection is more difficult in infants and young 
children than in adults. As a result of placental transfer of maternal lgG 
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antibody to HIV-I, virtually all neonates born to seropositive women are 
HIV-I antibody-positive at birth, and this maternally derived antibody may 
persist for up to 18 months of age (European Collaborative Study, 1988; 
Rogers et al., 1991 ). Testing of serial samples of blood from uninfected 
infants by the WB technique may reveal a sequential loss of viral bands, 
representing the decline of maternal antibody, but this requires at least 
several months of observation. Because maternal lgM does not cross the 
placenta, the presence of specific lgM antibodies could be used to 
indicate the presence of HIV infection in infants. However, there is no 
consistent lgM antibody response by the infected infant to enable 
diagnosis of prenatal infection. Furthermore, available methods to detect 
HIV-I specific lgM antibody have a poor sensitivity (Pyun et al., 1987). 
Assays for the detection of specific lgA antibody seem to offer a promising 
method of diagnosis, but these still require additional studies (Weiblen et 
a/., 1990). A small proportion of HIV-infected children are 
hypogammaglobulinemic, leading to false negative antibody tests once the 
maternally derived antibody has been catabolized (Borkowsky et al. , 
1987). 
In summary, present data on serum immunoglobulins in infants of 
seropositive mothers have shown that: (i) hypogammaglobulinemia (total 
lgG, lgA and lgM) is a common but relatively non-specific early finding in 
HIV-I infected infants, (ii) infected infants with advanced symptomatic 
disease may exhibit hypogammaglobulinemia presumably due to severe 
impairment of 8-cell function, (iii) serial follow-up of anti-HIV lgG is an 
inexpensive and acceptable method for diagnosing HIV-I infection in 
infants, but the long duration of maternal antibody prevents early 
diagnosis, (iv) testing for anti-lgM or -lgA is relative specific but may not 
be adequately sensitive in young infants, (v) no information exists on anti-
HIV-1 lgA and -lgM testing in infants less than 3 months of age, and (vi) no 
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data regarding the sensitivity and specificity of the ELISPOT assay in very 
young paediatric patients exist, especially for infants under 3 months. 
2.2 Antigen assays 
An ELISA assay for the detection of HIV antigen was first described by 
McDougal et al. (1985). High-titer anti-HIV lgG, purified from a 
seropositive individual, was used in a sandwich ELISA test format. The 
lgG (used as capture antibody) was bound to the plastic surface of a 
microtitre well. HIV-I culture supernatant fluid was added, followed, after 
incubation and washing, by incubation with an enzyme-labelled human 
anti-HIV antibody. If antigen was present, it allowed the formation of a 
"sandwich" of capture antibody, HIV antigen and enzyme-labelled probe 
antibody. The addition of enzyme substrate resulted in colour 
development, which revealed a positive reaction. These initial tests were 
used to detect HIV antigens in virus culture fluids. The sensitivities were 
not adequate for the detection of the very low titers of HIV antigen present 
in body fluids of most HIV-infected individuals. The subsequent 
development of a triple-antibody sandwich procedure, that used 
antibodies primarily specific for the p24 antigen, provided the needed 
amplification to detect HIV antigens in clinical specimens (Goudsmit et al., 
1986). Several HIV antigen ELISAs are now commercially available. 
Serum, plasma and cell culture fluids may all be tested. The sensitivity of 
the HIV antigen assays in detecting HIV infection directly in patient 
specimens varies from 4% in asymptomatic seropositive subjects to 70% 
in patients with AIDS (Kenny et al., 1987). The apparent lack of sensitivity 
in detecting HIV infection, limits it's use as a screening assay for HIV 
infection in low-risk groups. 
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2.2.1 Antigen assay for the 
diagnosis of infected infants 
Studies that compare the sensitivity of antigen detection with that of virus 
culture and the polymerase chain reaction assay (PCR) have shown that 
the antigen test is the least sensitive for the diagnosis of HIV-I in infants 
(De Rossi et al., 1988; Krivine et al., 1990). Krivine and co-workers 
reported a 96% concordance rate between viral culture and PCR results in 
PBMCs from 45 children born to seropositive mothers, however, p24 
antigen could be detected in only 50% of virus culture-positive infants, and 
in only 44% of PCR-positive infants. It was shown that the antigen assay 
could give false positive results with blood samples from infants in the first 
2 months of life (De Rossi et al., 1988). 
Recent studies have shown that detection of HIV-I p24 antigen may be 
enhanced by pre-treatment of samples with acid (Nishanian et al. , 1990). 
This is achieved by incubating serum samples with hydrochloric acid (HCI) 
at a pH of 2.5 to 3.0. Acid pretreatment dissociates antibody-antigen 
complexes and thereby releases the antigen enabling it to react in the 
ELISA which follows. Miles and co-workers used glycine hydrochloride to 
dissociate immune complexes, and they report that this is a simple 
serological procedure that may be of value during the diagnosis of HIV 
infection in neonates born to HIV infected women (Miles et al., 1993). 
2.3 . Viral Culture Methods 
2.3.1 Virus culture 
Barre-Sinousi and co-workers successfully isolated HIV-I in 1983. In 1984 
Gallo and co-workers successfully cultured HIV-I by using HTLV9 cells 
from a neoplastic T-cell line. Since that time, virus isolation from the 
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cellular component of blood, plasma, body fluids, amniotic fluid and tissue 
has been reported ( Coombs et al., 1989; Ho et al., 1989; Mundy et al., 
1987; Lewis et al., 1990). 
Recent advances have refined virus isolation techniques, greatly 
improving their sensitivity and specificity. Patient PBMCs are harvested 
from heparinized blood by Ficoll-Hypaque gradient separation. The 
PBMCs are co-cultivated with healthy donor mitogen-stimulated PBMCs in 
culture medium (RPMI 1640, supplemented with 20% fetal calf serum and 
interleukin-2) at 37°C in a 95% air - 5% CO2 environment. The co-cultures 
are maintained by the periodic addition of interleukin-2 and fresh mitogen-
stimulated healthy donor PBMCs. Culture fluids are collected periodically 
( about every 7 days) and tested for either HIV p24 antigen or reverse 
transcriptase. Cultured cells may also be examined by light microscopy 
for syncytium formation, although this criterion is not as specific as testing 
for viral products. Cultures that have no demonstrable evidence of HIV-I 
infection by 42 days are usually terminated. In early reports, the recovery 
rate by culture of virus seropositive patients ranged from 70 to 90% (Levy 
and Shimabukuro, 1985). The ability to culture virus from an individual 
may reflect that person's viral load. Newer improved culture methods can 
isolate HIV-I from about 97% of antibody-positive people (Jackson et al. , 
1988). 
Truly quantitative methods for viral culture have been reported by Ho and 
co-workers (1989). In this study, the patients' PBMCs were diluted in a 
10-fold series and then co-cultivated with a standard number of uninfected 
PBMCs. The highest dilution of PBMC that yielded a positive culture was 
considered as the end point of the assay. The quantity of infectious HIV-I 
was reported in tissue culture infective doses per number of PBMCs. This 
study showed asymptomatic but infected patients to have a 100-fold lower 
tissue culture infective dose than patients with AIDS or AIDS-related 
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complex (ARC). These findings imply that asymptomatic patients have a 
lower viral burden than symptomatic ones. 
Due to the risk to laboratory workers and the expense of HIV-I isolation, it 
is unlikely that culture methods will play a significant role in HIV-I testing, 
except in research settings. 
2.3.2 HIV-I Culture for diagnosis of 
infected infants 
Little data is available on recovery rates of virus from infants less than 3 
months of age. One study estimated the percentage of culture positive 
samples from infants tested very early in life (less than 3 months of age) to 
be approximately 50% (Rogers et al., 1991 ). This poor sensitivity of viral 
culture for the detection of HIV-I improves when older infants are tested. 
The poor sensitivity in the neonatal period (less than 1 month) may be due 
to several factors: (i) initial exposure to HIV-I may have occurred during 
delivery and the HIV-infection may not yet have progressed to the level of 
detection and (i i) even if infection occurs in utero, the quantity of 
circulating cell-free or cell-associated virus in the infant may be below the 
level of detection by culture. The application of quantitative culture 
methods may provide some benefit for newborns and infants with HIV-I 
infection: - for identifying infected infants at risk of rapid progression to 
symptomatic disease; for monitoring the natural progression of HIV 
infection in infants; and for assessing improvement after anti-retroviral 
therapy. 
The rate of successful recovery of virus by culture probably correlates with 
the amount of virus present in the infected patient (or infant). 
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2.4 Polymerase Chain Reaction 
One of the most promising techniques for the diagnosis of HIV infection is 
the polymerase chain reaction (PCR) which can be used to detect either 
proviral DNA sequences or genomic RNA sequences of HIV. The 
technique was initially developed in the 1980s and was first applied in the 
prenatal diagnosis of sickle cell anemia (Mullis and Faloona, 1987; Mullis, 
1990; Embury et al. , 1987). Adaptation and application of PCR 
techniques for the detection of HIV can result in numerous advantages: (i) 
the ability to amplify gene sequences with very low copy number would 
enhance the sensitivity of detection, (ii) detection of HIV proviral DNA 
could represent an earlier marker of infection than detection of antibody, 
and (iii) although an HIV infection in a patient whose B-cell function is 
impaired may not be identified serologically, it could be detected by this 
method (Jackson et al., 1990). 
2.4.1 PCR - "The three step cycle" 
The method is based on a three-step cycling process (Fig. 8) 
(Schochetman et al., 1988; Mullis and Faloona, 1987; Embury et al., 
1987). The typical set of three steps (denaturation, annealing and 
extension) is referred to as a cycle. Multiple cycles result in an 
exponential increase in the number of copies of the target sequence. 
During the late PCR cycles, a reduction in the exponential rate of product 
accumulation occurs and this phenomenon is referred to as the "plateau 
effect". Optimizing the number of PCR cycles is the best way to avoid 
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Fig. 8 The Polymerase Chain Reaction Cycle (Medicine Group, SA. 1992) 
2.4.1.1 Denaturation 
High temperature denaturation of double-stranded template DNA is the 
first step in the cycling process. Of the several physical and chemical 
means of dissociating complementary strands of DNA, heating (95°-100°C) 
is simple and efficient. The two strands will remain free in solution until 
the temperature is lowered sufficiently to allow annealing to take place. 
Ribonucleic acid can also be used as a template for amplification following 
the production of complementary DNA ( cDNA) using reverse transcriptase 
(Ottman et al., 1991 ). 
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2.4.1.2 Annealing 
In this step, the temperature is lowered to 40°C - 60°C to permit annealing 
between the oligonucleotide primers and template DNA. Specific primers 
are synthesized according to the sequence of the DNA template at the 
boundaries of the region to be amplified. Since the primers anneal to 
opposite strands, they can be viewed as having their 3' ends facing in 
opposite directions. Typically, the primers have different sequences and 
are not complementary to one another. The primers are present in large 
excess over the DNA template, and when the temperature is lowered the 
formation of the primer-template complex will be favoured over the re-
association of the two DNA strands. 
2.4.1.3 Primer extension 
The third step in the procedure is a DNA polymerase-mediated (5' to 3') 
extension of the primer-template complex. The temperature is raised to 
allow optimal activity of the DNA polymerase which is now able to extend 
each of the primers thus replicating the region between them. Initially, the 
PCR technique used the Kienow fragment of DNA Polymerase I of 
Escherichia coli with an extension step conducted at 37°C (Embury et al. , 
1987). The thermal !ability of the Kienow fragment required the addition of 
fresh enzyme after each denaturation step, which rendered the whole 
process very tedious and resulted in the rapid accumulation of denatured 
enzyme in the sample. Using a thermostable DNA polymerase purified 
from Therm us aquaticus ( Taq) greatly simplified the whole procedure 
because the addition of fresh enzyme after each denaturation step was no 
longer required (Saiki et al., 1988). The Taq polymerase allowed 
automation of the PCR process because all the initial reaction 
components now did not need to be replenished. Furthermore, the Taq 
polymerase has enabled DNA amplification to be performed at higher 
temperatures thus improving the specificity of the reaction (Saiki et al. , 
1988). 
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2.4.2 Detection of PCR product 
Detection of the amplified PCR product is usually achieved by 
hybridization with an oligonucleotide probe complementary to the original 
segment of HIV genome that has been amplified. Labelling of the probe 
can be achieved with different substances, e.g. enzymes (peroxidase or 
alkaline phosphatase), 22P, 35S, biotin or digoxigenin. Analytically, the 
amplified DNA is usually electrophoresed in gels (agarose or 
polyacrylamide) and detected by staining with ethidium bromide (EtBr), or 
by hybridization, using one of the above mentioned probes, after Southern 
blotting {Borkowsky et al. , 1989; Brandt et al., 1992). 
2.4.3 Applications 
The polymerase chain reaction provides a clinical utility for: (i) identifying 
HIV proviral sequences in infected individuals prior to the generation of 
antibodies (seroconversion) in the so called "window period', (ii) resolving 
the infection status of individuals with ambiguous or indeterminate 
serologi.cal status WB, (iii) documenting infection in seropositive 
individuals that test negative by other direct detection assays, (iv) 
demonstrating a dual HIV-I and HIV-II infection in a single individual , (v) 
differentiating latent HIV infection (proviral DNA) from active transcription 
(RNA) and (vi) monitoring the effect of antiviral therapy by determining 
the number of proviral copies per given number of cells thus quantifying 
the virus burden (Rayfield et al., 1988; Wages et al. , 1991 ; lmagawa et 
al. , 1989; Ou et al. , 1988; Holodniy et al., 1991 ). 
An alternative to the detection of HIV proviral DNA or transcripts is the 
direct id.entification of genomic HIV RNA from intact virions. The detection 
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of genomic RNA also offers the opportunity to monitor viraemia in HIV 
patients. Ottman and co-workers (1991) have described a method for 
direct detection of HIV genomic RNA based on ultracentrifugation of 
plasma or serum samples, followed by DNase treatment of the pellet of 
virions. A cDNA strand is then created using an exogenous reverse 
transcriptase. The PCR reaction is initiated only after synthesis of cDNA 
has been accomplished, and the reverse transcriptase is inactivated by 
heating. 
2.4.3.1 Diagnosis in infants 
The PCR technique is particularly useful as a research tool for the 
diagnosis of HIV infection in babies under 18 months of age, where 
serological tests are of limited value due to the persistence of maternal 
antibodies (see Section 1, Chapter 2.1 ). PCR avoids this problem 
because it detects the presence of viral nucleic acid. Chadwick and his 
co-workers demonstrated the usefulness of PCR in identifying infected 
children. as young as 2 months of age (Chadwick et al. , 1989). Additional 
advantages of PCR for infant diagnosis are that, only 500µ1 to 1 ml of 
blood is required (an amount that is feasible to obtain from a newborn) 
and, unlike virus culture which can take up to 4 weeks or longer to 
complete, PCR can be done in 1 - 3 days. Borkowsky and co-workers 
(1992) evaluated three possible techniques for the diagnosis of HIV in 
infants younger than 6 months of age and concluded that PCR was just as 
sensitive as culture (94% vs 96%). Both these assays could detect 
infection in 70% to 90% of children by 2 months of life and in >90% of 
infants thereafter, whereas the p24 antigen assay was shown to be less 
sensitive. 
Less information is available concerning testing for HIV-I RNA by PCR in 
infants and children. Escaich and co-workers used this technique to test 
12 newborns within 2 weeks after birth and identified 4 infants (33%) who 
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were HIV-I RNA positive, compared with 7 (58%) who were HIV DNA 
positive by PCR (Escaich et al., 1991 ). Although RNA PCR was less 
sensitive than DNA PCR, the RNA results were more predicative of which 
infants would rapidly progress to clinical disease. A positive HIV RNA 
PCR assay implies active viral replication. Samples other than blood (e.g. 
lymphoid tissue) may also be used to detect HIV-I RNA by PCR. 
The greatest problem facing the diagnostic application of PCR (and other 
nucleic acid amplification methods) is false positivity due to contaminating 
nucleic acids (Kwok and Higuchi, 1989; Rogers et al. , 1991 ; Borskowsky 
et al., 1992 and Petru et al. , 1992). The predominant source of 
contamination appears to be the PCR product from previous reactions 
( carryover) which remain because of the large number of copies 
generated. When numerous amplifications are performed using the same 
primer pair, considerable care must be taken to avoid carryover of even 
minute amounts of DNA from one reaction to another. A series of 
recommendations which should be followed in order to reduce the 
frequency and amount of carryover are given in Chapter 3, section 3.1. 
2.4.4 Nucleic acid sequence-based 
amplification 
A new amplification procedure termed nucleic acid sequence based 
amplification (NASBA) has recently been developed (Kiewits et al. , 1991 ). 
This nucleic acid amplification technique is based on the simultaneous 
activity of 3 enzymes without the necessity for thermal cycling or the 
intermediate addition of enzymes. This technique can be used to amplify 
either RNA or DNA from various sample preparations. The three enzymes 
are a reverse transcriptase, T? RNA polymerase and RNase H. Bruisten 
and co-workers compared NASBA with reverse transcriptase PCR (RT-
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PCR) for the specific detection of HIV-I RNA. Both techniques were 
shown to detect HIV-I viral sequences with equal efficiency (Bruisten, 
1993). NASBA displayed some advantages over RT-PCR which include 
(i) no requirement for a separate reverse transcriptase step (ii) no 
necessity for a thermocycler apparatus, because the reaction is performed 
isothermally, and (iii) a shorter period of time for completion of the test. 
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Optimization of HIV-I 
PCR in the virology 
laboratory 
3.1 Introduction 
3.1.1 The "Standard" PCR reaction 
T he polymerase chain reaction has a wide variety of applications, and it is not possible to describe a single set of conditions that will 
guarantee success in all situations. Nevertheless, the "standard" reaction 
will amplify most target sequences. This reaction defines a common 
starting point from which changes can be attempted (Saiki, 1989; Innis 
and Gelfand, 1990). 
The "standard" reaction is set up as a 100µ1 volume consisting of PCR 
buffer (SOmM KCI, 1 OmM Tris.HCI, pH8.4, 1.SmM MgCl2, 1 OOµg/ml 
gelatine), 0.25µM of each primer, 200µM of each deoxynucleotide 
triphosphate (dATP, dCTP, dGTP, dTIP), 2,5 units of Taq DNA 
polymerase, and template DNA (102 to 105 copies) . A drop of mineral oil 
is also added, in order to prevent evaporation. However, the type of 
thermocycler will determine whether or not it will be necessary to add the 
oil , e.g. a thermocycler where the lid of the reaction tube is heated, will 
not require any oil overlay. The mineral oil also helps to prevent cross-
contamination as it seals the reaction. Thirty-five cycles of amplification 
can then be performed in a DNA Thermal Cycler using the following 
temperature profile: Denaturation for 20sec at 94°C, primer annealing for 
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20sec at 55°C and primer extension for 30sec at 72°C. Cycling should 
conclude with a final extension step of 72°C for 5min (Saiki , 1989). 
A variety of parameters can then be modified, if better results are 
required or if the reaction has failed. These parameters can affect the 
specificity, fidelity and yield of the reaction and include the following: (1) 
enzyme concentration (2) primer concentration (3) annealing temperature 
(4) dNTP concentration (5) MgC'2 concentration in the PCR buffer, and (6) 
PCR buffer composition. 
3.1.2 PCR Parameters 
3.1.2.1 Taq DNA polymerase concentration 
The amount of polymerase is one of the more important parameters to be 
optimized for a particular assay. The optimum amount of enzyme, for 
most assays, will be between 0.5 and 2.5 units in a 50µ1-100µ1 reaction 
volume. Increased enzyme concentrations sometimes lead to decreased 
specificity with accumulation of non-specific background products. If the 
concentration is too low, an insufficient amount of desired product is 
made (Saiki , 1989; Innis and Gelfand, 1990). 
The Taq DNA polymerase lacks 3'-5' proofreading activity and the fidelity 
(i.e. nucleotide misincorporation frequency) can depend upon the 
concentration of free Mg2+ and dNTPs, (Tindall and Kunkel, 1988; Saiki , 
1989). The half-life of Taq DNA polymerase is 30min at 95°C, and it is 
recommended that no more than 30 amplification cycles should be 
performed (Rybicki , 1992). 
There are several other thermostable DNA polymerases available on the 
market. The Tf/ DNA polymerase is derived from the thermophilic 
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bacterium Thermus flavus (Rao et al., 1992). This polymerase is suitable 
for high-temperature synthesis of DNA, with optimal activity of above 
65°C, and can be used at temperatures up to 95°C. Pfu DNA polymerase 
is derived from the hyperthermophilic archaebacterium, Pyrococcus 
furiosus. Its proofreading activity enhances the fidelity of PCR by 
reducing the error-rate 12-fold compared to Taq DNA polymerase 
(Lundberg, et al. , 1991 ). When Pfu DNA polymerase is used in PCR, it 
also leaves the PCR products with blunt ends, which makes it more 
suitable when cloning into blunt-ended vectors. Another DNA 
polymerase is Tli DNA polymerase, derived from the bacterium 
Thermococcus litoralis, which is an extremely thermostable enzyme that 
replicates DNA at 75°C and remains functional even after incubation at 
100°C (Mattila et al., 1991 ). Vent DNA polymerase is also a thermostable 
polymerase from Thermococcus litoralis, but with an added 3' -5' 
exonucleas.e activity (proofreading). This polymerase also has a function 
which degrades the 3' -terminal mismatches of PCR primers, thus 
enhancing the DNA replication fidelity (De Noronha and Mullis, 1992). 
The Tth DNA polymerase is isolated from the bacterium Thermus 
thermophilus. This enzyme also has thermostable reverse transcriptase 
activity that is useful in synthesizing cDNA from RNA templates 
(Garballeira et al. , 1990). 
3.1.2.2 Deoxynucleotide triphosphate 
(dNTP) concentration 
The concentration of the deoxynucleotides (dNTP) in the PCR reaction 
can vary from 50 to 200µM. In order to minimize misincorporation errors, 
the four dNTPs (dATP, dGTP, dCTP, dTIP) should be used at equivalent 
concentrations. The fidelity of the Taq DNA polymerase will be reduced if 
the dNTPs are imbalanced (Saiki, 1989). It is also important to remember 
that the dNTPs quantitatively bind Mg2+ , thus reducing the level of free 
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magnesium ions which could interfere with the polymerase activity. If any 
significant changes were to be made to the dNTP concentration, it would 
probably be necessary to change the MgCb concentration in the PCR 
buffer as well (Innis and Gelfand, 1990; Saiki , 1989). 
3.1.2.3 Magnesium concentration 
The magnesium ion concentration can have an effect on the yield of the 
PCR products and the specificity of the reaction. Optimizing the Mg2+ 
concentration may prove to be very beneficial. Concentrations in the 
range of 0,5mM to 10mM are usually optimal. 
3.1.2.4 PCR buffer composition 
Some PCR protocols include 10% dimethyl sulfoxide (DMSO) in the 
standard buffer to reduce the secondary folding of the target DNA, but 
various reports have also shown that 10% DMSO can be slightly 
inhibitory to Taq DNA polymerase and decrease the overall yield of the 
amplification product (Saiki , 1989). 
Gelatin or bovine serum albumin ( 1 OOµg/ml) and non-ionic detergents, 
such as 0,01 % Tween 20 or 0,01 % NP40, are essential in stabilizing the 
Taq enzyme in order to obtain maximum efficacy of the enzyme (Innis and 
Gelfand, 1990). The melting temperature (Tm) of the DNA products is 
also lowered by these additives. Sarkar et al. (1990) reported that the 
addition of formamide to the PCR buffer (1 ,25-2,5%) can also improve the 
specificity of the reaction. 
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3.1.3 Primer selection 
In most appl ications it is the primer sequence and primer length that will 
determine the overall success of the PCR reaction . An increase in the 
primer length as well as an increase in the G+C content of the primer will 
result in an increased Tm- Consequently, 18- to 30-mer primers with a 
G+C content of 50-60% are generally used. The rule-of-thumb 
calculation: Tm= 4(G+C) + 2(A+ T)°C can be applied for the calculation of 
an estimated Tm- It is advised that the annealing temperature (Ta) should 
be 5°C below the lowest Tm of the pair of primers to be used (Innis and 
Gelfand, 1990). It might also be useful to use the more accurate 
calculation (Sambrook, 1989) which takes the salt concentration into 
account. This calculation of the Tm will reflect the reaction conditions 
when the following formula is used: 
Tm= 81 ,5 + 16,6[LogM + 0,41(%G+C) - 500/L] -0,61(%FA), 
where M= molarity of monovalent cations, usually Na+ concentration, 
L= length of oligonucleotide in basepairs, FA= %formamide in the 
hybridization solution, and %G+C= percentage G and C nucleotides in 
the DNA Innis and Gelfand (1990) also describe a few simple rules in 
their book to aid in the design of efficient primers. 
Degenerate primers can also be used, especially when search ing for new 
or uncharacterized sequences that are related to a known family of 
genes. Degenerate primers are a set of primers which have a number of 
options at several positions in the sequence, to allow annealing and 
amplification of a variety of related sequences. Degeneracies at the 3'-
ends of the primers should be avoided since that could lead to inefficient 
extension because of mismatched bases (Rybicki , 1992; Innis and 
Gelfand, 1990; Saiki , 1989). An example of degenerate primers are 
those described in chapter 6 to amplify a subset of the env region (V3-
region). 
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3.1.4 Contamination problems 
The amplification that makes PCR so useful also makes it very 
susceptible to contamination problems. Different sources of 
contaminating DNA have to be considered: (1) cross-contamination 
between samples, resulting in transfer of target DNA from one sample to 
another, (2) plasmid contamination from the laboratory environment 
[recombinant plasmids containing cloned target sequences], and (3) 
carry-over contamination of amplified target DNA [amplicons]. However, 
the major source of concern is carry-over contamination of amplicons, 
due to their relative abundance and ideal structure for re-amplification 
(Kwok and Higuchi, 1989). Large numbers of molecules are generated in 
a standard reaction and each tube may contain as many as 1012 copies of 
an amplicon. Contamination of reagents, buffers, laboratory glassware, 
autoclaves and ventilation systems can occur as a result of this amplicon 
build up. In diagnostic laboratories, where assays are generally tuned for 
maximum sensitivity (1 to 10 template molecules), amplicon 
contamination can become an acute problem (Kwok and Higuchi, 1989). 
Amplicon contamination of reagents, pipetting devices, laboratory 
surfaces or even the skin of workers can yield false positive results 
(Kitchin et al. , 1990). One way to control contamination is to prevent the 
physical transfer of DNA between amplified samples and between 
positive and negative experimental controls . 
The following guidelines should be applied routinely to prevent or reduce 
false positive rates in the laboratory: 
3.1.4.1 Laboratory design and technique 
It is important to physically separate the three main stages of the PCR 
protocol: (1) reagent preparation, (2) sample preparation and addition, 
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and (3) post-PCR analysis. In an ideal laboratory each of these areas 
should be a separate room but, as most laboratories have limited space, 
this separation can be achieved by providing separate dedicated 
workstations in two rooms. Each area should have its own dedicated 
equipment (pipettes, gloves, laboratory coats, tips, tubes, microfuges, 
waste bins, and even writing material) and these must not be transferred 
between the areas. By restricting access to these areas to trained 
personnel only, one not only reduces the distractions caused by the 
presence of unnecessary personnel, but also reduces potential additional 
sources of contamination, and the areas remain tidy and fit for their 
intended purpose (Kwok and Higuchi, 1989; Kwok, 1991 ). It is highly 
recommended that benchtop hoods (with UV lights for decontamination) 
should be used when preparing the reagents and samples, and when 
adding the samples. Personnel should never be allowed to enter the 
"clean" preparation areas after they have worked in the post-PCR areas 
unless they have changed their laboratory coats and gloves. The risk of 
contamination is greatly reduced by wearing gloves and changing them 
frequently. It is also advisable to use tubes with caps that do not require 
a great force to remove, as liquid at the bottom of the tube may splash 
out, causing aerosols. It is recommended that fluids be spun down to the 
bottom of the tube before it is opened. 
3.1.4.2 Autoclaving solutions 
Autoclaving can be used to sterilize those solutions and equipment that 
can be autoclaved without affecting their performance, but care should be 
exercised, especially when autoclaving pipette tips and glassware, as the 
autoclave can be another potential source of contamination. It is worth 
considering using disposable plastic-ware, pipettes and sterile 
commercial plugged tips. 
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The source of water should also be carefully considered as this could be 
a potentially disastrous source of contamination. It is preferable to buy 
water from an outside supplier or, if this is not possible, to use water from 
a source entirely separate from one's normal work areas. 
3.1.4.3 Reagent aliquots 
It is necessary to minimize the number of repeated samplings from a 
stock reagent. All PCR reagents can be combined into a "master-mixture" 
before dispensing them into a suitable volume for a single PCR reaction. 
The mastermixes should be checked for possible loss of activity (Taq 
enzyme) after a large batch has been prepared. Aliquots of all reagents 
should be made as this will also minimize the chances for sporadic 
contamination. 
3.1.4.4 Plugged tips or positive 
displacement pipettes 
Aerosols containing sample DNA can contaminate the barrel of pipetting 
devices which can lead to cross contamination of samples. This can be 
prevented by using disposable, plugged tips. The use of disposable 
plungers is also recommended when positive displacement pipettes are 
used in the laboratory. 
3.1.4.5 Preparation and addition of 
template 
The method used for template preparation should be kept as simple as 
possible, with the minimum amount of steps, to avoid creating possible 
contamination opportunities. In addition, the DNA sample should also be 
added last to minimize the opportunity for cross contamination. It is also 
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recommended that the specimens are prepared in a biological safety 
cabinet and that any clinical specimen should be treated with universal 
safety precautions. The work surface of such a cabinet should routinely 
be decontaminated with a 10% bleach solution, followed by a 70% 
ethanol rinse. The bleach should be made up fresh every day. 
3.1.4.6 Careful choice of positive and 
negative controls 
A highly concentrated solution of plasmid DNA, containing the target 
sequence, should not be used as the positive control as this can result in 
the introduction of many amplifiable molecules into the sample 
preparation area. The plasmid DNA should be diluted and, depending 
upon the detection system, as few as 10 to 100 copies may be sufficient 
to use as a positive control. The inclusion of multiple negative controls is 
an essential part of PCR. Firstly, a "no DNA" reagent control is included 
which contains all the necessary components for PCR, except the 
template DNA. Secondly, negative sample controls should also be 
included with each set of amplifications. The negative sample controls 
should not contain target sequences, but should be processed through all 
the sample preparation steps. The DNA from low risk individuals, such as 
laboratory personnel, can be used as the negative DNA control. 
3.1.4.7 
control 
Direct methods of contamination 
The adoption of the guidelines for laboratory lay-out and good laboratory 
practice (described above) will serve as good preventative measures to 
reduce the occurrence of contamination. However, several other 
procedures may be introduced that can directly reduce existing 
contamination levels. 
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3.1.4. 7 .1 Ultraviolet light irradiation 
Ultraviolet (UV) light is capable of damaging DNA and rendering it 
incapable of amplification by PCR (Sarkar and Sommer, 1990). The 
sensitivity to UV light varies enormously, as both the sequence and the 
size of the contaminating fragment plays a role here. Sarkar and Sommer 
(1990) showed in their study that DNA fragments of <700bp are highly 
susceptible to UV inactivation, in contrast to fragments <250bp that are 
much less susceptible. Irradiation of the entire area used for the pre-PCR 
procedures can assist in preventing "carry-over''. 
3.1.4. 7.2 Photochemical method 
Contamination can be minimized by the addition of 4'-aminoethyl-4,5'-
dimethyl-isopsoralen (4'-AMDMIP) to the PCR mixture prior to 
amplification (Cimino et al., 1991 ). It does not interfere with primer 
annealing or Taq polymerase activity and is thermally stable. The tubes 
are exposed to longwave UV light after amplification. The UV light 
penetrates the tubes and photochemically activates the isopsoralen. The 
activated psoralen then forms a complex with pyrimidine residues on the 
amplified DNA that prevents Taq polymerase from passing along the DNA 
strand in the next amplification reaction. These compounds do not form 
interstrand crosslinks and thus do not interfere with hybridization assays 
when the products are being analyzed. The efficiency of this 
photochemical procedure can be extremely high, depending on the length 
and nucleotide base composition of the amplicon, and amplicons greater 
than 300 basepairs (bp) in length with roughly 50% G+C content can be 
rendered virtually completely inadequate for re-amplification . A drawback 
of this method is that inhibition of PCR has been observed at high 
isopsoralen concentrations, e.g. very short and high GC-rich amplicons 
need high concentrations of isopsoralen (Cimino et al. , 1991 ; Isaacs et 
a/. , 1991 ). 
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3.1.4. 7 .3 Enzymatic method 
In the enzymatic method the DNA is modified by using dUTP instead of 
dTIP during PCR, resulting in incorporation of dU instead of dT in the 
amplicon. This modified DNA does not occur naturally and can be 
distinguished from target DNA by the presence of this "unnatural" 
nucleotide base U. The bacterial enzyme, uracil-N-glycosylase (UNG) is 
added to the PCR reaction and digests the carry-over fragments by 
cleaving the uracil base from the phosphodiester backbone of any uracil-
containing DNA (Fig. 9). UNG has no effect on normal thymine-
containing template DNA The enzyme is added prior to amplification so 
that contaminating dU-fragments are degraded and cannot serve as 
substrates for further amplification. The UNG is then heat-inactivated 
prior to PCR cycling, to prevent degradation of newly amplified uracil-
containing DNA products (Longo et al., 1990; Bebee et al., 1992; King 
and Ball , 1993). 
Potential problems with the UNG protocol include incomplete destruction 
of UNG activity when it is heat denatured before PCR cycling. As a 
result, residual UNG activity may affect the sensitivity of the system by 
inactivating uracil-containing strands as soon as they are made. It has 
been shown that when dUTP is substituted for dTIP it is essential to 
simultaneously adjust the concentrations of the dNTP and MgCb to 
ensure the most efficient amplification (Perkin Elmer Cetus, 1991; Bebee 
et al., 1992; Wang et al., 1992). 
When using reverse transcription PCR (RT-PCR) there is another 
enzymatic method, employing a restriction endonuclease digestion, that 
can be used to deal with contamination problems. Restriction enzymes 
recognize specific double-strand DNA sequences but act on the 
equivalent single strand sequence inefficiently, if at all. A suitable enzyme 
can thus selectively destroy contaminant DNA but leave the reverse 
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transcribed single strand cDNA intact to initiate amplification (Dougherty 
et al. , 1993). 
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Fig. 9 Diagram of the UNG restriction-system . The top duplex molecule represents 
natural T-containing DNA from clinical specimens; the bottom duplex represents 
amplified DNA containing U. Following treatment with UNG, T-containing DNA is 
unaffected , but the uracil bases are cleaved from U-containing amplified DNA (Sirko and 
Ehrlich, 1994). 
All these protocols that assist with contamination control will mostly be 
effective in the case of amplicon build up, and there are no quick 
solutions for an existing (T-containing) contamination problem. Good 
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laboratory practice is still highly recommended as no sterilization protocol 
is either 100% efficient or completely foolproof (Kwok and Higuchi, 1989). 
3.2 Materials and Methods 
3.2.1 Choice of • primers and 
template 
Since HIV shows marked heterogeneity, proviral sequences of HIV-I, II 
were amplified by using primer pairs and probes (Table 5) derived from 
highly conserved regions of the HIV genome. The primers and their 
respective probes (prepared by Professor Bates from the Department of 
Biochemistry, University of Cape Town) were identical in sequence to 
well-characterized primers and probes from published literature (Ou et al., 
1988; Kellogg et al., 1990; Brandt et al., 1992). 
DNA extracted (see chapter 4.2) from lymphocytes from a known 
seropositive, PCR-positive adult patient was used as the template in all 
the PCR optimization reactions. This DNA was used in preference to a 
plasmid containing HIV-I sequences since that had previously led to false 
positive results due to amplicon contamination. Furthermore, the plasmid 























































































































































































































































































































































































3.2.2 Changing PCR parameters 
3.2.2.1 Magnesium concentration 
A dilution series of 1 M MgC'2 was made in ultrapure water and the 
following concentrations of 1 ,5mM, 2,5mM, 3,5mM, 4,5mM, 5,5mM, 
6,5mM, 7,5mM, 8,5mM, 9,5mM and 10,5mM were evaluated. Unless 
otherwise stated, the assessment of parameters was performed using the 
"standard" PCR protocol (Chapter 3.1.1 ). Agarose gel electrophoresis 
and Southern blot hybridization were performed on the PCR products to 
evaluate the effect of different MgCl2 concentrations, for each of the 
different HIV primer pairs. 
3.2.2.2 Taq DNA polymerase concentration 
A dilution series of Taq polymerase enzyme was made that ranged from 
0.25 Units to 2.5 Units per 50µ1 reaction sample. All samples contained 
the calculated optimum MgCl2 concentration for the correlating primer 
pair. The "standard" PCR protocol was used for amplification, followed by 
agarose gel electrophoresis and Southern blot hybridization to evaluate 
the effect of the different concentrations of the enzyme. 
3.2.2.3 Primer concentration 
The primer concentration was not optimized. The recommended 
concentration of 50pmol of each primer per reaction was used after the 
Taq and MgC'2 concentration had been optimized (Ou et al. , 1988; 
Kellogg and Kwok, 1990; Brandt et al. , 1992). 
3.2.2.4 Annealing temperature 
An annealing temperature of 55°C was used during the amplification of all 
the primer pairs examined in this study as described in the literature (Ou 
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et al., 1988; Kellogg et al. , 1990; Brandt et al. , 1992; Lynch et al., 
1992). 
3.2.2.5 Sensitivity check after optimization 
of the parameters 
The sensitivity of the PCR, after optimization, was assessed by using 
different dilutions of the plasmid pBH10 (pUC 19 cloning vector 
containing an insert of a truncated HTLV-111 proviral isolate of HIV-1) as 
template (Hahn et al., 1984). The plasmid was stored as glycerol stock 
cultures at -70°C in the Department of Medical Microbiology at the 
Medical School, UCT. Plasmid DNA was amplified in bacterial cells and 
large scale preparations were obtained using isopycnic gradient 
centrifugation in caesium chloride (CsCI) gradients according to the 
method described by Sambrook et al. , (1989). 
3.2.2.5.1 Plasmid preparation 
A sample from the glycerol stock culture of pBH10 was streaked onto a 
Luria agar plate containing 1 mg/ml ampicillin and incubated at 37°C 
overnight. A single bacterial colony was selected and inoculated into 
10ml Luria broth also containing ampicillin . The culture was incubated for 
6hr at 37°C with shaking, whereafter it was inoculated into 200ml Luria 
broth (containing ampicillin) and incubated for a further 16hr at 37°C with 
shaking. 
Bacterial cells were harvested by centrifugation at 6000rpm at 4°C for 
15min in a J2-21 Beckman centrifuge (JA-10 rotor) . The culture 
supernatant fluid was removed and the bacterial pellet was resuspended 
in 3ml of 25% sucrose in 0,05M Tris-HCI pH8.0. The cell suspension was 
then transferred to a polypropylene tube and maintained on ice. 
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Cells were lysed by the addition of 10mg powdered lysozyme (Sigma) 
whereafter the cells where kept on ice for another 5min and 0,25M 
Na2EDTA, pHS.O, was added. Cellular proteins were denatured by the 
addition of 5ml Triton/Doc solution (1 % Triton X-100, 0,4% Na-
deoxycholate in 0,01 M Tris and 1 mM Na2EDTA, pHS.O). This suspension 
was mixed very carefully and kept on ice for 30min whereafter it was 
centrifuged at 15000rpm for 45min at 4°C using a Beckman JA-20 rotor to 
remove bacterial proteins and associated chromosomal DNA The 
plasmid-containing supernatant was removed and the volume adjusted to 
10ml with ultrapure water. 
3.2.2.5.2 Plasmid purification 
9,5g of CsCI (Boehringer Mannheim) was added to the DNA solution in 
order to adjust the density to 1,6g/ml. Ethidium bromide (Merck) was then 
added (0,2g/ml) and the solution was transferred to two polyallomer 
tubes, which were then heat sealed. This solution was ultracentrifuged at 
50 OOOrpm for 20hr at 20°C in a vertical Vti65 rotor and Beckman L 7 -55 
ultracentrifuge to separate plasmid DNA from residual cellular 
components. The fraction containing the plasmid was identified as a 
visible band upon illumination of the tubes with low energy (302nm) UV 
light. The plasmid band was removed from the tube by puncturing the 
side of the tube with a needle and syringe, and transferring the plasmid 
fraction into an Eppendorf microfuge tube. 
Ethidium bromide (EtBr) was extracted by mixing the plasmid DNA 
solution with an equal volume of isoamyl alcohol , allowing the two phases 
to separate and discarding the upper organic phase (which should be 
pink as it contains EtBr). This was repeated four times. The aqueous 
phase was then diluted by the addition of three volumes of ultra-pure 
water. The plasmid DNA was precipitated by the addition of 2,5 times the 
volume of 100% cold ethanol at -70°C overnight. The precipitate was 
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concentrated by centrifugation at 12000rpm in a Beckman microfuge and 
the pellet was washed in 70% ethanol, dried in a Speed Vac vacuum drier 
and resuspended in 100µ1 ultra-pure water. 
The yield and quality of the plasmid DNA was determined by measuring 
the optical density of the solution in a Beckman DU-24 spectrophotometer 
over a wavelength range of 220nm to 310nm. The approximate 
concentration of the DNA in solution could then be calculated by 
multiplying the absorbance of the solution by the dilution factor and by 50 
( as it is known that an absorbance reading of 1 at 260nm corresponds to 
a DNA concentration of SOµg/ml). The yield was in the order of 65µg/ml. 
An estimation of the purity of the DNA was also obtained by calculating 
the ratio of the absorbance readings at 260nm and 280nm. A ratio of 
approximately 1 ,8 is characteristic of a pure preparation (Sambrook et al., 
1989). 
3.2.3 Incorporation of uracil-N-
glycosylase 
3.2.3.1 Magnesium concentration 
It was necessary to determine the optimal MgCl2 concentration to achieve 
maximum amplification and to verify the suitability of the dU-containing 
products for further analysis. A dilution series of 1 M MgCb was made in 
ultra-pure water and concentrations ranging from 1 ,SmM to 1 O,SmM were 
evaluated using agarose gel electrophoresis and Southern blot 
hybridization after PCR was performed. 
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3.2.3.2 Deoxy-uridine triphosphate 
concentration 
Substitution of dTTP with dUTP in conjunction with the use of UNG 
(Chapter 3.1.4.7.3) had been demonstrated to selectively prevent carry-
over contamination. The optimum dUTP concentration for each primer 
pair was established by preparing a dilution series of dUTP (200µM to 
1 OOOµM) and including a different concentration in each separate PCR 
mixture. The "Standard" PCR protocol was used, followed by agarose gel 
electrophoresis and Southern blot hybridization, and the optimum dUTP 
concentration was judged by the intensities of the bands. 
3.2.3.3 Incorporation of UNG 
After optimizing the MgCl2 and dUTP concentrations, the following 
protocol was followed to incorporate UNG (Gibco/BRL) into the PCR 
mixture as a preventative measure for carry-over-contamination. Half a 
unit UNG was added to a 50µ1 PCR reaction mixture containing the DNA 
template and incubated at 37°C for 1 Omin (Package insert, UNG Gibco 
BRL). The enzyme was then denatured for 1 Omin at 94°C before PCR 
was performed. The products were analysed by agarose gel 
electrophoresis and Southern blot hybridization. 
3.2.4 PCR product manipulation 
3.2.4.1 Agarose gel electrophoresis of PCR 
products 
The PCR products were resolved by horizontal, submerged gel 
electrophoresis (Sambrook et al.; 1989) in 4,5% agarose (Promega) at 70 
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volts for 2hr using a TAE-buffer (0,04M Tris-acetate, 1 mM EDTA pH8.0). 
After staining with ethidium bromide (Merck) the DNA fragments were 
visualised by transillumination of the gel with ultraviolet light (UV) at 
302nm on a UVP transilluminator. 
3.2.4.2 Southern transfer of DNA fragments 
Following gel electrophoresis, the DNA fragments were transferred onto 
Hybond N membrane (Amersham) using a modification of the method 
described by Southern, 1975. The gel was rinsed in distilled water and 
the DNA fragments within the gel were depurinated by immersing the gel 
in denaturing buffer (1 ,5M NaCl and 0,5M NaOH) for 30min at room 
temperature with shaking. Hereafter, the gel was rinsed in distilled water 
and placed in neutralizing buffer (20mM NaOH and 1 M ammonium 
acetate) for 40min at room temperature with shaking. A capillary blot was 
set up by placing the gel onto a clean glass plate, wetting the nylon 
membrane (Hybond N) with neutralizing buffer and placing it on top of the 
gel. A plastic disposable pipette was used to roll out any air bubbles that 
might have been trapped under the membrane and which might prevent 
complete transfer of the DNA Three sheets of 3MM (Whatman) paper 
were cut to size, soaked in neutralizing buffer and placed on top of the 
Hybond N membrane. The 3MM paper was, in turn , covered with a 
generous amount of paper towels and weighted with a glass plate and 
bricks. Transfer was allowed to proceed overnight. After careful 
dismantling of the apparatus, the membrane was marked with pencil to 
allow later identification of the lanes. The DNA was cross-linked to the 
membrane by exposure of the membrane to short wave UV light (250nm) 
in a UV-crosslinker (Hoefer Scientific Instruments). The membrane was 
then briefly washed in 6X SSC (sodium chloride /sodium citrate buffer) 
before hybridization. 
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3.2.4.3 Digoxigenin labelling of 
oligonucleotides 
Oligonucleotide probes were labelled with digoxigenin-dUTP (DIG-dUTP) 
using a DIG oligonucleotide tailing kit (Boehringer Mannheim) to generate 
the non-radioactive probe. For each reaction , oligonucleotides 
corresponding to 1 OOpmol 3'0H ends (5µ1) were mixed with 4µ1 of 5X 
tailing buffer (1 M potassium cacodylate; 0, 125M Tris.HCI ; 1,25 mg/ml 
bovine serum albumin, pH6.6), 4µ1 of 25mM CoC'2: 1 µI of 1 mM DIG-
dUTP; 1 µI of 1 OmM dATP; 1 µI of terminal transferase, and made up to a 
final volume of 20~tl with ultra-pure water. The reaction was incubated at 
37°C for 3hr and placed on ice. Two microlitres of a glycogen-EDTA 
solution (1 µI 20mg/ml glycogen, and 200µ1 0.2M EDTA, pH8.0) was 
added to stop the reaction. The labelled oligonucleotide was then 
precipitated with 2,5µ1 4M LiCI and 75µ1 prechilled (-20°C) absolute 
ethanol and left at -70°C for at least 90min, before centrifugation at 
12000g. The pellet was washed with 50µ1 of cold 70% (v/v) ethanol, dried 
under vacuum and dissolved in 1 OµI of ultra-pure water. The labelled 
probe (1 OµI) was then added to 20ml of prehybridization solution (6X 
SSC, 1 % blocking solution [Boehringer Mannheim] and 0, 1 % SOS), to 
make it ready for use. The DIG-system guarantees the detection of 
0,03pg homologous DNA using chemiluminescence (Boehringer 
Mannheim, 1993). 
3.2.4.4 Hybridization of labelled 
oligonucleotides to DNA fragments 
Membranes bearing immobilized HIV-1 DNA fragments were incubated at 
42°C for 4hr, using a shaking water bath, in an aqueous prehybridization 
solution (see above). A formamide hybridization solution is usually 
recommended when a RNA probe is used in the hybridization step. The 
prehybridization solution was then replaced with hybridization solution 
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containing the DIG-labelled probe (chapter 3.2.4.3). Hybridization was 
allowed to take place overnight at 42°C in a shaking water bath. After 
each hybridization procedure, the membrane was washed at successively 
higher stringency conditions until optimal specificity was reached, as 
shown by chemiluminescent detection. A combination of high salt 
concentration in the wash buffer and low temperatures are usually 
referred to as a low stringency condition, whereas a combination of low 
salt concentration and high temperatures usually indicate a high 
stringency condition. 
To determine optimum specificity the blot was first washed in 2X SSC; 
0, 1 % (w/v) SOS at 42°C for 2x5min and then in 0, 1X SSC; 0, 1 % SOS for 
2x15min at increasing temperatures (thus increasing the stringency 
condition) ranging from room temperature to 88°C. 
3.2.4.5 Chemiluminescent detection of the 
hybridized probes 
The blots were washed briefly (1-5min) in washing buffer consisting of 
0,3% Tween-20 in buffer 1 (0, 1 M maleic acid, 0, 15M NaCl , pH7.5), and 
then immersed for 30min at room temperature in buffer 2 [blocking stock 
solution (proteolytic fragments of casein in powder form) diluted 1: 10 in 
buffer 1]. The membranes were then covered with antibody conjugate 
solution (anti-digoxigenin - AP, Fab fragments) diluted 1: 10 000 in buffer 
2, and gently shaken for 30min at room temperature. The unbound 
conjugate was removed by washing the blots for 2x15min at room 
temperature in washing buffer. An equilibration step of 2-5min in buffer 3 
(0, 1 M Tris-HC1 , 0, 1 M NaCl, 50mM MgCl2, pH9.5) preceded the addition 
of the diluted substrate [lumigen PPD, 4-methoxy-4-(3-phosphate-phenyl-
spiro-1,2-dioxetane-3,2'-adamantane) disodium salt] (1:100 in buffer 3) 
before the blots were dried on 3MM (Whatman) paper and sealed in 
plastic bags. The sealed blots were pre-incubated for 15min at 37°C 
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before exposure for 90min at room temperature to X-ray (Agfa Curix RPI) 
film, in the presence of a Cronex intensifying screen. After exposure, the 
X-ray film was developed by immersion in developer for 3min, stop 
solution for 1 min and fixer for 3min. The developer used was Polycon A 
(Champion photochemistry) diluted 1 in 5. The stop solution consisted of 
2% (v/v) acetic acid, and the fixer used was Amfix (Champion 
photochemistry) diluted 1 in 4. 
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3.3 Results 
3.3.1 Changing PCR parameters 
3.3.1.1 Optimum magnesium concentration 
for PCR mixtures containing dTTP or dUTP 
The optimum MgCb concentration was determined by the most intense 
band of PCR product after Southern blot hybridization with a DIG-labelled 
oligonucleotide probe. 
The chemilumigram of primer pair SK145,431 showed equally strong 
signals at both extremes of the dilution series, i.e. at 1,5 - 3,SmM and at 
10,SmM. Weaker signals were detected in the 4,SmM to 9,5mM range 
(Fig. 10). 
1 2 3 4 5 6 7 8 9 10 --- ----
--- -142bp 
Fig. 10 Optimization of the MgCl2 concentration for primer pair SK 145,431 , using 
dTTP-containing (200µM) mastermixes, is illustrated in the magnesium titration above. 
Increasing MgCl2 concentrations are shown from left to right: Lane 1 1,SmM; Lane 2 
2,SmM; Lane 3 3,SmM; Lane 4 4,SmM; Lane 5 5,SmM; Lane 6 6,SmM; Lane 7 
7,SmM; Lane 8 8,SmM; Lane 9 9,SmM; Lane 10 10,SmM. Ten microlitres of the PCR 
products was separated on a 4,5% agarose gel , the DNA was transferred to a nylon 
membrane by Southern blot and hybridized with a DIG-labelled oligonucleotide probe. 
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The primer pair SK38,39 showed a similar pattern, of two strong signals. 
This phenomenon was not observed for primer pair, SK29,30. 
Established optimum MgClz concentrations (Table 6) for the respective 
HIV primers when using dTIP-containing mastermixes were: 1 ,5mM for 
SK38,39; 2,5mM for SK29,30; 1 ,5mM for SK68,69; and 1 ,5mM for 
SK145,431. In the case of primer pairs SK145,431 and SK38,39 where 
equally strong signals were shown, the lower concentration of MgC'2 was 
chosen for economic reasons 
It was necessary to re-adjust the MgClz concentration, when dUTP-
containing mastermixes were used for HIV PCR. The optimum 
concentrations were determined in the same manner as for the dTIP 
mastermixes and were found to be: 3,5mM for SK38,39 (Fig. 11 ). 
The optimum Mg2+ concentration for the primer pair SK29,30 was not so 
clear (Fig. 12), and a concentration of 3,5mM was chosen on the basis of 
best sensitivity and specificity (compared to the dTIP control included in 
the PCR run), as judged by the intensity of the band (maximum 
sensitivity) , with minimal non-specific bands present (maximum 
specificity) . 
An optimal MgC'2 concentration of 4,5mM was determined for SK145,431 
in the dUTP system (results not shown). 
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1 2 3 4 5 6 7 8 9 10 11 
--115bp 
Fig. 11 Optimization of the MgCl2 concentration for primer pair SK38,39, using dUTP-
containing (200mM) mastermixes. Increasing MgC'2 concentration are shown from left 
to right: Lane 1 1,SmM; Lane 2 2,SmM; Lane 3 3,SmM; Lane 4 4,SmM; Lane 5 5,SmM; 
Lane 6 6,SmM; Lane 7 7,SmM; Lane 8 8,SmM; Lane 9 9,SmM; Lane 10 10,SmM. Lane 
11 is the dTTP control containing 1,SmM MgCl2. Ten microlitres of the PCR product 
was separated on a 4,5% agarose gel, the DNA was transferred to a nylon membrane by 
Southern blot and hybridized with a DIG-labelled oligonucleotide probe. 
1 2 3 4 5 6 7 8 9 10 11 
---104bp 
Fig. 12 Optimization of the MgCl2 concentration for primer pair SK29,30, using dUTP-
containing (200mM) mastermixes. Increasing MgCl2 concentration are shown: Lane 1 
1,SmM; Lane 2 2,SmM; Lane 3 3,SmM; Lane 4 4,SmM; Lane 5 5,SmM; Lane 6 6,SmM; 
Lane 7 7,SmM; Lane 8 8,SmM; Lane 9 9,SmM; Lane 1 O 1 O,SmM. Lane 11 is the dTTP 
control containing 1,5mM MgCl2. Ten microlitres of the PCR product was separated on 
a 4,5% agarose gel, the DNA was transferred to a nylon membrane by Southern blot and 
hybridized with a DIG-labelled oligonucleotide probe. 
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Table 6 Optimum magnesium concentration 
for the different HIV primer pairs 
*This primer set was eliminated from the study due to early contamination problems. 
3.3.1.2 Optimum Taq DNA polymerase 
concentration 
The optimal concentration of Taq DNA polymerase was determined by 
the intensity of the HIV-specific band on an EtBr-stained agarose gel. 
Two of the primer pairs, SK145,431 (Fig. 13) and SK29,30, showed an 
increasing accumulation of non-specific background products as the 
enzyme concentration was increased. This was not noted with primer 
pair SK38,39 (Fig. 14). With all the primer pairs it was also observed that 
when very low enzyme concentrations were used in the reaction, an 
insufficient amount of product was made (not visible on an agarose gel). 
For this reason it was decided to confirm positive PCR specimens by 
Southern blot hybridization with a DIG-labelled probe. 
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1 2 3 4 5 6 7 8 9 
- 142bp 
Fig. 13 Optimization of the Taq DNA polymerase concentration for primer pair 
SK145,431. Lane 1, MWVI; Lane 2, 0,25U; Lane 3, 0,5U; Lane 4, 0,75U; Lane 5, 
1,0U; Lane 6, 1,25U; Lane 7, 1,5U; Lane 8, 2,0U; Lane 9, 2,5U . Ten microlitres of PCR 
product was separated on a 4,5% agarose gel, and stained with EtBr. 
1 2 345 678 9 
--- 115bp 
Fig. 14 Optimization of the Taq DNA polymerase concentration for primer pair 
SK38,39. Lane 1, MWVI; Lane 2, 0,25U; Lane 3, O,SU; Lane 4, 0,75U; Lane 5, 1,0U; 
Lane 6, 1,25U; Lane 7, 1,5U; Lane 8, 2,0U; Lane 9, 2,SU. Ten microlitres of PCR 
product was separated on a 4,5% agarose gel, and stained with EtBr. 
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Chosen optimal Taq DNA polymerase concentrations are summarized in 
Table 7. 
Table 7 Optimum Taq concentration for the 
different HIV primer pairs 
3.3.1.3 Optimum concentration of dUTP 
when using the UNG-system 
The substitution of dUTP required an adjustment of the dUTP 
concentration to obtain the same sensitivity as that shown by the dTTP 
system. The optimum dUTP concentrations were determined by 
comparing the intensity of the bands produced with different dUTP 
concentrations (as detected on the chemilumigram after Southern blot 
hybridization) with that of the control dTTP (200µM) band and selecting 
the minimal dilution that gave comparable signals. The optimal dUTP 
concentrations were similar for all 3 HIV primer pairs tested: 400-600µM 













Fig. 15 Optimization of the dUTP concentration for primer pairs SK29,30 (A), 
SK145,431 (B), and SK38,39 (C) is illustrated above. Increasing dUTP concentrations 
are shown from left to right: (A , B and C) : Lanes 1, 200µM; Lanes 2, 400µM; Lanes 3, 
600µM; Lanes 4, 800µM; Lanes 5, 1 OOOµM ; and Lanes 6, 200µM dTTP controi. Ten 
microlitres of the PCR product was separated on a 4,5% agarose gel, the DNA was 
transferred to a nylon membrane by Southern blot and hybridized with a DIG-labelled 
oligonucleotide probe. 
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Table 8 Optimum dUTP concentration 
compared with the dTTP concentration for 
the different HIV primer pairs 
*Due to contamination problems, this set of primers was eliminated from the study 
before the introduction of the UNG-system. 
3.3.1.4 Confirmation of HIV PCR sensitivity 
after optimization of the magnesium-, Taq-, 
and dUTP concentrations 
3.3.1.4.1 Confirmation of sensitivity using a 
dilution series of pBH1 O 
After optimization of the MgCl2, Taq DNA polymerase and dNTP 
concentrations, the PCR sensitivity was confirmed using different 
dilutions of the plasmid pBH10. The plasmid titration showed that the 
optimised system could detect as little as one copy of plasmid when using 
either of the primer pairs , SK38,39 (Fig. 16A) or SK145,431 (Fig. 168). 
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A B 
1 2 3 1 2 3 
115bp- -142bp 
Fig. 16 Confirmation of HIV PCR sensitivity after optimization, using the primer pairs 
(A) SK 38,39, and (B) SK145,431 with decreasing amounts of the plasmid (pBH10). 
Lane 1, 100 copies; Lane 2, 1 O copies; and Lane 3, 1 copy. Ten microlitres of the PCR 
product was separated on a 4,5% agarose gel, the DNA was transferred to a nylon 
membrane by Southern blot and hybridized with a DIG-labelled oligonucleotide probe. 
The LT~ primer set was also subjected to this sensitivity test, and as 
expected, gave negative results (no amplification), probably because the 
plasmid, pBH10 only contains a fragment of one of the L TR regions of 
HIV and is thus not a suitable template for this primer set. 
3.3.1.4.2 Comparative sensitivity of PCR 
systems containing either dTTP or dUTP for use 
on clinical material 
DNA from three PCR-positive samples (2 adults and 1 infant) were used 
in duplicate to compare the dTIP system with the dUTP system. The two 
systems displayed comparable sensitivity as judged by the intensity of the 
DNA bands obtained after Southern blot hybridization. There was no 
significant loss of product yield when the dUTP system was used (Fig. 
17). 
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1 2 3 4 5 6 7 8 9 10 11 12 
--115bp 
dUTP dTTP 
Fig. 17 A comparison of the dTTP and dUTP systems after optimization, on duplicate 
clinical samples: dUTP PCR (lanes 1 - 6) : lanes 1 and 2, pas adult patient no.1; lanes 
3 and 4, pos infant; lanes 5 and 6, pos adult patient no. 2. dTTP PCR (lanes 7 - 12): 
lanes 7 and 8, pas adult patient no. 1; lanes 9 and 10, pas infant; lanes 11 and 12, pos 
adult patient no. 2. 
3.3.2 Incorporation of UNG as a 
preventative measure for "carry-
over" contamination 
The incorporation of the UNG enzyme in the reaction mixture prior to 
amplification resulted in a substantial loss of amplification signal after 
Southern blot hybridization (Fig. 18). The enzyme was therefore titrated 
to determine whether lowering the concentration would improve the 
amplification signal. In addition, the PCR protocol was altered to include 
an extra step at the end of the program whereby the reactions were held 
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at 72°c: prior to any analysis. Neither of these alterations yielded a 
significant improvement and a loss of product yield and sensitivity was 
still noted (results not shown). Likewise, storage of the PCR products at 
4°C before analysis did not result in an improved detection. The adverse 
effect on the product yield induced by the UNG-system was not only 
apparent when using dUTP-containing mastermixes, but were also 
observed when dTTP-containing mastermixes were used (not shown). 
1 2 3 4 
--104bp 
Fig. 18 The incorporation of UNG (to control "carry-over" contamination) is shown after 
HIV PCR and Southern blot hybridization have been performed using primer pair 
SK29,30. Lanes 1 and 2, positive patient DNA amplified using dUTP mastermixes 
without the addition of UNG; lanes 3 and 4, DNA from the same positive patient, but 
amplified using dUTP mastermixes with the incorporation of O,SU UNG and heat 
inactivation before the onset of PCR. 
3.3.3 Optimal stringency conditions 
when hybridizing with DIG-labelled 
oligonucleotide probes 
Optimal specificity and sensitivity after Southern blot hybridization was 
achieved by using a 42°C washing temperature combined with a low salt 
wash buffer (0, 1 X SSC, 0, 1 % SOS). Higher temperatures, using the 
same low salt buffer, resulted in weaker signals on the chemilumigram, 
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indicating a loss of sensitivity at these higher temperatures. A faint signal 
was still visible after washing the membranes at 78°C, but no signal was 
visible when the membranes were exposed to a washing temperature of 





Fig. 19 Optimal stringency washing conditions were determined by increasing the 
temperature during the 2X1 Smin washing step (with the 0, 1 X SSC, O, 1 % SOS buffer) 
after hybridization, (A) 42°C; (B) 57°C; (C) 67°C; (D) 78°C. 
Temperatures above 42°C resulted in progressive loss of signal. 
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3.4 Discussion 
Before a laboratory assay can be applied in a diagnostic system, it is 
essential that it be evaluated to ensure maximum specificity and 
reproducibility so that false positive diagnoses are eliminated. Maximum 
sensitivity is also required to avoid false negative results. In the case of 
PCR it is not always possible to simultaneously optimize each criterion for 
both those samples that contain high copy numbers and those with very 
low copy numbers of target DNA. In this study the protocol was optimized 
for low copy numbers since the work was aimed primarily at the screening 
of infants. 
It is known that both specificity and sensitivity are affected by the levels of 
Mg2+ in the PCR reaction, and these results showed that the optimal 
concentration of MgCl2 varied depending upon the choice of dNTP (the 
concentration of available Mg2+ is affected by the phosphate 
concentration of the buffer, and dNTPs are the main source of phosphate 
groups). Concentrations of 1,5mM MgCb and 200µM of dTIP were 
optimal when using the dTIP-system, however, when the dUTP-system 
was used a two-fold to three-fold increase in the MgCb and dUTP 
concentrations were required to achieve similar results to those shown by 
the dTIP-system. The higher concentrations of dUTP that were needed 
probably dictates the simultaneous requirement for higher MgCb 
concentrations, since high concentrations of dNTPs appear to 
quantitatively bind Mg2+, and hence reduce the available magnesium in 
the PCR buffer. This in turn could also affect the efficiency of the Taq 
DNA polymerase. The observed accumulation of non-specific 
amplification products at higher Mg2+ concentrations (3,SmM to 9,5mM) 
corroborates observations made by Erlich (1989). In the case of 2 primer 
pairs (SK38,39 and SK145,431) it was not possible to distinguish 
between two apparently optimal levels of MgCl2. The reasons for this are 
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not clear, but since there was little effect on the final degree of 
amplification the lower concentration of MgCb was chosen, both for 
economic reasons and to avoid possible undue ill effects on the 
performance of the Taq enzyme (Innis and Gelfand, 1990; Saiki , 1989). 
All four primer pairs performed well and the optimal Taq DNA polymerase 
concentrations for each of the primer pairs were found to be similar (1 ,0 
to 1 ,5 units). The concentrations required were in some instances higher 
than those described by other researchers. For example, Simmonds et 
al. (1990) used 1,SU/100µ1 reaction volume, Ou et al. (1988) used 
0,6U/50µ1 and Kwok and Sninsky (1993) used 2,SU/100µ1 in their HIV 
PCR reactions. In titrations with two different primer pairs, SK29,30 and 
SK145,431, it was noted that an increase in Taq concentration led to an 
accumulation of non-specific background products. Although this might 
indicate decreased specificity, it was ensured that only HIV specific 
products were detected by making use of specific probes. It is 
nonetheless, essential to use some excess of polymerase when PCR is 
applied as a diagnostic assay for different patient samples, because of 
the potential inhibiting activity of haem-related products in the sample. 
After the optimal MgClr, Taq-, and dNTP concentrations had been 
incorporate_d into the standard protocol , a PCR run was performed on a 
dilution series of pBH10 to verify the sensitivity of the assay for each 
primer pair. Whether a single band, many bands or a smear was visible 
on the gel , Southern blot analysis and oligonucleotide hybridization was 
performed as a specificity control. The fact that the optimized system was 
able to detect a single copy of target plasmid DNA was encouraging. 
However, it is necessary to bear in mind that results obtained with dilute 
samples do not give a true reflection of the situation in diagnostic assays 
where clinical samples may vary widely from one another. It might in 
future be useful to employ a quantitative assay to determine whether the 
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target copy number in the patient sample is sufficient or too low,. Alimenti 
et al. (1994) described the quantitation of HIV in whole blood of infected 
children using a quantitative microculture method for PBMCs, and Menze 
et al. (1992) developed and optimized a competitive RT-PCR assay for 
the quantitative detection of HIV-1 viremia in PBMCs. In the present 
study the use of a nested primer set, which can potentially increase the 
sensitivity of the assay, was ruled out as this type of system is very prone 
to "carry-over'' contamination and thus increases the opportunity of false 
positive results. This decision was re-inforced by early experiments 
during which the nested env primer pair (C1 C2 as outer primers and 
SK68,69 as inner primers) was eliminated from this study as a result of 
contamination which could not be cleared from our diagnostic system. 
Amplicons were detected in the buffers as well as in the water bath 
situated in the DNA preparation room (results not shown) requiring many 
months of effort and stringent measures to eliminate. 
It was found that the specificity of the assay could be further increased by 
optimizing the stringency conditions of the washes after oligonucleotide 
hybridization. The combination of a temperature of 42°C, with a low salt 
concentration in the washing buffer (0, 1 X SSC) provided very stringent 
conditions which guaranteed the optimum specificity and sensitivity of the 
assay. 
The greatest concern in PCR protocols is the inadvertent introduction of 
contamination. For that reason, dUTP-system was chosen in preference 
to dTTP-system ( despite the fact that the two dNTPs performed equally 
well) . This was a precautionary measure so that in the event of amplicon-
related contamination it could more easily be controlled by utilizing the 
UNG enzyme. However, although this enzyme has been put forward as a 
solution to amplicon contamination problems, in our hands it was not 
successful as the presence of the enzyme appeared to inhibit the 
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amplification. The loss of amplification signal, after using the UNG-
protocol, could be due to the breakdown of amplification products by 
residual UNG activity during or shortly after amplification. However, 
decreasing the enzyme concentrations did not alleviate the problem, nor 
did extreme changes in the temperature of the PCR product prior to gel 
electrophoresis have any beneficial effect. Similar observations 
regarding the adverse effect of UNG have been made by other 
researchers when using the UNG-protocol during PCR assays for 
amplification of mycobacterial sequences (B. Allan, personal 
communication). As the UNG enzyme compromised the sensitivity of the 
PCR protocol, it has been omitted from all routine PCR amplifications. 
However, dUTP is still incorporated and should any "carry-over" 
contamination problem arise, the enzyme can be incorporated as one of 
the measures used in a broad program of eradication to clear all the 




Application of HIV PCR in 
amplification of HIV-1 
sequences from seropositive 
sera. 
4.1 Introduction 
Serological assays are used to identify persons who have been exposed to HIV-I or -II, but they do not conclusively determine a 
current infection as indicated by the frequent occurrence of serology 
indeterminate results. The most reliable demonstration of a viral infection 
is based on isolation of the virus by cell culture or on the detection of the 
viral genome in patients' cells (Laure et al., 1988). The isolation of HIV 
involves prolonged co-cultivation of peripheral blood mononuclear cells 
(PMBCs) with phytohemagglutinin (PHA)-stimulated lymphocytes from an 
uninfected donor. This procedure is labour intensive, time consuming, 
costly, requires special laboratory facilities that are not readily available 
in most diagnostic laboratories, and lacks sensitivity in that viruses 
cannot be isolated consistently from persons with documented infections 
(Ou et al. , 1988; Loche and Mach, 1988). The polymerase chain 
reaction can be used directly to determine the presence of HIV genetic 
information in the DNA from PBMCs of a patient (Laure et al. , 1988; Ou 
et al., 1988; Loche and Mach, 1988; Lifson et al. , 1990). The PCR 
approach has been reported to be extremely sensitive ( detecting 1-10 
molecules of HIV DNA in the total nucleic acid from one million cells (Ou 
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et al., 1988), and allowing the detection of infection (presence of viral 
DNA) in the early stages before antibody production begins, sometimes 
referred to as the "window period" (lmagawa et al., 1989). 
After optimization of the PCR parameters (Chapter 3), this technique was 
used to detect HIV-1,11 proviral sequences in PMBCs of patients who were 
screened in the routine laboratory for HIV antibodies. The objective was 
to correlate the PCR results with the serological status of these patients 
and thus to gauge the sensitivity and specificity of the optimized PCR 
protocol. 
4.2 Materials and Methods 
4.2.1 Patient population 
The study population consisted of 153 randomly selected patients whose 
blood was sent for HIV screening to the routine diagnostic laboratory in 
the Department of Clinical Virology at Groote Schuur Hospital (Table 9) . 
Some of the patients either had clinical signs that were suggestive of an 
HIV infection (such as pneumonia, tuberculosis, Kaposis' sarcoma) or 
they were considered to be at risk of being infected with HIV e.g. infants 
of HIV positive mothers or sexual contacts of HIV-infected persons. 
However, for a number of patients, the clinical details were not supplied 
on the request forms. The study population included 55 males (8 white 
males, 12 coloured males, and 35 black males) , 57 females (2 white 
females, 17 coloured females, and 38 black females) and 41 whose 
gender was unknown. 
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Table 9 Source of blood samples from 153 
randomly selected patients referred for HIV 
screening 
Institutions Number of 
patients tested 
Groote Schuur Hospital \ 
·····Red.£ross War ··:~~e>ri~)···~h)J~flns···HospitJ/············· 26 
Private Pathologists .. 
·. __ .:;;.. . . ·:::.-:\\:· 




.. Ge~rge, ~udtshJ~)h, M6~~~/bay Hos~itals ) 5 .. ···•···· · 
·MoXbray Mater~rtyH~:tft~j > .•.... 
Conradie Hospital · 
Brooklyn Chest: Hospital </ .. ·. · · ·· 
. . . . : . . 










*Unknown details due to incomplete information received on the request forms. 
Serum samples were initially screened for the presence of HIV 
antibodies. As a follow-up, a sample of each seropositive individual's 
blood was collected in a tube containing ethylenediaminetetra-acetic acid 
(EDTA) and processed to separate the PBMCs 
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4.2.2 HIV antibody detection 
All the serum samples were initially evaluated for antibodies to HIV-I and 
HIV-II by one ELISA test (Abbott 3.0, recombinant HIV-I/HIV-II antigens, 
Abbott Diagnostics Division, detecting lgG and lgM simultaneously) and 
positive results were confirmed using a second ELISA (Enzygnost, 
synthetic env peptides, Behring) as well as a rapid' assay, either the rapid 
agglutination test (Capillus latex agglutination assay, using recombinant 
polypeptides from the env region, Cambridge Biotech Limited); or the 
rapid ELISA (Clonatec Rapid HIVl,11 Ab using two synthetic peptides from 
the, gp41 for HIV-I and gp36 for HIV-II, regions). A commercial western 
blot assay (New LAV-blot I, Diagnostics Pasteur) was performed on 
serum samples that showed discrepant serology results (i.e. if one or both 
the confirmatory assays were negative). The western blot was 
considered positive if the specimen reacted with at least two of the 
following bands: gp160, gp120, gp41 , p24. Any other pattern of bands 
was interpreted as representing an indeterminate result. 
4.2.3 DNA preparation 
Peripheral venous blood from each seropositive patient was collected in 
sterile EDTA, and stored at 4°C for not longer than 48hr before 
processing. Negative control blood samples were included among the 
patients' blood samples so that no bias was introduced. The PBMCs 
were isolated and DNA prepared using the lysis method as described by 
Kawasaki (1990) with a few alterations. 
One hundred microlitres of whole blood was mixed with 1,4ml of TE buffer 
(10mM Tris-HCI, 1mM EDTA, pH7.6) to lyse the red blood cells, and 
centrifuged for 45sec at 13,000g in a Beckman E microfuge. The pellet of 
concentrated PBMCs was resuspended in 1 ml TE buffer by vortexing, 
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and washed by repeat centrifugation. This "washing" procedure was 
repeated until the supernatant fluid was clear. Normal blood contains in 
the order of 5000 white cells per microlitre, thus the pellet from 100µ1 of 
whole blood will contain 500 000 or more nucleated cells. The final pellet 
was resuspended in 300µ1 of K-buffer (50mM KCI , 10mM Tris-HCI, 2,5mM 
MgC'2 pH8.3, 0,5%(w/v) Tween-20 and 1 OOµg/ml of fresh proteinase K) 
and incubated for 2hr at 56°C to lyse the PBMCs and release DNA The 
proteinase K was inactivated at 95°C for 1 Omin. 
The DNA preparations were stored at 4°C and an aliquot of the whole 
blood was kept at -20°C. To assess the quality of the DNA preparation 
and to verify that the DNA was suitable for PCR analysis, PCR was 
performed using primers, SGDQ1 and SGDQ2, to amplify the human 
leukocyte antigen DQa (HLA-DQ-a) (Innis and Gelfand, 1990). Only 
samples that were positive for this single copy cellular gene were used in 
the HIV PCR assay. 
4.2.4 HIV PCR test procedure 
PCR test procedures were performed using a University PCR ESU 
temperature cycler. Reaction solutions contained 200µM of each of 
dATP, dCTP, dGTP (Boehringer Mannheim) and the optimum 
concentrations of dUTP as established in chapter 3, 50pmol of each 
different set of HIV-1 ,11 primers, and 1X reaction buffer (Boehringer 
Mannheim). Ten microlitres of the cell lysate was then added to make a 
final reaction volume of 50µ1. The magnesium and Taq DNA polymerase 
concentrations were adjusted to the optimal concentration for each primer 
set, as previously determined in chapter 3. Each patient's DNA sample 
was run in duplicate together with a negative DNA control , a positive DNA 
control and a negative reagent control. Two HIV-I and one HIV-1,11 
specific primer pairs, SK38,39; SK29,30 and SK145,431 (as described in 
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chapter 3, table 5) were used for DNA amplification. Primer locations on 

















Fig. 20 Location of primers and their probes, used in this study, on the HIV gen?me 
The following cycling parameters were employed for the DNA 
amplification: DNA was denatured by heating to 94°C for 2min. The 
primers were then allowed to anneal to their target sequences at 50°C for 
30sec, and extension of the target sequence was achieved by increasing 
the temperature to 72°C for 60sec. The DNA duplexes were denatured 
again by heating the reaction to 94°C for 20sec. The cycle, commencing 
at this denaturation step, was then repeated 40 times. 
All pipetting steps prior to amplification were performed using plugged 
tips. The PCR reagents and DNA isolations were prepared in separate 
rooms (from where PCR products were generated and analyzed) to 
decrease the likelihood of false positive reactions caused by "carry-over" 
or specimen cross contamination. 
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The PCR products were analyzed by agarose gel electrophoresis and 
Southern blot hybridization, as previously described in chapter 3.2.4. 
The PCR was only considered positive if the DNA sample was reactive 
with at least two of the HIV primer pairs, in duplicate, after hybridization 
with the respective DIG-labelled probes (Fig. 21 ). 
Whole blood 
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Fig. 21 Strategy for detection of HIV by PCR . Reactivity with two different primer sets 








4.3.1 Serology results 
Of the 153 patients screened, 138 were found to be HIV seropositive by 
the two different ELISAs (Abbott 3.0 [Fig. 22] and Enzygnost Behring) as 
well as the rapid screening test. 
A 
Fig. 22 ELISA (Abbott 3.0) antibody screening test for HIV specific antibodies. Row A 
on the plate contains 3 negative and 2 positive controls, and the rest of the wells are 
patient sera. The orange coloured wells are an indication of sera containing HIV specific 
antibodies. 
Eleven patients were HIV seronegative by both the Abbott 3.0 ELISA and 
the rapiq agglutination test; 2 gave indeterminate serology results, and 
two were not tested for HIV antibodies because of insufficient volume of 
blood. The two sera with indeterminate or discrepant serology results 
both gave low positive results on the ELISA screens and the rapid 
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agglutination test was negative. Western blot analysis was performed on 
these two sera, and both were found to be negative (the specimens did 
not react with any of the HIV-specific proteins on the western blot strip). 
4.3.2. Amplification results 
4.3.2.1 HLA-DQ-a PCR results 
It was demonstrated that all the samples tested contained amplifiable 
DNA since the HLA-DQ-a gene could be amplified. (The absence of an 
HLA product, after EtBr staining would indicate either the presence of an 
inhibitor of the PCR or an insufficient amount of cellular DNA) The HLA 
primers yielded a 254bp fragment (Fig. 23). 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
----254bp 
Fig. 23 Amplification results for the HLA-DQ-a. gene in PBMCs from patient samples. 
Lane 1 MWVI; Lanes 2-14 cell lysate from 13 patients. 
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4.3.2.2 HIV proviral DNA results 
The criteria for a positive HIV PCR result were that all samples were 
required to be reactive, in duplicate, with at least two different HIV primer 
pairs (Fig. 24). 
1 234 567 891011 
A ----104bp 
1 2 34567891011 
B 
----142bp 
Fig. 24 Detection of HIV-1 DNA in PBMC by using PCR and oligonucleotide 
hybridization . Cell lysates were amplified with primers SK29,30 (A), and SK145,431(B). 
Lanes 1 Blank control ; Lanes 2-3 pos patient controls; Lanes 4-5 Neg DNA controls; 
Lanes 6-7 patient no1; Lanes 8-9 patient no2; Lanes 10-11 patient no3. 
All 11 seronegative specimens were negative by PCR with all three HIV 
primer pairs. The two serology-indeterminate and western blot negative 
specimens were also PCR negative with all three HIV primer pairs. The 
two specimens that were insufficient for HIV serology, were also PCR 
negative with all three primer pairs. Of the 138 seropositive specimens, 
115 were PCR positive with at least two HIV primer pairs, and the 
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Fig. 26 Analysis of the 115 PCR positive specimens identified in this study, with (a) 
presenting the total amount of PCR positive specimens according to the sex of the 
patients, and (b) representing the male and female population of the positive 
specimens. 
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Figure 26 shows the female to male ratio of those samples that were PCR 
positive, indicating 65% of these patients to be female and only 20% 
male. Sixty-four percent of the PCR positive males were black, 18% 
coloured and 18% white. In contrast, 82% of the PCR positive female 
Different combinations of the three HIV primer pairs were used to 
determine the PCR status of these 138 samples. Initially 25 samples 
were tested with the nested env (C 1C2 , SK 68,69) and gag-p24 (SK38,39) 
primer pairs and a good correlation was obtained as all 25 samples were 
positive with both primer pairs (Fig. 27 A) . However, further testing with 
the same primer combination indicated that contamination had been 
introduced ( shown by a positive reaction in the blank reagent control and 
in the negative DNA control) . As a result, the env primer pair was 
discarded and eliminated from further tests. In future tests the env primer 
set was replaced with the L TR (SK 29,30) primer set. Twenty-seven sera 
were tested with this combination (Fig. 278) and identical results (26 
positive, 1 negative) were obtained with both primer pairs. Because there 
is a possibility that gag-p24 will not detect HIV-II sequences, it was 
decided to include a gag-p17 (SK145,431) primer pair in the assay. Four 
sera assayed with each of the two different gag primer pairs (Fig. 27C) 
did not reveal any difference. The gag-p17 (SK 145,431) primer pair was 
combined . with the L TR (SK 29,30) primer pair to assess the final 82 
specimens and identical results (Fig. 270) were obtained (61 positive and 
21 negative). This combination of primers were therefore considered to 






















































Fig. 27 PCR results of the different HIV primer combinations used to detect the 
provirus in the PBMCs of patients tested in this study. 
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4.4 Discussion 
After optimization of the HIV PCR assay (chapter 3) for our laboratory, a 
number of routine specimens were analyzed in this system to establish 
the degree of correlation between PCR results and serology results. 
When PCR is developed for a diagnostic assay, it is essential to use 
several primer pairs in order to identify the best single primer pair for that 
specific target organism. However, the heterogeneity of HIV-I also 
stresses the need for different primer pairs, to ensure the detection of all 
HIV variants. All primer pair combinations in this study showed a good 
correlation. The SK38,39 (gag-p24) and SK68,69 (env) primers were 
initially used for this study as they were well described in the literature 
(Ou et al., 1988; Rogers et al. , 1991). The env primer pair was later 
omitted from this study as a result of contamination, and was replaced by 
the L TR primer set SK29,30 and the gag-p17 primer set SK145,431 
(Borkowsky et al., 1992; Kellogg and Kwok, 1990). Kwok and Sninsky 
( 1993) mention that they and others have analyzed more than 1000 
samples using the primer combination of SK38,39 and SK462,431 (both 
in the gag-region) and found greater than 98% concordance between the 
two pairs. SK462 is a derivative of the previously described SK145, 
which was initially designed to amplify both HIV-I and HIV-II , but as more 
isolates were sequenced it became apparent that SK145,431 will only 
amplify a subset of HIV-lls. The modified primer pair that replaces SK145 
with S1<462 will now amplify H1Vma1-like sequences (HIV-I with two 
mismatches). 
It was found that 83% of the seropositive patients were also PCR positive, 
and 17% were PCR negative. The reasons for the 17% PCR negativity 
was not as a result of insufficient DNA because amplification for the HLA-
DQ-a gene was positive. Analysis of the patient data revealed that all 23 
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PCR negative (but seropositive) samples were from infants less than 15 
months old. The seropositive status of these PCR negative infants could 
be a reflection of the mother's antibody status since maternal antibodies 
can persist in the infant for 15 to 18 months. As these infants were not 
part of a prospective study, it was not possible to obtain follow-up blood 
samples to determine their true antibody status after 18 months of age. 
Not all babies born to HIV-positive mothers are infected. The 
transmission rate of HIV-I from mother-to-infant is estimated at 20-65% 
(Soeiro et al. , 1992). We did in fact find that 27 seropositive infants were 
also PCR positive. A fuller investigation of the application of PCR to the 
diagnosis of infants is given in chapter 5. 
All the seronegative samples were also PCR negative. These samples 
were taken from: 1) adult patients with no apparent risk for HIV infection, 
but for whom pathologists had requested a screening test to exclude an 
HIV infection, 2) infants who were born to HIV positive mothers, but who 
had remained seronegative after 12 months of age, and 3) husbands 
whose wives were HIV positive, but who themselves had remained 
seronegative. Thus, the correlation between negative PCR results and 
negative serology was not unexpected. Cases have been described 
where the serology is negative but the PCR is positive. For example, in 
blood samples from patients undergoing seroconversion, PCR can detect 
HIV proviral DNA in the lymphocytes before an ELISA can detect any HIV 
specific antibodies (Bruisten et al. , 1992; lmagawa et al. , 1989). We did 
not identify any such cases in this study as all PCR positive samples 
were also HIV-antibody positive in the initial screening. However, a few 
seroconversion cases have since been identified in our laboratory 
(unpublished data). Positive HIV diagnosis was based on clinical 
grounds and the initial detection of only the p24 HIV specific band on the 
western blot assay, followed by the appearance of more HIV specific 
bands in subsequent specimens from the same patient. Antibodies to the 
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gag proteins (p18, p24, and precursor p55) are generally the first to 
appear in a patient with recent HIV infection. These antibodies are also 
the first to disappear in advanced cases of AIDS. An early 
seroconversion is generally reflected on the western blot assay as a 
pattern with antibodies to the p24 and/or gp160. Antibodies to the other 
virus-specific proteins will become detectable as the disease progresses. 
The western blot of indeterminate sera was negative for all HIV-specific 
bands, which could indicate that the initial serology was probably not HIV 
specific. 
Indeterminate PCR results (e.g. where only one of the duplicate PCR 
reactions are positive after probing) did not pose a problem in this study, 
but such results may occur, for example in samples containing very low 
copy numbers of HIV. The safest way to deal with samples of this nature, 
is to request a follow-up sample (within a week or two), and to repeat the 
PCR. Simmonds et al. (1990) showed that the frequency of infected 
PBMCs from a patient with AIDS was about 1 per 500, and from an 
asymptomatic patient it was about 1 per 10 000. In our case (using 500 
000 cells from 100µ1) there were between 50 to 1000 infected cells per 
100µ1 of whole blood. 
The majority of PCR positive specimens were obtained from female 
patients. The gender bias is probably a reflection of the sources of 
clinical material used in this study. These comprised hospitals with ante-
natal clinics and facilities for paediatric care. Often clinically ill infants 
are first shown to be infected with HIV and this leads to subsequent 
identification of HIV positive mothers, thus more females than males were 
screened. Worldwide, heterosexual spread is the most common way in 
which HIV is transmitted, followed by vertical spread from infected mother 
to infant. The large numbers of infected women and babies identified in 
this study is an indication that heterosexual transmission is also prevalent 
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in the local community. The majority of all the PCR positive patients were 
black. Again this might be related to the fact that most of the specimens 
were received from state hospitals where patient care is provided free, or 
at minimal cost, for pregnant women and their children. These hospitals 
serve mainly indigent members of the black and coloured communities. 
The few specimens from white patients were received from private 
pathologists in the Cape Town area who referred their positive sera to our 
laboratory in order to verify the results that they had obtained. 
A few important technical notes were made during this study that help to 
achieve maximum sensitivity when HIV PCR is performed, and include 
the following: 1) Whole blood specimens should be processed as soon as 
possible after collection of the specimen, as long periods of storage of the 
whole blood at room temperature or 4°C can affect the yield of amplifiable 
DNA It was our experience, however, that whole blood could be stored 
at -20°C for 12-24 months and still produce amplifiable DNA 2) 
Adequate washing procedures during the extraction of the PBMCs from 
whole blood is essential, as any trace of haeme-related compounds may 
inhibit amplification. 3) The inclusion of two different HIV primer pairs is 
advised as this increases the sensitivity and ensures greater likelihood of 
detecting any HIV-1 variants. The inclusion of sufficient positive and 
negative controls and confirmation by hybridization are essential at this 
stage, since PCR procedures are prone to contamination and 
amplification of non-specific DNA sequences. 
The PCR technique thus provides a highly sensitive and specific 
alternative to HIV culture and p24 antigen detection for the direct 
detection of HIV, being particularly useful in resolving the infection status 
of indeterminate serology individuals and babies born to HIV-infected 
mothers (chapter 5). It can also serve as a handy molecular tool to 
characterize genetic variability (chapter 6). 
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Chapter 5 
Application of HIV PCR in 
amplification of sequences 
from infants born to 
seropositive mothers 
5.1 Introduction 
I nfection of children with human immunodeficiency virus type I has been recognized since 1983 (Rubinstein et al., 1983), and the number of 
HIV-I infected children has increased in recent years in parallel with the 
increase in HIV-I infected women of childbearing age. The overwhelming 
majority of childhood HIV-I infections are believed to be transmitted pre-
or perinatally from infected women (Fall on et al., 1989). Neonates born 
to HIV seropositive mothers may demonstrate signs associated with HIV 
infection or AIDS within the first year of life. These clinical signs can 
include: 1) pneumonitis 2) oral candidiasis 3) diarrhoea 4) gastro-
intestinal complaints 5) swollen lymph nodes 6) non-pruritic macular 
erythematous rash 7) acute central nervous system disorders 
(encephalitis) 8) headache, muscle aches, sore throat, low- or high-
grade fever (Levy, 1984). These symptoms could persist for 3 weeks, 
with lymphadenopathy and failure to thrive for many months. By the time 
these infected infants reach the age of two, about three-quarters of them 
will present with clinical symptoms of the disease (Gibb and Wara, 1994). 
The frequency of materno-fetal transmission of HIV-I varies from 20% to 
65%, with African countries having the highest transmission rates (Ryder 
et al. , 1989; Hira et al., 1989; Soeiro et al., 1992; Newell et al., 1992, 
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also see chapter 1.7.1.5 for further information), but accurate diagnosis of 
infection in these babies is not a simple procedure. 
The use of serological methods is inadequate to differentiate infected 
infants from uninfected infants born to HIV-seropositive women, since the 
mother's antibodies (lgG) cross into the infant's bloodstream via the 
placenta, and may persist in the infant for 15 to 18 months. The currently 
available ELISAs (see chapter 2) cannot distinguish between the 
passively acquired maternal antibodies (lgG) and antibodies produced by 
the infant in response to an HIV infection. The detection of other classes 
of immunoglobulin (lgM and lgA) that do not cross the placenta have . 
been considered for the diagnosis of true infection. lgM antibodies to HIV 
are produced early in the course of infection but they are only detectable 
in the blood for a relatively short period of time. lgM may disappear 
before maternal lgG leaving a time period where it is impossible to 
distinguish between lgG from infant or mother. The production of lgA 
occurs shortly after lgM, and remains stable for many years. As lgA 
antibodies are mainly secreted by cells of the mucous membranes of the 
body, they can be detected in mucous secretions as well as in the blood. 
However, it has been shown that HIV infection is not reliably detected by 
the lgA antibody assay during the first three months of life (Gaetano et 
al. , 1987 and Martin et al., 1991 ). Thus, assays that directly detect the 
presence of infectious virus, or viral components, are required for the 
diagnosis of HIV infection in infants. 
The detection of viral proteins such as the p24 core antigen, can also be 
considered as evidence of viral infection. However, p24 antigenaemia is 
not always observed in all infected infants, and the assay lacks sensitivity 
(Borkowsky et al. , 1992). Viral culture is a specific and sensitive means 
of diagnosis but the detection of HIV by this method can take from 1 to 4 
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weeks or longer to complete, is expensive and requires special biosafety 
precautions (Petru et al. , 1992). 
Ideally, a laboratory test should permit diagnosis as soon as possible 
after infection, and thus allow antiviral or other prophylactic therapy to be 
administered at the earliest opportunity. In the majority of cases babies 
are infected at the time of confinement and it is not known precisely how 
soon thereafter the infection can be diagnosed with accuracy. The 
sensitivity of viral tests for HIV is often less than 50% in the first weeks of 
life, and even tests like HIV PCR and culture are highly sensitive only 
after 2 months of age (Krivine et al. , 1990). 
This chapter describes the use of PCR to detect the presence of HIV 
proviral DNA in PBMCs from infants less than 15 months of age, and 
examines the possible advantages of PCR as opposed to serological 
assays for the diagnosis of HIV infection. 
5.2 Materials and Methods 
Forty-five infants, all less than 15 months of age and born to HIV-
seropositive mothers were included in this study. Their sero-status was 
determined as described in chapter 4.2.2 by using the protocol by which 
all initial screening tests were done with one ELISA (Abbott 3.0 
recombinant HIVl ,11) and positive results were confirmed using a second 
ELISA (Enzygnost Synthetic env peptides, Behring) and a rapid HIV 
assay (Capillus Latex Agglutination using recombinant polypeptides from 
the env region , Cambridge Biotech Limited) . 
Peripheral blood mononuclear cells from these infants and from healthy 
adult donors (as controls) were concentrated from whole blood, and DNA 
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was extracted using the method described in chapter 4.2.3. All DNA 
preparations were subjected to PCR with the HLA-DQ-a primer pair to 
verify that the DNA was suitable for further PCR analysis. 
Two sets of primers and their probes were used for HIV-I, and/or HIV-II 
amplification: SK29,30 (Ou et al. , 1988) and SK145,431 (Kellogg and 
Kwok, 1990). A third HIV-I primer pair, SK38,39 (Ou et al. , 1988) was 
available in case any discrepant PCR results were obtained (chapter 
3.2.1 ). In order to be considered positive, the samples were required to 
yield positive results with at least 2 different HIV primer pairs, in 
duplicate, after hybridization with the respective DIG-labelled probes. 
Ten microl itres of cell lysate was amplified for 41 cycles in a 50µ1 reaction 
mixture. The PCR test procedure and cycling parameters were performed 
according to the optimized conditions as previously described in chapter 
4.2.4. All the samples were tested in duplicate and each PCR run 
included a positive DNA control , a negative DNA control and a negative 
reagent control. Analysis of the PCR products included agarose gel 
electrophoresis and Southern blot hybridization with DIG-labelled 
oligonucleotide probes (see chapter 3.2.4). 
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5.3 . Results 
5.3.1 Comparison of HIV-PCR results 
with serology 
Serological assays indicated that 42 of the 45 infants had antibodies to 
HIV-1, and three of the infants were seronegative. Analysis of the DNA 
isolated from the PBMCs from all 45 infants gave positive amplification of 
the HLA-DQ-a gene indicating that there was sufficient DNA to amplify 
and there were no inhibitors to the amplification. 
The 3 seronegative samples also tested negative for HIV proviral DNA by 
PCR with 2 different HIV primer pairs and their probes. Twenty seven 
(64%) of the 42 seropositive infants were also PCR positive, in duplicate, 
after hybridization with two different HIV probes, as shown in figure 28. 
The remaining 15 (36%) seropositive infants were negative for HIV 
proviral DNA by PCR. 
1 2 3 45 67 89 1011 
----104bp 
Fig. 28. Detection of HIV-1 proviral DNA in PBMCs of infants (< 15 months of age) by 
using PCR and oligonucleotide hybridization. Cell lysates were amplified with primers 
SK29,30. Lane 1, blank control ; lanes 2-3, pos patient control; lanes 4-5, neg DNA 
control; lanes 6-7, patient no1 ; lanes 8-9, patient no2; and lanes 10-11, patient no3. 
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Forty-three of the 45 infants were evaluated using the primer pair 
combination of SK29,30 and SK145,431 (Fig. 29A), and the remaining 
two were evaluated with the primer combination of SK29,30 and SK38,39 
(Fig. 298). Both of these primer combinations gave perfect correlation, 



























Fig. 29 Results of HIV PCR with the different primer combinations: A) SK29,30 and 
SK145,431 , B) SK38,39 and SK29,30. 
Figure 30 (next page) illustrates the comparison of the serostatus with the 
PCR-status of all 45 infants. 
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3 Sero Neg 
45 Infants 
ELISA - to determine 
antibody status 
42 Sero Pos 
PCR 
jts Neg I 
64% 36% 
Fig. 30. Results of assays for HIV serum antibodies and proviral DNA performed on 45 
infants less than 15 months of age, born to HIV sero-positive mothers. 
5.3.2 Collation of patient data with 
HIV test results 
The 3 seronegative, PCR-negative samples were repeat specimens from 
infants 13, 12, and 14 months old respectively. All three had been tested 
previously and found to be HIV seropositive; two at the age of 3 months 
and one at birth. No clinical data was available for two of these infants, 
but the third one was reported to be clinically well at the time of follow-up. 
For those infants who were seropositive, the PCR status was examined 
with respect to the age of the infants and the clinical data that was 
available at the time that the specimens were received (Table 10). 
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Table 1 O Combined data of the 42 seropositive 
infants. 
Age Baby Age Gender Sero- PCR- Clinical data 
group no status status 
1 1 day F • D 0 
2 1 day M • D 0 
3 5 days F • D 0 
4 7 days M • D adoption program 
5 1 month M • • 0 
6 1 month M • • 0 
0-3 7 1 month F • • a:, • tuberculosis "" 
months 8 2 months M • • 0 • 
9 2 months M • D 0 
10 2,5 M • • gastroenteritis 
months 
11 3 months M • • Pneumocystis pneumonia 
12 3 months F • • previous HIV-seropos 
13 3 months M • D 0 
14 3 months M • D 0 
15 3 months M • D 0 
16 4 months M • • 0 hepatosplenomegaly 
lymphadenopathy, gastro 
17 4 months M • • pneumonia, diarrhoea 
18 4 months M • • 0 * full blown AIDS 
19 4 months M • • 0 
20 4 months M • D 0 
21 4 months F • D 0 
4-6 22 4 months F • D e 
months 23 6 months M • • lymphadenopathy hepatosplenomegaly 
24 6 months M • • prev HIV seropos 
25 6 months F • • pneumonia, candida 
26 6 months F • • diarrhoea, hepatomegaly 
27 6 months M • D 0 
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Age Baby Age Gender Sero-
group no status 
28 7 months F • 
29 7 months M • 
30 8 months F • 
7-9 31 8 months M • 
months 32 9 months M • 
33 9 months F • 
34 9 months M • 
35 10 months M • 
36 12 months F • 
37 12 months M • 
10-12 38 12 months F • 
months 39 12 months M • 
40 12 months F • 
>13 41 13 months F • 
months 
42 14 months F • 
© =mother HIV positive, •=father HIV positive, 
M=male, F=female, •=positive, D=negative 




D no data available 
• lymphadenopathy hepatosplenomegaly 
• cryptosporidium diarrhoea 
• prev HIV seropos 
D 0 
• 0 prev HIV seropos 
• 0 prev HIV seropos 
• prev HIV seropos 
• lymphadenopathy 
• prev HIV seropos 
• failure to thrive, enlarged lymph nodes 
• hepatosplenomegaly pneumonia 
gastroenteritis 
• tuberculosis, pneumonia 
The 15 seropositive but PCR-negative infants included 8 who were 3 
months of age or younger, 4 who were >3 months but <6 months old, and 
3 who were >6 but <9 months old. Nine of these infants were males and 
the remaining 6 were females. The only available clinical information 
regarding all the infants was that their mothers were HIV seropositive. 
The mother of one of these infants was only diagnosed as being HIV 
seropositive after her baby had been tested seropositive. This baby was 
part of an adoption program for which HIV screening was required. 
The group of 27 seropositive and PCR-positive infants consisted of 17 
males and 10 females which was not significantly different from the 
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gender ratio seen in uninfected (PCR-negative) babies. This group 
included 7 infants who were between 1 and 3 months old, 8 who were >3 
but <6 months, 4 who were >6 but <9 months, 6 who were >9 but <12, 
and 2 who were between 12 to 15 months old (Fig. 31 ). Clinical data was 
available for only 15 of these infants. Signs indicative of 
immunosuppression and opportunistic infections were associated with a 
number of HIV-infected babies of 3 months and older, and included the 
following: Pneumocystis carinii pneumonia, tuberculosis (Mycobacterium 
tuberculosis) , cryptosporidiosis, chronic diarrhea, candidiasis, 
lymphadenopathy, full blown AIDS, hepatomegaly, failure to thrive, 
hepatosplenomegaly, and enlarged lymph nodes. Positive PCR results 
were obtained for 11 infants who were screened for HIV because their 
mothers and/or fathers had been diagnosed as being HIV seropositive. 
Four of the seropositive babies were under a week old and they were 
also PCR negative. However, positive PCR results were obtained for 3 
babies of only 1 month of age. All 8 infants older than 9 months were 














Fig. 31 Illustration depicting the number of PCR-positive assays (dark blocks) in 
seropositive infants of various age categories (given in months) . 
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5.4 Discussion 
The primers that were evaluated and chosen in chapter 3 and 4 
(SK29,30; SK145,431 ; SK38,39) gave reliable and reproducible results 
when applied to diagnosis of HIV in infants. One should be aware of 
problems that might arise because of incompatibility between the primers 
and new divergent genetic strains. However, a recent study performed by 
Van Rensburg and Engelbrecht in South Africa, indicated that different 
gag primers (SK38,39; gag22,Sk39; gag a/b,gag c/d nested), L TR 
primers (SK29,30), and env primers (SK68,69) were able to detect all 
HIV-I subtypes (8, C, and D) presently known to occur in the Western 
Cape (unpublished data, Vth International Congress on the Impact of 
Viral Diseases in the Developing World, July 1995). 
In cases of neonatal infection with HIV, an early diagnosis is desirable for 
the clinical management of the infected infant especially when antiviral 
treatment is an option, as this treatment may be more effective if it is 
given as soon as possible after infection. PCR methodology is 
increasingly being used to determine the presence or absence of HIV 
infection in neonates and is preferred to viral culture because results may 
be obtained far more rapidly, and the technique requires a smaller 
sample size. 
Because of the presence of maternal antibodies, serology results are 
inadequate to determine true infection in babies born to seropositive 
mothers. In this study we were able to confirm infection by the detection 
of proviral DNA in 64% of the seropositive infants examined. Fifteen of 
the PCR positive infants (but none of the PCR negative infants) displayed 
clinical symptoms indicative of an HIV infection, and these babies were all 
older than 3 months. The majority of perinatally infected children develop 
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HIV associated symptoms within the 1st year of life (Scott et al., 1990). 
Early manifestations in most of these infants include oral candidiasis, 
splenomegaly, hepatomegaly, lymphadenopathy, diarrhoea and failure to 
thrive. However, some infants will present with more severe AIDS-
defining illnesses during this time. Friedland and McIntyre reported in 
1992 when they studied perinatally acquired HIV infection in infants born 
to HIV positive mothers at the Baragwanath Hospital, that most of these 
infants became symptomatic before the age of 6 months and over 70% of 
them presented with the clinical features described above. In the case of 
adults, clinical signs of HIV infection only become evident after the 
"latent" stage of the disease, that can last from 8. to 15 years, when the 
virus load in the body increases and more cells become infected 
(Schaub, 1994). 
A PCR negative status in the presence of positive serology does not 
necessarily exclude infection with HIV, especially in very young babies. It 
is recognized that in babies under 2 months of age the sensitivity of the 
PCR test is less than 50% (Krivine et al., 1990). This may reflect very low 
levels of virus in the peripheral blood or that the virus is confined in 
lymphoid organs. If there is an initial lag period before the virus begins to 
replicate, the number of infected lymphocytes (or PBMCs) may be very 
low, thus reducing the probability of their presence in the small samples 
of blood that can be taken from very young babies. These considerations 
are relevant in the assessment of the PCR negative status of the four 
babies who were under one week of age. It has been reported that an 
increase in viral load in the PBMCs seems to occur during the first few 
weeks of life, as indicated by an increase in the p24 antigen levels 
(Krivine et al. , 1990 and Borkowsky et al., 1992). Our study group did not 
include any infants of between 1 and 4 weeks of age, but indeed 5 of the 
6 babies aged between 1 and 2,5 months gave PCR positive test . This 
suggests that the single PCR negative result in this group is likely to be a 
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true indication of the absence of infection. It would nevertheless be 
recommended that such an infant be re-tested at a later age to confirm its 
true HIV status. The other 10 infants who were seropositive but PCR 
negative were older than 3 months, and one could therefore probably 
predict with greater confidence that they were not infected. 
The 3 seronegative infants who also tested PCR negative are examples 
of infants who had lost their passively acquired maternal antibodies, since 
they had previously been HIV seropositive when tested at birth to 3 
months of age. Only by repeat assays at the age of 13 months could the 
HIV negative serostatus of these infants be verified. The absence of true 
infection in these infants could probably have been determined at least 
10 months earlier with the help of HIV PCR. 
In summary, it was shown in this study that PCR can be of good value as 
a diagnostic assay for the detection of an HIV infection in the majority of 
infants in the neonatal period although, for reasons given above, it cannot 
provide proof of infection in newborn babies (<1 week in age). In spite of 
the high cost of the PCR assay, the overall benefit of an early diagnosis 
may be sufficient to warrant its being put to more widespread use. 
Another possible application for PCR in infants (or adults) is quantitative 
PCR, for the evaluation of the effectiveness of new drugs and in 
monitoring disease progression, where an increase in viral load, usually 
indicates an increase in disease progression (Ho et al., 1989; Alimenti et 
al. , 1994). 
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Chapter 6 
Genetic characterization of 
the V3-region of HIV-I from a 
mother and her infant 
6.1 Introduction 
Nucleotide sequence variation between isolates of HIV-I has been well documented (Burger et al., 1991 ; Hahn et al., 1984; Ait-
Khaled and Emery, 1993; Howell et al., 1991; Milich et al., 1993) and, 
based on sequence analysis, the virus has been classified into 9 
subtypes. Subtypes A to H belong to the so called M group of HIV-I, and 
the other sequences that do not fit into this group are included in the 0 
group (Myers, 1994). Subtypes A to F exhibit up to 30% variation in their 
env coding sequences. Variability in the env gene of HIV-I is especially 
marked in the region coding for the surface glycoprotein (gp120). Six 
constant and five hypervariable domains have been identified in this 
protein. The second conserved domain of 98 amino acids (C2) plays a 
role in HIV-I infectivity and antibody neutralization (Willey et al., 1986; 
Ho et al. , 1988). The third variable region (also known as the V3 loop) is 
associated with several functions: infectivity, viral fusion , and syncytium 
formation (Ivanoff et al., 1992; Freed et al. , 1991 ). The V3 loop is also 
the principal neutralization domain (PND) that contains T- and B-cell 
epitopes and is thus the main target of antibody and T-cell mediated 
immune responses. HIV-I mutants containing only a single amino acid 
change at residue 128 of the V3 loop, can escape neutralization by 
antibodies directed against the V3 region. Two observations indicate that 
V3 has a critical function : 1) the overall length of V3 is conserved, 
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suggesting that deletions or insertions cannot be tolerated, and 2) 
random amino acid substitutions in V3 cannot be tolerated (Scott et al., 
1990). Genetic analyses of the V3 domain were thus essential in 
previous strategies aimed at developing an immunogen that would induce 
neutralizing antibodies to the majority of circulating virus strains (Looney 
et al., 1988; Scott et al. , 1990). 
Several studies have shown that there are two different states 
(phenotypes) of HIV-I in the pathogenesis of AIDS. Slow replicating 
macrophage-tropic non-syncytium-inducing (NSI) isolates are 
predominant in the early (primary) asymptomatic stage of HIV-I infection. 
At later stages, rapid disease progression and rapid decline of CD4+ T-
cells, as well as reduced survival time after AIDS diagnosis, are usually 
associated with the presence of syncytium-inducing (SI) HIV-I isolates 
(Schuitemaker et al. , 1992). The acquisition of the SI phenotype is linked 
to substitutions of acidic or neutral amino acids by more basic amino 
acids in the V3 loop. Milich et al. (1993) examined the pattern of basic 
amino acid sequences and identified distinct groups of V3 sequences in 
infected patients that appeared to correspond to the two different stages 
of infection (the NSI viral phenotype or asymptomatic stage, and the SI 
phenotype or late stage of infection). The presence of basic amino acids 
has also been shown to change virus tropism in cell culture (Hwang et al. , 
1991 ; Shioda et al., 1992). 
The HIV-I virus evolves within an individual during the course of infection 
(McNearney et al. , 1992). Studies have shown that the env gene of 
isolates from unrelated individuals differs by 6% to 22%, and in closely 
related contacts by 2% to 6% (Burger et al. , 1991 ). Certain host and viral 
factors may influence this rate of evolution (see chapter 1.6). Following 
sexual or parental transmission, genetic analysis of HIV-I strains 
generally shows a genetic distance between the consensus sequences of 
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viruses from the donor and the recipient, of less than 1 % (Wolfs et al. , 
1992; McNearney et al. , 1990). The virus population of the recipients at 
seroconversion is extremely homogeneous, indicating that a limited 
number of variants or even a single variant initiates the infection in the 
new host. In the case of vertical transmission of HIV-I from mother to 
infant, it has been suggested (Wolinski et al. , 1992) that particular 
variants, such as those that escape the maternal immune response or 
variants with a tropism for certain cells, can be preferentially transmitted. 
This suggestion was based on their findings that the HIV variant 
transmitted to an infant represented a minor genotype in the env maternal 
sequence set. In contrast, however, Swedish researchers (Scarlatti et al., 
1993) who compared V3-regions of viruses from infected infants and their 
mothers, found no evidence of selection of virus variants during 
transmission. These conflicting data stimulated an examination (in this 
study) of variants involved in maternal transmission of HIV-I in the local 
community. 
For this purpose, the sequence set of the V3 loop was examined in 
multiple isolates from one sample of peripheral blood from an HIV-
infected mother and compared with that of her 3 month old infant. It was 
decided to compare sequences from the V3 loop because of the rapid 
changes that occur in this region of the HIV-I genome compared to other 
regions. This consequently allows the differentiation between closely 
related strains. Furthermore, because of the specific functions ascribed 
to specific sites on the V3 loop, sequence data could possibly yield added 
information regarding the nature of infectious variants. 
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6.2 Materials and Methods 
Clotted and EDTA blood were obtained from a three month old black male 
infant and his mother, from Conradie hospital (Cape Town). 
The 3 month old infant was diagnosed as HIV-I antibody positive before 
his mother's HIV status was known. At the time that his first blood 
specimen was taken, on November the 23rd, the infant had a clinical 
diagnosis of pneumonia. This blood specimen was positive for HIV-
specific antibodies by 2 different ELISA tests and 1 rapid test. A second 
specimen of clotted blood, as well as an EDTA-blood specimen, was 
taken on November the 29th and this specimen also yielded a positive 
HIV- antibody result as well as a positive HIV PCR result (specific L TR 
and gag sequences could be amplified from the extracted DNA). Clinical 
information given at the time of the second specimen was that the infant 
had "full blown AIDS". Consequently, a blood specimen from the mother 
was requested, and this also yielded a positive HIV-I antibody result. No 
clinical details were given for the mother, and none were available after 
inquiries at the Conradie Hospital. 
6.2.1 Determination of HIV antibody 
and PCR status 
The antibody status of the mother and infant was determined by one 
ELISA (Abbott 3.0 recombinant HIV-1,11) and confirmed on a second 
commercial ELISA (Enzygnost, synthetic env peptides, Behring) and on a 
rapid HIV assay (Capillus Latex agglutination assay, Cambridge Biotech 
Limited) [chapter 4.2.2]. 
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HIV-I infection in the infant was confirmed by PCR as described in 
chapter 4.2.3. All DNA preparations were initially amplified with the HLA-
DQ-a primer pair to verify that the DNA was suitable for PCR analysis. 
6.2.2 Amplification and cloning of 
the V3 loop fragment 
Ten microlitres of the prepared DNA samples were amplified by PCR with 
nested primer pairs which flanked the V3 loop region of the env gene. 
The primers were designed by Dr C. Williamson from the Department of 
Clinical Virology, Medical School, UCT, and are described in Table 11. 
Degeneracies were included in the primers in order to select for both 
Western and African strains of HIV. Primer length was limited to between 
18 and 25 nucleotides and degeneracies near the 3' ends were avoided. 
The expected amplification sizes for the outer and inner primer pairs were 
calculated at 424bp and 329bp respectively. 
Table 11 Degenerate nested primers used for 
the amplification of the V3-region of HIV-1 
ENV primer pairs Sequence (5'-3') Size of 
fragment 
6545 outer forward GCACAGTACAATGTACACATGG 
*************************C: 
6944 outer reverse TAGAAAAATTCTCCTCTACAATTAA 
********************C:***C: 
424 bp 
6599 inner forward TGAATGGCAGTCTAGCAGAAG 
**A*********T****C 
6910 inner reverse TTCTGGGTCCCCTCCTGA 
AA*A 
329 bp 
*Bold letters illustrates where degenerecies may occur 
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The "standard" PCR protocol (chapter 3.1.1) was used for the 
amplification, except that, as mentioned before, the annealing 
temperature was changed to 43°C to accommodate the primers. Briefly, 
the samples were first amplified for 30 cycles with the outer primers 
(50pmol of each), then 5µ1 of the product from the first PCR was amplified 
for 40 cycles with the inner primers (50pmol). HIV-I negative DNA 
controls, blank reagent controls and positive patient DNA controls were 
included in each run . 
6.2.2~ 1 Purification of PCR product 
In order to obtain sufficient DNA, four separate PCR amplifications were 
performed for each patient and then PCR products were pooled. The 
excess of PCR primers was removed and the PCR products were 
concentrated by selective ammonium acetate precipitation [pCR-ScriptTm 
SK(+) cloning kit (Stratagene)] . A 1/10 volume of 10X STE buffer (1M 
NaCl, 100mM Tris.HCI, 10mM EDTA, pH8.0), an equal volume of 4M 
NH40Ac, pH4.9 and 2,5 volumes of 100% (v/v) ethanol , at room 
temperature, were added to 100µ1 of the pooled product. The suspension 
was immediately centrifuged in a Beckman microfuge at room 
temperature for 20min at 8000 rpm. The DNA pellet was washed in 
70%(v/v) ethanol , dried in a Speed Vac SC 110 vacuum drier (Savant) , 
resuspended in 20µ1 of TE-buffer (1 OmM Tris-HCI , 1 mM EDTA, pH7.6) 
and stored at 4°C until used for cloning (section 6.2.2.2). The DNA 
concentration was estimated by comparing the intensity of the DNA band 
with that of a known standard (molecular weight marker II , Boehringer 
Mannheim) after electrophoresis on agarose gel and staining with EtBr. 
6.2.2.2 Cloning of the purified product 
The PCR amplified fragment of the env gene of HIV-I was cloned into the 
pBluescriptSK(+) phagemid (a 2958bp phagemid derived from pUC 19) 
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(Fig. 32) according to an adaptation of the method given in the 
manufacturer's instructions (Sfratagene). Briefly, 1 Ong of pBluescript 
vector was ligated to 65ng of purified PCR fragment in the presence of 1X 
ligation buffer [25mM Tris.HCI pH7.5; 1 OmM MgCl2; 1 OmM dithiothreitol ; 
20µg/ml bovine serum albumin (BSA) and 1 OmM rATP and 4U T 4 DNA 
ligase, in a final reaction volume of 11 ~LI. The restriction endonuclease 
EcoRV, was used in the ligation, instead of the Srf 1 recommended by the 
manufacturer. The ligation sample was mixed gently, incubated for one 
hour at room temperature, heated for 1 Omin at 65°C and stored on ice 
until used for the transformation. A similar ligation, but omitting the PCR 
fragment, was prepared in parallel to assess the extent of vector self-
ligation. 
Pvu l 2416 
Ssp I 2850 Ssp I 22 




Kpn 1657 T7 t 
Sac 1759 t 
T3 
Fig. 32 Restriction endonuclease map of the cloning vector, pBluescriptSK(+) obtained 
from Stratagene. 
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The ligated plasmid was transformed into LK111 competent Escherichia 
coli cells (Dagert and Ehrlich, 1979). Two vials, each containing 100µ1 of 
competent cells, were thawed on ice, and 2µ1 of either the ligation mixture 
(with DNA) or the ligation control (without DNA) were added. After 
swirling the vials very gently, they were placed on ice for 30min, heat 
shocked at 42°C for 60sec and placed on ice for 2min. Pre-warmed Luria 
broth (0,9ml) was then added to each vial and incubated for one hour at 
37°C with aeration at 225rpm in a Lab-line orbital shaker. The 
transformed cells were plated onto Luria agar containing 50mg/ml 
ampicillin, 20mg/ml 5-bromo-4-chloro-3-indolyl-~-D-galactoside (X-gal 
substrate) [Boehringer Mannheim] and 200mg/ml isopropyl-~-D-thio-
galactopyranoside (IPTG). Three hundred microlitres of each sample 
were plated onto separate agar plates and incubated at 37°C overnight. 
Transformed colonies were identified by the blue/white colour selection 
technique of Sambrook et al. (1989). Bacteria containing plasmids with 
inserts appear as white colonies against a background of blue colonies 
lacking inserts. Insertion of DNA at this multiple cloning site interrupts 
the ~-galactosidase W-gal) gene and destroys its activity. This results in 
the appearance of white colonies when X-gal is supplied as the substrate. 
Cells containing plasmids without inserts express ~-gal activity and 
catalyze the conversion of X-gal substrate into a blue pigment, thus 
giving rise to blue colonies. 
Forty-six white colonies were selected, 25 from the mother and 21 from 
her infant. These colonies were re-plated onto duplicate X-gal-, IPTG-
and ampicillin- containing Luria agar grid plates using a single sterile 
pipette tip per colony. The plates were incubated at 37°C overnight. One 
of the grid plates contained a piece of nylon membrane (Hybond N, 
Amersham) that was later used for colony blot hybridization. The same 
tip as used to inoculate the grid plates was also used to inoculate the 
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bacteria into 2ml of Luria broth (containing 50mg/ml ampicillin) . This was 
incubated overnight at 37°C with aeration (shaking at 200rpm in a Lab-
line orbital shaker) and then used for small-scale preparations of 
plasmids. 
6.2.3 Small scale plasmid 
preparations 
A quick boiling method was used for the plasmid isolation (Berghammer 
and Auer, 1993). Aliquots of 1 ,Sml of an overnight culture were 
transferred into microfuge tubes (Eppendorf) and centrifuged in a 
Beckman microfuge E at 12000rpm for 30sec. The supernatant fluid was 
carefully removed by pipetting and the cell pellet resuspended in 30µ1 of 
lysis buffer [1 OmM Tris-HCI , pH8.0; 1 mM EDTA; 15% (w/v) sucrose; 
2mg/ml lysozyme; 0,2mg/ml pancreatic RNase and 0, 1 mg/ml BSA], and 
incubated with shaking at room temperature for Smin to allow the 
lysozyme to perforate the bacterial cell wall. The suspension was boiled 
for 60sec in a water bath and centrifuged in a Beckman microfuge E at 
12000rpm for 20min at room temperature. Cell debris and genomic DNA 
formed a compact pellet, stabilized by the heat-precipitated BSA. The 
supernatant fluid was then used for restriction enzyme analysis. The 
restriction enzyme Pvull, which cleaves the vector at two sites, was used 
for the analysis. The smaller fragment contains the cloning cassette and, 
should there be an insert, this band will migrate at a slower rate than the 
same fragment from non-recombinant plasmids when subjected to 
agarose gel electrophoresis. Eight microlitres of DNA was mixed with 1 µI 
of 1 OX Buffer M (Boehringer Mannheim) and 1 µI Pvull , [2 units/microlitre] 
(Boehringer Mannheim), in a final volume of 1 OµI. The mixture was 
incubated at 37°C for 2hr and then heated at 65°C for 1 Omin to inactivate 
the enzyme. The total 1 OµI volume of sample was then electrophoresed 
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in 2,5% agarose containing 0, 1 mg/ml EtBr (Merck). The stained DNA 
fragment was visualized on a UVP transilluminator. 
6.2.4 Colony blot hybridization 
The following procedure was used to liberate the DNA from the bacterial 
colonies and to bind it to the nylon membrane Hybond N (Amersham). 
Four pieces of Whatman 3MM paper were cut and fitted onto the bottoms 
of four glass petri dishes. Each piece was saturated with one of the 
following solutions: 10% SOS, denaturing solution, neutralizing solution, 
or 2X SSC (Appendix A) . The nylon membrane was removed from the 
agar grid plate (chapter 6.2.2.2) after overnight incubation, and placed 
(colony side up) on the 10% SOS saturated filter paper, for 5min. This 
treatment limits the diffusion of the plasmid DNA during denaturation and 
neutralization, resulting in a sharper hybridization signal. After exposure 
to the SOS, the membrane was transferred to the second sheet of 3MM 
paper which had been saturated with denaturing solution. After a 1 Omin 
exposure, the membrane was transferred to the third 3MM paper, 
saturated with neutralizing solution, and left for another 1 Omin. After 
neutralization, the membrane was transferred to the last 3MM paper, 
which had been saturated with 2X SSC, and left for 5min. Finally, the 
membrane was also washed in 2X SSC by shaking at room temperature 
for 30min, and then dried, colony side up, on a sheet of 3MM paper. The 
DNA was then fixed to the nylon membrane by crosslinking, using a UV 
Crosslinker 1000 (Hoefer Scientific Instruments). This was followed by 
hybridization (see chapter 3.2.4.4) with a DIG-labelled probe. The PCR 
product from a PCR- and seropositive adult patient was labelled with 
digoxigenin for use as a probe, using the method described by Lo et al. 
(1990). Briefly, this method entailed using the "standard" PCR reaction , 
except that dTTP was replaced with a mixture of 0,065mM dTTP and 
0,035mM DIG-dUTP (Boehringer Mannheim). 
149 
6.2.5 Large scale plasmid 
preparations 
Eight positive clones (identified by colony blot hybridization) were 
selected for each patient (mother and infant) and large scale plasmid 
preparations were performed, using the Nucleobond AX PC kit (Macherey 
- Nagel, Germany) to purify the DNA. Each positive colony was 
inoculated into 100ml Luria broth, containing ampicillin, and incubated at 
37°C overnight with shaking. The bacterial cells were concentrated by 
centrifugation at 6000rpm for 1 Smin at 4°C in a Beckman J2-21 
· centrifuge, fitted with a JA-10 rotor. Cell disruption, isolation and 
purification of plasmid DNA was achieved using the Nucleobond AX PC . 
kit (MachereY,:-Nagel, Germany), according to the manufacturer's 
instructions. 
6.2.6 Sequencing of the cloned 
DNA fragments 
Double-stranded plasmid DNA was sequenced by the dideoxy chain 
termination method (Sanger, 1977) using a T7 Sequencing kit (Pharmacia 
P-L Biochemicals). The DNA was denatured by mixing 1 OµI DNA (1,5 -
2,0µg of DNA) with 6µ1 of ultra-pure water and 4µ1 of 1 M NaOH, and 
incubating the mixture at 37°C for 1 Smin, whereafter it was placed on ice. 
The solution was neutralized by the addition of 8µ1 3M sodium acetate 
(pH4.8). After the addition of 100µ1 of ice-cold absolute ethanol, DNA 
was precipitated by placing the tube at -70°C for 2hr. The precipitate was 
concentrated by centrifugation, washed with 70% ethanol, dried in a 
Speed-Vac vacuum drier and resuspended in 1 OµI of ultra-pure water. 
The denatured DNA was then mixed with 2µ1 of annealing buffer (T7 
Sequencing kit) and 2µ1 of the universal forward or reverse primer (T7 
Sequencing kit). The reaction mixture was incubated at 37°C for 30min in 
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a water bath, followed by 30min at room temperature and 4°C overnight 
or 5min at room temperature, to ensure primer annealing. 
Labelling was achieved by adding 3µ1 of labelling mix (T7 Sequencing 
kit) , 1µ1 of (a-35S]-dATP (10µCi , Amersham) and 2µ1 of 1:5 diluted T7 DNA 
polymerase to the solution containing the annealed template and primer. 
This mixture was centrifuged briefly and then incubated for 5min at room 
temperature. The reaction was terminated by transferring 4,5µ1 of the 
sample into four pre-warmed dideoxynucleotide (ddATP, ddTIP, ddCTP, 
and ddGTP) tubes at 37°C for 5min. Termination solutions contained 
4µM of one specific ddNTP as well as 40µM of all dNTPs in 50mM NaCl. 
After 5min incubation, 5µ1 of stop solution (T7 Sequencing kit) was 
added. 
The principle of this method relies on the following: If a 
dideoxynucleotide triphosphate (ddNTP) is incorporated into a DNA 
strand, in place of dNTP, the chain cannot be extended further as 
ddNTPs contain no 3'-hydroxyl group. Terminations therefore occur 
specifically at each site of incorporation of ddNTP , e.g., if a primer and 
template are incubated with DNA polymerase in the presence of a mixture 
of ddTIP and dTIP, as well as the other three dNTPs, a mixture of 
fragments is obtained that all have dTIP 5' ends, and have ddTIP 
residues at their 3' ends. If this termination procedure is applied with all 
four nucleotide analogues separately, and the resulting fragments are 
electrophoresed side by side in adjacent lanes, a sequence ladder is 
produced which then can be used to determine the base sequence of the 
DNA 
A 6% denaturing acrylamide gel was used to separate the mixture of 
fragments. A 100ml working solution composed of 12ml of a 50% (w/v) 
bis-acrylamide solution (50% acrylamide 2,5% N,N'-
bismethyleneacrylamide [NNB]), 10ml 1 OX NNB buffer (Appendix A), 48g 
urea and 84ml distilled water. The mixture of urea, NNB and water was 
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warmed to dissolve the urea, before the acrylamide was added. 
Polymerization of the acrylamide was initiated by the addition of 175µ1 of 
a 20% (w/v) ammonium persulphate solution and 40µ1 of TEMED 
(N,N.N',N'-tetramethylene-diamine). The liquid solution was slowly 
poured into the 0,4mm space between two glass plates of dimensions 
40cm by 34cm, by lifting the plates to an angle of about 80°. At this angle 
the plates were only filled about 3/4 of the way, and they were then 
lowered, onto a rubber bung, to an angle of about 15° so that the 
acrylamide now filled the whole of the space. The straight edge of two 
shark's tooth combs (Hoefer Scientific Instruments) were inserted 
between the plates to provide a single, level well. The gel was allowed to 
set for at least one hour. If left overnight, the combs were covered with a 
piece of moist filter paper, and wrapped in clingwrap to prevent 
evaporation. The combs were removed, plates assembled in the 
electrophoresis tank (Omeg Scientific Instruments) and the gel warmed to 
42°C by a pre-electrophoretic run for 30min at 35W ( constant power) 
using 1X NNB in the lower tank and 0,6X NNB in the upper tank. The 
upper well was thoroughly rinsed with 0,6X NNB buffer to remove excess 
urea and the shark's tooth combs were then inserted into the well to 
create numerous evenly spaced partitions. The samples were heated to 
78°C for 2min and 3µ1 of each sample was loaded into the wells. 
Electrophoresis was allowed to continue for either 3,5 or 5,5 hr at ?OW, 
whereafter the buffer was removed from the upper buffer chamber and 
the top plate was slowly separated from the bottom plate by levering up 
one corner of the plate. The gel was transferred to 3MM Whatman paper, 
covered with clingwrap and dried on a SGD 4050 Slab gel dryer (Savant) 
at 80°C under vacuum for 2hr. The clingwrap was removed and the dried 
gel was subjected to autoradiography for one to five days. This entailed 
exposing the gel to Agfa Curix RPI X-ray film in the presence of a Cronex 
intensifying screen. The X-ray film was then developed as described in 
chapter 3.2.4.5. 
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6.2.7 Sequence analysis 
Eight clones from the mother and five clones from her infant were 
sequenced. The V3 loop of all the clones was sequenced in both 
directions, whereas the variable region 3 env domain was only 
sequenced in one direction. The HIV sequences that were obtained from 
the mother and her infant were named according to the standardized 
sequence nomenclature proposed by the WHO (Korber et al. , 1994). The 
sequences of the mother's clones were named: 93ZA208.* (with * 
representing the 8 different clones, e.g. 93ZA208.i; 93ZA208.2; 
93ZA208.W; 93ZA208.7; 93ZA208.P; 93ZA208.X; 93ZA208.1 ; 
93ZA208.J) and the sequences of the infant's clones were named 
93ZA209.* (* = X, 6, D, 5, 1 ). The first two characters refer to the year of 
isolation, the second two characters refer to the location where the 
sample was taken (ZA = South Africa) and the third three characters refer 
to the reference number for the study subject (208 = mother, 209 = infant) 
followed by *, indicating the name of the different clones. 
Sequences were aligned using the computer program Clustal V (Higgins 
et al., 1992), and the final alignment was done manually. The computer 
program TREECON (version 2.2) [Van den Peer and De Wachter, 1992] 
was employed for phylogenetic analysis, using the neighbour-joining 
approach and the distance matrix method (Kimura, 1980). 
Insertions/deletions were ignored and SIVcPZGAs sequence was used as 
an outgroup. The validity of the branching pattern was assessed by 
performing 100 bootstrap analyses on the sequences. A branch point 
with a bootstrap value of >80% was considered reliable. The 13 datasets 
included a 347bp sequence (with gaps) and a 304bp sequence (without 
gaps) that were analyzed to draw the tree. Two representative reference 
sequences of each of subtypes A, B, C, and D of HIV-I were also included 
in the phylogenetic analysis. 
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The computer programs Genepro (version 6.1) were used to deduce the 
amino acid sequences of the V3 loop, and alignments were done using 
Clustal V (Higgins et al., 1991 ; Higgins and Sharp, 1988). 
6.3 Results 
The mother and her infant were both sero-positive by HIV-I diagnostic 
criteria (chapter 4.2.2). As this infant was younger than 15 months old, 
the positive serology could have been attributed to maternal antibodies, 
and PCR (as described in chapter 5) was used to confirm his positive HIV 
status. DNA extracted from PBMCs from both mother and infant yielded 
positive HLA-DQ-a signals when amplified with the primers of this single 
copy gene. The 424bp product that was amplified by the outer V3 
primers could not be visualized on an EtBr-stained agarose gel. After a 
nested amplification with the V3 inner primers, a 329bp fragment was 
visualized on an EtBr-stained agarose gel (Fig. 33). 
1 2 3 4 5 6 7 8 9 
---329bp 
Fig. 33 ·Ethidium bromide stained agarose gel showing the 329bp fragment generated 
by the V3 inner primers. Lane 1, MWVI ; lanes 2 to 5 amplification product of the infant; 
lanes 6 to 9 amplification products of the mother. 
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The 329bp fragment was cloned and positive clones were identified by 
colony blot hybridization [Figure 34(A) and (B)]. The clones are streaked 
in shape of alphabetical/numerical character for easy identification. 
(A) ~THER (B) INFANT 
neg colony - - -
control 
Fig. 34 Chemilumigram of the mother's clones (A) and her infant's clones (8) after 
colony blot hybridization. Clones were probed with a dig-labelled probe. Each clone are 
streaked in shape of an alphabetical/numerical character for easy identification. 
Recombinant clones were not as readily detected by restriction enzyme 
analysis as by the colony blot hybridization (results not shown), and it 
was therefore decided to use the hybridization method as indicator of 
plasmids containing the cloned PCR fragment. 
6.3.1 Sequence variation 
Eight positive clones from the mother (2, P, W, 1, J, 7, I, X) and 5 positive 
clones from her infant (6, X, 1, D, 5) were selected by colony blot 
hybridization, and the DNA sequences were determined for each clone. 
The 329bp PCR fragment was sequenced (up to 320bp), and contained 
the immunodominant V3 loop. The computer-generated alignment of 
DNA sequences from both the mother and her infant are shown in figure 
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Fig. 35 DNA sequence alignment of the V3 region of HIV-I as amplified from the 
PBMCs of the mother and her 3 month old baby. (A) shows the sequence alignment of 
the 8 positive clones obtained from the mother and (B) shows the sequence alignment of 






































































































































































































































































































































































































































































































































































































































M>ther Infant M>ther Infant 
ACGT ACGT ACGT ACG T 
Fig. 36.· Sequencing gels illustrate the base sequence of the V3 region of two clones 
from both mother and infant. 
The population of HIV-I env sequences from the mother were largely 
homogeneous. Five of the 8 clones yielded identical sequences. In 
contrast, the infant's sequences were more divergent. Base similarity 
analysis between the consecutive pairs of viral sequences was 
determined and the values are listed in table 12 (page 158) in the form of 
a matrix. The mean intra-sample variation in sequences from the mother 
is 1,04% (range 0,6 to 2%). The infant's mean intra-sample variation is 
1,8% (range 0,3 to 3,4%). Inter-patient sequence analysis between 
mother and baby showed a mean variation of 3,88% (range 2,4 to 5, 1 %). 
A phylogenetic tree (Fig. 37) was generated using the aligned V3 
sequences of HIV-I variants from the mother, her infant and previously 
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published subtypes: U455, Z321 representing subtype A; JRFL, LAI 
subtype B; NOF, 07 47, 0760 subtype C; JYI, NDK subtype D; and 
SIVcpz (Myers, 1994). This tree showed that DNA sequences from both 
the mother and baby clustered with the HIV-I subtype C. They were, 
respectively, 86,4% and 87,5% similar to the sequences of other known 
subtype C viruses. 
The predicted amino acid sequences of the V3 region of virus clones from 
the mother and her infant are shown in figure 38(A) and 38(8). In all 
cases an identical tetrapeptide motif, GPGQ (shown in bold in fig . 38), 
was present at the crown of the V3 loop. However, the same degree of 
identity did not extend across the entire octameric tip of the V3 loop: 
Whereas all variants isolated from the mother displayed an RIGPGQTF 
amino acid sequence, the predominant sequence in variants from the 
baby was found to be RIGPGQAF, indicating a substitution of threonine 
(T) with an alanine (A). Furthermore, both the mother's and the baby's 
sequences lacked a potential N-linked glycosylation site at the start of the 
V3 loop (as indicated in fig . 38). Valine (V) replaced asparagine (N) at 
this site in all the sequences. 
Other substitutions were also observed within the V3 domain of variants 
from the infant. Clones D and 5 showed a threonine (T) at position 42 
and glycine (G) at position 59, whereas clones 6, 1, and X all showed a 
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Fig. 37 Neighbour-joining phylogenetic tree resulting from 100 bootstrap replicates on 
the partial env sequence set. The tree was rooted on the SIVcPZGAB sequence. 
Horizontal distances are proportional to sequence differences between species, vertical 
distances are arbitrary. Figures along the horizontal branches represent percentage 
bootstrap values greater than 95%. Clones derived from the mother and her baby are 


































































































Fig. 38 The deduced amino acid sequences of the V3 loop region of HIV-I clones from 
the mother (A) and her infant (8) . The valine which replaces a potential N-l!nked 
glycosylation site is marked with an asterisk (*) . The tetrameric tip is shown in bold 
letters, and the V3 loop is indicated by the arrowed line. 
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6.4 Discussion 
Phylogenetic analysis of HIV-I viruses isolated from both the mother and 
her infant in th is study, have placed them in the same cluster as the other 
known HIV-I subtype C viruses. To date, forty isolates of HIV-I subtype C 
have been sequenced, of which 38 have been published (Myers, 1994). 
Amongst these is the first described South African isolate of HIV-I (NOF) 
[Dietrich et al., 1992] as well as numerous isolates from India and Zambia 
(Myers, 1992). 
Data obtained from the analysis of the V3-loop of viral isolates from the 
mother/infant pair in this study is consistent with their subtype C 
classification: e.g. the absence of a potential N-linked glycosylation site 
proximal to the first cysteine of the V3 loop. This glycosylation site is 
commonly present in all HIV-I sequences except those of subtype C 
(Myers, 1994; Orloff et al. , 1993). The sequence of the octameric tip 
found in the V3 loop of our mother-infant pair, is also consistent with 
subtype C classification. The most common motif found in subtype C is, 
RIGPGQTF, but other subtypes differ in that HIGPGQAF is characteristic 
of subtype A, HIGPGRAF of subtype B, PIGPGQAL of subtype D, 
TIGPGQVF of subtype E and HIGPGQAF is characteristic of subtype F. 
It has been shown that amino acid changes near the center of this tip can 
influence the specificity of anti-V3 neutralizing antibodies (Myers, 1994). 
The central V3 tetrapeptide motif, GPGQ, was present in all the 
sequences from both mother and baby, and thus correlates with the 
findings that this motif is seen among HIV-I sequences of subtypes A, C, 
D, and E, in contrast to the GPGR motif that is commonly seen in subtype 
B. It's thought that this tip has a specific conformation (it forms a turn) 
that is important for neutralizing antibody epitopes as well as T-cell 
epitopes (Myers, 1994). 
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Information regarding the degree of similarity between variants from the 
mother and infant in this study, differs to a large extent from previous 
studies. We found that the virus population harboured by the mother 
displayed highly homogeneous V3 sequences (1 ,04% variation) 
compared to virus isolates from her 3 month old infant, which showed a 
higher degree (1 ,8%) of heterogeneity. Most other studies have indicated 
that there is a trend towards higher variability with time, and generally, 
sequences of isolates from mothers were far more heterogeneous than 
those of isolates from their infants. For example, Wike et al. (1992) 
examined the sequence diversity of HIV-I between 4 maternal-infant 
transmission pairs, of which 3 were from the United States and the fourth 
from Rwanda. Isolates from the mothers in their study showed extensive 
diversity (5% in the V3 region) while the infants' isolates were more highly 
conserved with a mean distance of 2,5% (V3 region) between sequences. 
No clin ical data or ages were given for these infants. In a similar study, 
comparing the variation in a mother and her child following transmission, 
Mulder-Kampinga et al. (1993) observed a heterogeneous sequence 
population in the maternal samples that were taken at 6, 4, and 2 months 
prior to delivery and 10 months after child birth, with a mean nucleotide 
variation (V3 region) of 2,4% to 4,2%. The sequence population of the 
infant was highly homogeneous until the age of 6 weeks (<0,7%) and only 
showed more heterogeneity at 9 months of age (1 ,8%). These authors 
suggested intra-uterine transmission based on their find ings that the 
homogeneous sequence population in the child at birth was more closely 
related to the sequence population of the mother during the first and 
second trimester of pregnancy than to the sequence population at 
del ivery and 10 months after delivery. 
A third group of researchers, Wolinsky et al. (1992) analyzed different 
regions from the env gene (including the V3 region) from 3 mothers and 
their 2-4 month old babies. The viral sequences from the mothers in their 
study also showed a greater variability than that of their infants', who 
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showed a narrow distribution of variants. Scarlatti et al (1993) compared 
sequences from the V3 region from 10 mother-infant pairs. The mothers 
were all drug users or sexual partners of drug users. Nine of the 10 
infants were shown to be asymptomatic and one child was reported to 
have hepatitis and hepatosplenomegaly. Similar results regarding the 
extensive heterogeneity of the maternal samples and homogeneous 
infant isolates were shown in their study. The reasons for the 
discrepancy between our findings and those of others are not clear. It is 
conceivable that the apparent homogeneity of the mother's variants was 
not a true reflection of her entire virus population. It could have been 
biased by selective amplification following low virus yield in the original 
blood specimen. An indication of this possibly occurring was given by the 
fact that the original PCR band obtained from the mother's blood sample 
was fainter than that of the baby's. Nevertheless, other reasons must be 
sought to explain the relative diversity of the variants from the infant. 
Although the 1,8% of heterogeneity which were observed was 
considerably higher than that of the mother, it was not as high as the 
2,5% diversity observed in vertically infected infants by Wike et al. 
(1992). 
The degree of nucleotide variation found in our 3 month old infant was 
only attained in the infant described in the study by Mulder-Kampinga et 
al. (1993), at 9 months of age. It may be relevant that the 9 month old 
infant was described as clinically asymptomatic with immunological 
disorders, whereas our infant had pneumonia and a week later his 
symptoms were described as "full blown AIDS" . It is possible that the 
more rapid onset of disease might be related to the higher nucleotide 
variation in the younger infant. The early and rapid onset of disease in 
neonates is not uncommon, and seropositive infants as young as one 
month of age have been seen to manifest AIDS symptoms (Davachi, 
1994). It has been suggested that a rapid progression is more 
pronounced in African infants, than in infants from the West. The nature 
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of the selective pressures are unknown, but it is thought that nutritional 
status may play a role. Semba et al. ( 1994) suggests a strong 
association between maternal vitamin A deficiency and an increase in 
vertical transmission of HIV-I. 
Fouchier et al. (1995) investigated the role that phenotypic variability of 
HIV-I plays in the pathogenesis of AIDS. They suggested that a rapid 
decline of CD4 T-cells, a reduced survival time after AIDS diagnosis and 
a rapid disease progression are associated with the presence of 
syncytium-inducing (SI) HIV-I isolates. They showed that the presence of 
positively charged amino acid residues at position 306 and/or 320 in the 
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Fig. 39 Diagrammatic presentation of the 
amino acid sequence variation in V3 
regions from syncytium- and non-
syncytium-inducing (NSI) HIV-I isolates. 
Arginine (R) at position 306 in the V3 loop 
and/or arginine or lysine (K) at position 
320 are associated with syncytium 
inducing isolates (Adapted from Fouchier, 
1995). 
De Wolf et al. (1994) examined SI- and NSl-associated V3 mutations in 
HIV-I subtypes other than subtype B. The cytopathic abilities of the 
different variants were predicted, based on the V3 loop amino acid 
sequences, assuming that positively charged amino acid substitutions at 
position 306 and 320 in the V3 loop is related to T-cell line tropic, SI-
viruses, and that uncharged or negatively charged amino acid 
substitutions at these respective positions correlated with macrophage-
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tropic, NSl-variants. On comparing their culture results with their V3 
sequence results, they found a positive correlation for 28 of the 29 NSI 
virus stock samples, and 10 of the 12 SI virus stock samples, thus 
confirming that this type of analysis could be used for the prediction of 
biological phenotypes, not only for subtype B variants, but also for 
subtype A, C, D, and E variants. They concluded that prediction of 
disease progression could be made by determining the SI capacities of 
HIV-I isolates. 
The application of the above predictive criteria (based on the amino acids 
present at positions 306 and 320 of the V3 loop) indicates that isolates 
from both the mother and her infant in our study, are consistent with the 
NSl-phenotype (Fig. 40(A), 40(8). 
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Fig. 40 Schematic presentation of the amino acid sequence variation in the V3 loop 
from the mothers' isolates (a) and her infants' isolates (b) . The absence of positively 
charged amino-acids at positions 306 and 320, in both cases, indicates that the isolates 
are of the NSI variety. 
From available sequence data, it appears that a mutation at position 306 
is not commonly found in subtype C isolates. A comparison of 38 
published subtype C sequences (Myers, 1994), reveals only one isolate 
(ZA.NOF) with a substitution at position 306, where a serine (S) residue 
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is substituted for an arginine (R) residue (indicative of SI phenotype). No 
substitution is noted at position 320 for this isolate. 
Conflicting evidence thus arises from the different studies: the 3 month 
old infant in our study, diagnosed with "full blown AIDS", was shown to 
harbour a NSI HIV-I isolate, despite the findings of Fouchier et al. (1995) 
that a rapid disease progression is associated with the presence of a SI 
HIV-I isolate. However, Saag et al. ( 1994) reported that SI variants are 
not required for HIV disease progression, and that only half of AIDS 
patients harbour SI variants, indicating that NSI HIV variants can also 
cause AIDS and death. Although varying opinions exists, it is necessary 
to bear in mind that factors such as the moment and manner of sampling, 
choice of primers and possible selection by amplification, virus load, and 
stage of disease may all variably influence the outcome of genetic 
epidemiological studies. 
This type of study has not been done before in the local community on 
HIV-I subtype C isolates, and data presented here should be useful for 
future comparative studies. 
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Conclusions 
One of the main achievements of this study was to devise, optimise and 
instigate a PCR assay for resolving the infection status of babies born to 
HIV-infected mothers, in the neonatal period. In order to achieve this, it was 
necessary to adapt and optimise a standard PCR protocol to ensure 
maximum sensitivity and specificity for HIV proviral DNA, and then to ensure 
that the assay was accurate and reproducible before it could be applied in 
our routine diagnostic laboratory. 
Genetic variation is a hallmark of HIV-I, -II , and in the light of this variability, 
appropriate choice of primers in a diagnostic PCR assay is a factor of major 
importance. Consequently, different primers directed against various 
conserved regions in the HIV-I genome were used to ensure detection of all 
variants. A standard PCR protocol was optimised for all the sets of primers 
(SK29,30; SK145,431 ; SK38,39; SK68,69 nested) used during this study. 
In general this required an increase in the concentrations of MgCl2, Taq 
DNA polymerase and dUTP, to give best performance with the primers of 
choice. The four sets of primers that were selected all performed equally 
well. Using them in various combinations in duplicate tests on 138 HIV 
seropositive sera ( selected at random from the routine diagnostic 
laboratory), we were able to show 100% correlation between their 
respective PCR results. For the initial optimization reactions a plasmid, 
pBH10, that contains truncated HIV sequences, was chosen as template. 
As this plasmid-PCR system generates high copy numbers of HIV 
sequences, contamination was a very high risk that became an unfortunate 
reality. A great deal of time and effort was spent in an attempt to eliminate 
the problem, but without success. Finally, there seemed no alternative but to 
discard the contaminated primer pair involved (SK68,69) from the study, and 
a valuable lesson was learned regarding the need for meticulous attention 
to methods of containment. 
169 
As a precautionary measure, a dUTP-enzymatic system was incorporated 
into our HIV PCR assay. This incorporation led to more optimization 
experiments as the optimum concentration of dUTP in the PCR mixture 
differed from the previously established dTTP concentration. Theoretically, 
dU-containing fragments will be degraded by the UNG enzyme with no 
effect on the specific dT-containing template, but in our hands, the 
incorporation of the UNG-enzyme into the system resulted in severe 
inhibition of all amplification. Nevertheless, it was decided to maintain the 
incorporation of dUTP in all our HIY PCR reactions in order to generate dU-
containing amplification products, so that in the event of unforeseen 
contamination, the UNG enzyme could be used in a broad program of 
eradication to clear all contaminants. 
A major requirement of diagnostic assays applied to detection of infection in 
very young babies, is high sensitivity, since the volume of blood samples is 
invariably small. Our optimized PCR system compared very favourably with 
other published systems, and was able to detect as little as one copy of 
plasmid DNA Specificity is another prime consideration in HIV diagnosis. It 
was established that a good correlation existed between the optimised HIV 
PCR assay and currently used 3rd generation ELISA assays:- The eleven 
seronegative patients were PCR negative and 83% (115/138) of the 
seropositive patients were also shown to be HIV PCR positive. Analysis of 
patient data revealed that the remaining 17% (23/138) that were negative by 
PCR, were all infants less than 15 months of age and their positive HIV 
sero-status was most probably a reflection of acquired maternal antibodies 
from their seropositive mothers. Taking all these results into consideration, 
it was concluded that the correlation between the HIV PCR and antibody 
results for older patients was close to 100%. This was very encouraging as 
it indicated that our HIV PCR system could identify all the HIV-I subtypes 
that were detectable by ELISA in our local community. 
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A number of important technical considerations were made apparent while 
performing the PCR assay on human DNA specimens, and they include: 1) 
Whole blood specimens should be processed as soon as possible after 
collection, as long periods of storage (24 - 48hr) at room temperature or 4°C 
can affect the yield of amplifiable DNA; 2) the specificity of the assay could 
be further increased by a combination of a temperature of 42°C, with a low 
salt concentration in the washing buffer (0, 1 X SSC) during the washes after 
oligonucleotide hybridization; 3) Adequate washing procedures during the 
extraction process that releases DNA from PBMCs are essential as haeme-
related compounds can inhibit amplification; 4) Sufficient positive and 
negative controls should be included in each PCR run and HIV PCR results 
should be confirmed with specific probes by Southern blot hybridization 
since contamination and amplification of non-specific "back-ground" DNA 
sequences can pose potential problems in the interpretation of results; and 
5) A constant vigilance is required to avoid the introduction of new sources 
of contamination. 
Since a prime objective for the newly devised PCR assay was accurate 
diagnosis of HIV infection in very young babies, its performance was 
evaluated using blood specimens from 45 infants under 15 months of age, 
all born to HIV seropositive mothers, and for whom serology results were 
therefore inadequate to determine true infection status. The 3 infants who 
were seronegative were also PCR negative but HIV proviral DNA was 
detected in the PBMCs of 27 (64%) of the 42 seropositve infants. The 
positive PCR tests correlated well with the clinical data indicative of active 
HIV-infection for the majority of these infants. The remaining 15 (36%) 
seropositive infants were PCR negative, which, on the basis of the 
established high level of sensitivity and specificity of the assay, was strongly 
indicative of the absence of infection. We could, however, not exclude an 
HIV infection in all the babies who were very young (under 4 - 6 weeks of 
age) as low levels of virus could be present in peripheral blood or the virus 
could be confined in lymphoid organs at this young age (Krivine et al., 
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1990). This also reduces the number of infected lymphocytes in the small 
samples of blood that can be taken from very young babies. In infants older 
than 3 months, one could predict with greater confidence that a negative 
PCR result probably indicates the absence of active infection. An additional 
application for a sensitive and specific PCR assay is to assist in the 
interpretation of the so-called "indeterminate" serological findings. It was 
decided that in spite of the high cost of the HIV PCR assay, the overall 
benefit of an early diagnosis may be sufficient to warrant its being put to 
more widespread use. 
The same PCR protocol was also applied in the second part of this study to 
amplify HIV V3-specific sequences from an HIV seropositive, clinically well 
mother and her 3 month old infant, diagnosed with full blown AIDS. These 
DNA fragments were then cloned and sequenced (8 clones from the mother 
and 6 from her infant). This examination was stimulated by the increasing 
amount of conflicting data on the genetic variants involved in maternal-fetal 
transmission. 
HIV is known to evolve within an individual during the course of infection 
resulting in nucleotide sequence variation within that individual. 
Examination of the V3-region in the env gene of HIV-I isolates from our 
mother-infant pair confirmed this variation. It was found that the virus 
population harboured by the mother was highly homogeneous (only 1,04% 
variation) compared to the virus population of her infant which showed a 
higher degree (1,8%) of heterogeneity. Regarding the degree of variation, 
our data differed from other studies where an extensive heterogeneity was 
shown in maternal samples and more homogeneity in infant samples. New 
data from this study, although obtained from only a single mother-infant pair, 
should add to the pool of information concerning variants involved in 
materno-fetal transmission and their rate of evolution, and suggests that 
fixed rules do not apply. Each investigation will undoubtedly be influenced 
by the clinical status of the patients at the time of sampling (stage of 
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disease, duration of infection, virus load, etc.) as well as the varying 
parameters of the respective technical protocols and the degree of selective 
amplification. These factors could in part account for the range of divergent 
opinions from different groups of researchers. Other conflicting evidence 
from this study includes the finding that the 3 month old infant (in whom 
AIDS was already well advanced) harboured only a non-syncytium-inducing 
type of HIV-I, despite the findings of others that a rapid disease progression 
is associated with the presence of syncytium-inducing HIV variants. It is 
reasonable to assume that the probability of transmission from mother to 
infant, as well as the rate of deterioration in the immune function, is 
dependent on many factors, and we conclude that the presence or absence 
of a SI-virus is insufficient to be used as a sole prognostic marker. 
Phylogenetic analysis of the HIV-I viruses isolated from both mother and her 
infant have placed them in the same cluster as other known subtype C 
viruses. This classification was substantiated by more detailed genetic 
analysis of the V3 loop, which indicated the absence of a potential 
glycosylation site proximal to the first cysteine residue of the V3 loop, and a 
GPGQ central tetrapeptide motif of the V3 loop, characteristic of subtype C 
viruses. This provides further confirmation to other published data that 
subtype C viruses are present in South Africa. 
In summary, this study has resulted in the development of a sensitive and 
specific PCR assay which will be (and is already being) used for HIV 
diagnostic purposes, particularly in the case of infants. It has also been 
shown that this technique can be effectively applied to a variety of genetic 
epidemiological studies. Since there is at present little information available 
on subtype C viruses involved in materno-fetal transmission in South Africa, 
data arising from this study should be useful for future comparative studies. 
It is hoped that the work presented in this thesis will make a significant 




Solutions and Buffers 
50% (w/v) Acrylamide and 2,5% (w/v) N,N'-bismethyleneacrylamide 
250g acrylamide 
12, Sg N, N' -bismethyleneacrylamide 
Dissolve in distilled water and adjust volume to 500ml. Filter and store at 
4°C in a dark bottle. 
Ampicillin (100mg/ml) 
2g Ampicillin 
Dissolve in 20ml distilled water, aliquot and store at -20°C. 
Buffer 1 for Chemiluminescent detection 
0, 1 M maleic acid 
0,15M NaCl 
pH7.5 
Blocking stock solution 
10% solution in distilled water. Autoclave and store at -20°C. 
Buffer 2 for Chemiluminescent detection 
Blocking stock solution diluted 1 :10 in Buffer 1 
Final concentration = 1 % blocking solution (Boehringer Mannheim) 
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Wash buffer for Chemiluminescent detection 
Buffer 1 and 0,3% (w/v) Tween-20 
Buffer 3 for Chemiluminescent detection 




Denaturing buffer for Southern blot 
200g NaOH (0,5M) 
876,6g NaCl (1 ,SM) 
Make up to 10 I with distilled water 
Ethidium bromide (EtBr) stock solution 
1 g EtBr 
Dissolve in 100ml distilled water (wearing a mask). Stir for 1 hr on a 
magnetic stirrer and store in a dark bottle at room temperature. 
IPTG (200mg/ml) 
0,2g IPTG 





2,SmM MgCb, pH8.3 
1 OOµg/ml fresh proteinase K 
0,5% Tween 20 
Lithium chloride (4M) 
42,39g lithium chloride 
Dissolve the lithium chloride in 250ml of distilled water and sterilize by 
autoclaving. Store the solution at room temperature. 
Luria agar 
1 Og tryptone 
Sg yeast extract 
Sg NaCl 
15g agar 
Dissolve the agar in 500ml of distilled water and dissolve the tryptone, 
yeast extract and NaCl in a separate 300ml aliquot. Mix the two solutions 
and increase the volume to 11. Dispense the solution into bottles and 
sterilize by autoclaving at 1 Spsi for 1 Smin. Store at room temperature. 
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Luria broth 
1 Og tryptone 
5g yeast extract 
10g NaCl 
Dissolve the above components in distilled water and make up to 11. 
Dispense the solution into bottles and sterilize by autoclaving at 15psi for 
15min. Store at room temperature. 
Lysis buffer for small scale plasmid preparations 
10mM Tris.HCI 
1mM EDTA 
15% (w/v) sucrose 
2mg/ml lysozyme 
0,2mg/ml RNase 
0, 1 mg/ml bovine serum albumin 
Aliquot and store at -20°C 
Neutralizing buffer for Southern blot 
8,0g NaOH (20mM) 
770,8g Ammonium acetate (1 M) 
make up to 10 I with distilled water 
10X NNB buffer 
162,0g Tris base 
27,5g Boric acid 
9,3g EDTA 
Make up to 1000ml with distilled water. 
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Proteinase K (Boehringer Mannheim) 
Dissolved at 20mg/ml in 10mM Tris.HCI (pH7.5) 
20X SSC buffer 
175,3g NaCl 
88,2g Tri-sodium citrate 
Dissolve the components in 800ml distilled water and adjust the pH to 7.0 
with a small volume of 1 OM NaOH. Increase the volume to 1000ml with 
distilled water. Sterilize by autoclaving at 1 Spsi for 1 Smin and store at 
room temperature. 
10% sos 
1 OOg Sodium dodecyl sulphate 
Dissolve in 900ml of distilled water and heat to 68°C to assist disolution. 




1 M TE buffer (pH 9.0) 
Dissolve the sucrose in TE buffer and then make up to 100ml with the TE 
buffer. Sterilize the solution by autoclaving at 1 Opsi for 1 Omin and store 
at room temperature. 






1 OX Tag PCR buffer 
1 OOmM Tris. HCI 
15mM MgCb 
500mM KCI 
1 mg/ml gelatine, pH8.3 at 20°C, Boehringer Mannheim Biochemica 
50X Tris-acetate buffer (TAE) 
242g Tris. HCI 
57, 1 ml glacial acetic acid 
100ml 0,5M EDTA pH8.0 
Make up to 1000ml with distilled water and autoclave at 15 psi for 15min. 
Tris-EDTA buffer (TE) 
10mM Tris.HCI 
1mM EDTA, pH7.6 
Triton/doc solution 
4,0ml TritonX-100 
0,4g Sodium deoxycholate 
1,0ml Tris.HCI (pH8.0) 
0,2ml of 0,5M EDTA (pH8.0) 
Dissolve the above constituents in 80ml distilled water, then adjust the 
volume to 100ml. Sterilize the solution by autoclaving at 15psi for 15min 
and store at room temperature. 
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X-qal (20mq/ml) 
0, 1g X-gal 
Dissolve in 5ml dimethylformamide and store at 4°C. 
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Appendix B 
Nucleotide code - single letters 
A adenosine triphosphate 
C cytidine triphosphate 
G guanosine triphosphate 
T thymidine triphosphate 
U uridine triphosphate 




D aspartic acid 
C cysteine 
Q glutamine 

















Black and white negatives of the chemilumigrams and Polaroid photographs 
were taken with a 35mm Leica DBP (Ernst Leitz, Germany) using an llford 
HPS ASA 400 black and white film. The prints were made using an Opemus 
Sa enlarger fitted with a no. 3.5 filter from the llford multigrade filter set, and 
exposing them to llford multigrade Ill glossy photographic paper (England). 
The prints were developed by a 2 to 3min immersion in llford paper 
developer (llfospeed) diluted 1 :9 with water. They were then transferred 
into 2% acetic acid that acted as a stop solution and lastly fixed by 
immersion in Super Amfix (Champion) high speed fixer for paper (1 :9 
dilution), for 5-1 Omin. The prints were washed for 1 Omin in running water 
and dried in a warm air dryer. 
The colour photographs were taken with the same 35mm camera using Fuji 
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